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ABSTRACT
PRECLININCAL DEVELOPMENT OF AVAREN-FC: A NOVEL LECTIN-FC
FUSION PROTEIN TARGETING CANCER-ASSOCIATED HIGH-MANNOSE
GLYCANS
Matthew William Dent
November 17, 2021

This dissertation explores the anticancer activity of Avaren-Fc (AvFc), a novel
lectin-Fc fusion protein or “lectibody” targeting cancer and virus-associated highmannose glycans. Previously, we have shown that AvFc recognizes a broad selection of
established cancer cell lines from a wide array of tissue types, can potently induce
antibody-dependent cell-mediated cytotoxicity (ADCC) against them, and exhibits anticancer activity in vivo. However, the exact mechanism of action remains elusive. We
hypothesized that the primary mechanism of action is through Fc-mediated effector
functions, and the purpose of this dissertation is to explore this question through the use
of Fc variants that either increase or decrease ADCC activity relative to the WT molecule
using the B16F10 murine melanoma model.
Chapters 1 and 2 give a comprehensive overview of glycosylation and its role in
cancer and disease, the molecule AvFc, the mechanism of action of the various Fcmediated effector functions, and the current status of plant-made cancer biologics.
Chapter 4 discusses the efficacy of AvFc in a human liver chimeric mouse model of HCV
v

infection, which helped not only to establish AvFc’s activity in vivo but also
demonstrated its safety and feasibility as a drug candidate. The bulk of the data obtained
regarding the anticancer activity of AvFc are contained in Chapter 5, which establishes
that Fc-mediated functions are the primary mechanisms of action and that AvFc
administration is associated with the recruitment of FcγR-bearing cells to the tumor
microenvironment. Interestingly, these studies also indicated that the presence of preexisting immunity in the presence of anti-drug antibodies to AvFc did not obviate its
activity in vivo. Further exploration of the anticancer activity of AvFc is detailed in
Chapter 6, which discusses the use of AvFc as a therapeutic for ovarian cancer (OVCA)
and details its in vitro and in vivo activities. The results presented herein provide
evidence to suggest that cancer-associated high-mannose glycans may be a viable
pharmacological target and that AvFc is a unique and potent first-in-class agent with
significant anticancer capabilities through recognition of this glycobiomarker, warranting
its further development as a therapeutic against cancers with limited therapeutic options
such as OVCA.
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CHAPTER 1: BACKGROUND
1.1: Glycoconjugates
Glycosylation, the enzymatic formation of glycosidic linkages between
oligomeric carbohydrate chains called glycans to biological macromolecules, is one of
the fundamental biochemical modifications and a key pathophysiological regulatory
mechanism [1]. The various glycoconjugates are defined by the monosaccharide
composition of the glycan moiety, the class of macromolecule (protein, lipid, or other
saccharides) they are linked to, and the nature of that linkage. Glycans are built through
the sequential action of glycosyltransferase enzymes, which are localized to multiple
organelle compartments and catalyze the formation of glycosidic bonds between
activated nucleotide monosaccharide donors and the acceptor sugars. The sum of the
glycans on the cell surface make up a structure known as the glycocalyx, which not only
creates a protective barrier but plays a significant role in protein structure and quality
control, cell-cell signaling, and adhesion both between cells and between cells and the
extracellular matrices. Glycans can also act as ligands for a class of proteins called lectins
that are expressed on a number of tissues, especially those of the immune system in
vertebrates. Each of these classes of glycoconjugates have distinct functions in the cell,
and defects in the glycome in humans are linked to a remarkable number of diseases [2].
While glycosylation occurs in one form or another across the tree of life, such as in
bacterial and archaeal cell wall synthesis, the focus of this dissertation will be on
metazoan (animal) glycosylation, in particular the glycosylation of proteins performed by
1

mammals, as well as some brief discussion of the glycosylation of recombinant proteins
in plants.
One of the major classes of glycoconjugates are the glycoproteins. The attachment
of glycan structures to proteins is one of the fundamental post-translational modifications
and occurs on proteins that are processed in the endomembrane system [1]. There are two
major forms of protein glycosylation: asparagine or N-linked glycosylation and serine or
threonine-linked glycosylation, called O-glycosylation. The resulting glycans are
therefore referred to as N-glycans and O-glycans glycans, respectively. N- and O-glycans
significantly impact the structure and function of mature proteins and are extremely
important to ensure quality control and folding during translation. The composition of
these glycans varies significantly between species, cell types, and even proteins.
Significant changes in N- and O-glycosylation patterns may be useful biomarkers to
identify different disease states, and defects in these pathways are known to cause several
human diseases [2]. A more detailed discussion of N-linked glycosylation follows in
section 1.2.
O-glycosylation is a common glycoprotein modification that occurs at the OHgroups of serine and threonine residues. Almost all O-glycans have one of four major
core structures that can be extended to give linear or branched chains, and structures are
built one sugar at a time by enzymes called glycosyltransferases [3]. Each of the 4 cores
begins with α1,3-linked N-acetylgalactosamine (GalNAc), which is then linked to either a
Gal or GlcNAc sugar by a β1,3-linkage. Cores 2 and 4 also contain an additional GlcNAc
residue attached by a β1,6-linkage [4]. Extension of these cores occurs in the Golgi
apparatus, where the biosynthetic glycosyltransferases are embedded into the membrane
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facing the Golgi lumen and interact with proteins as they are trafficked through the
endomembrane system [5]. Unlike N-glycans, O-glycans only rarely contain mannose
(Man), glucose (Glc), or xylose (Xyl) but may contain GalNAc, Gal, fucose (Fuc), and
sialic acids [4]. The expression and activity levels as well as the localization of these
enzymes determine the range of O-glycans that can be synthesized, creating tremendous
inter-species and even inter-tissue or cell heterogeneity. The functions of O-glycans vary
widely. The most well-known class of proteins containing O-glycans are the mucins,
which can contain hundreds of these glycans attached to a protein scaffold with high
molecular weight. The hydrophilic nature of O-glycans and their negative charge
promotes the binding and sequestration of water and salts, allowing mucins to form
viscous gels that line the mucosal epithelial surfaces of the body [6, 7]. These mucous
layers provide a physical and chemical barrier to outside agents and pathogens in addition
to keeping surfaces hydrated. Some mucins, like the P-selectin glycoprotein ligand 1
(PSGL-1) are membrane bound and act as ligands for lectin receptors such as the
selectins and galectins [8]. Other O-glycan-containing proteins are the targets of selectins
and galectins expressed on the surface of cells of the immune system, and function in
immune cell trafficking throughout the body as well as signal transduction [9]. O-glycans
also make up the ABO and Lewis blood group antigens, and loss of some
glycosyltransferases such as GALNT3 and GALNT2 are associated with the tumoral
calcinosis and cardiovascular disease [10-12]. While O-glycans are important for the
structure and function of many proteins, arguably the more important post-translational
modification for recombinantly produced therapeutic proteins is N-glycosylation, which
will be discussed further.
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1.2: N-glycosylation of proteins
Asparagine-linked, or N-linked, glycosylation is an important post-translational
modification that plays a significant role in the control of protein folding as well as the
structure and function of mature proteins. Like O-glycosylation, N-glycosylation occurs
on secreted and membrane-bound proteins that are trafficked into the ER for processing
through the endomembrane system. Unlike O-glycans, which can in theory be applied to
any serine or threonine residue, the minimal sequence to which these glycans can be
attached is Asn-X-Ser/Thr-X, where X can be any amino acid except for proline [1]. Also
unlike O-glycans, which are built sugar-by-sugar, N-glycans are first assembled
separately into a large precursor glycan structure attached to dolichol phosphate in the ER
membrane prior to their attachment to the protein, at which point they are trimmed and
extended by a number of glucosidases and glycosyltransferases expressed in the lumenal
space of the ER and Golgi apparatus. This “en bloc” transfer of large N-glycans can be
limited by the structure of the nascent protein itself, and as such while ≈ 70% of all
proteins contain the N-X-S/T-X sequon only an estimated 70% of the sites are actually
occupied by one [1]. All N-glycans share a common core structure with the sequence
Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ1-Asn (Figure 1) and different types
of N-glycans are then defined based on the extension of this core. The three major types
of N-glycans are: high-mannose glycans, which have between 2 and 6 additional
mannose sugars that extend both arms of the trimannose core, complex glycans, where
both the α3- and α6-mannose arms contain polysaccharide chains initiated with β1,2GlcNAc, and hybrid glycans, where the α3 arm is extended with β1,2-GlcNAc while the
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other contains additional mannose residues. In addition, multiple GlcNAc residues can
extend from the core creating multi-antennary and bisecting structures, which can be
further built upon to create large multi-branched glycans (Figure 6). There is significant
glycan-site heterogeneity, and the presence of an N-glycosylation sequon does not
guarantee either the presence of a glycan or a particular glycan structure, and as such the
same site on multiple proteins may be occupied by different glycan structures in a rather
stochastic fashion. As with O-glycans, the expression and localization of the various
glycosyltransferases as well as the availability of substrate define the range of glycans
that can be generated, and this can vary tremendously between species and in different
disease states [1, 2, 13, 14].
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Figure 1. The major classes of N-glycans.
N-glycans can be divided into 3 major classes: high-mannose, complex, and hybrid.
High-mannose glycans contain between 5 and 9 mannose sugars (including the
trimannose core). Complex glycans, on the other hand, have both the α3- and α6mannose arms extended by GlcNAc. Hybrid glycans have the α3-mannose arm extended
by GlcNAc while the other contains mannose. The core glycan structure can also be
extended by multiple GlcNAc residues to create large multi-antennary and bisecting
structures (see Figure 6).

6

1.2.1: Synthesis of the dolichol-phosphate precursor
The biosynthesis of N-glycans takes place in two phases and primarily occurs
within the ER and Golgi apparatus of eukaryotic cells. The first phase, which is well
conserved among eukaryotes, is the generation of the dolichol-phosphate-linked (Dol-P)
glycan precursor structure (Figure 2). Dolichol is a polyisoprenol lipid made up of
repeating five-carbon isoprene units, as many as 19 in mammals, that is found on both the
inner and outer ER membrane. Phosphorylated dolichol (Dol-P), which is generated by
dolichol kinase (DOLK), is acted upon by the glycosyltransferase ALG7, which catalyzes
the addition of a single GlcNAc-1-phosphate and forms Dol-P-P-GlcNAc [15]. This
structure is expanded upon with a second GlcNAc and 5 Man residues by subsequent
cytoplasmic glycosyltransferases and then translocated across the ER membrane to the
lumenal face through the action of a flippase enzyme RFT1 [16]. Further processing by
ER-resident glycosyltransferases generates the final precursor glycan, Dol-P-PGlcNAc2Man9Glc3, which is then transferred to receptive asparagine residues on nascent
proteins as they are translocated into the ER lumen by the oligosaccharyltransferase
(OST) enzyme complex [16]. Transfer of the complete glycan precursor leaves behind
Dol-P-P, which can be reused for precursor synthesis by conversion to Dol-P via a
dolichol phosphatase (DOLPP) [17].
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Figure 2. Synthesis of the dolichol-phosphate precursor.
The initial synthesis of the N-glycan precursor begins on the cytoplasmic face of the ER
with the phosphorylation of dolichol by DOLK and attachment of 2 GlcNAc and 5
mannose residues by the N-acetylglucosaminyltransferases ALG7/13/14 and the
mannosyltransferases ALG1/2/11. The Dol-P-P-GlcNAc2Man5 structure is flipped to the
ER lumen by RFT1 and expanded by subsequent mannosyltransferases ALG3/9/12 and
glucosyltransferases ALG6/8/10 to form the full-length precursor Dol-P-PGlcNAc2Man9Glc3. Transfer of the precursor glycan onto asparagine residues of nascent
peptides is performed by OSTA, while the leftover Dol-P-P is recycled to the cytoplasmic
face of the ER and processed by DOLPP to regenerate dolichol phosphate.
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1.2.2: Initial glycan processing and quality control of protein folding
The second phase of N-glycan biosynthesis takes place exclusively in the ER and
in the Golgi apparatus and involves a number of glycosidases and glycosyltransferases
that trim the precursor glycan down to the GlcNAc2Man3 core and rebuild it into the
various complex type glycans typically seen on mature glycoproteins (Figure 4). It is
during this phase that the quality control systems for protein folding primarily operate
(Figure 3). The initial trimming of two of the Glc residues by glucosidase I and II (GI and
GII, or MOBS and GANAB) generates a monoglucosylated structure that is recognized
by either calnexin (CNX) or calreticulin (CRT), which form part of a loose complex of
protein chaperones that includes BiP/Grp78, ERp57, and Grp94 among others [18]. Both
CNX and CRT contain ER retention signals, and their binding to N-glycosylated proteins
bearing a single glucose prevents premature export to the Golgi apparatus, giving the
immature proteins time to properly fold and form oligomeric structures, if necessary, as
well as form disulfide bonds (which are catalyzed by the ERp57 oxidoreductase) [19].
Proteins that fail these steps and remain unfolded are acted upon by the ER degradationenhancing α-mannosidase-like proteins (EDEMs), which generate an isomer of
Man7GlcNAc2 that contains an exposed α1,6-mannose residue which is specifically
targeted by the lectin OS9 [20, 21]. Binding by OS9 leads to retrotranslocation of the
protein to the cytosol, ubiquitinylation, and degradation of the misfolded protein by the
proteasome. A second reaction by GII results in the removal of the final Glc residue,
preventing CNX/CRT binding and allowing for export of the glycosylated proteins to the
cis-Golgi [22]. This can be reversed by an enzyme called UGGT, which causes the
misfolded protein to re-bind to CNX/CRT and continue folding.
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Figure 3. Simplified diagram of protein quality control in the ER.
CNX/CRT binds to glucosylated N-glycans and increases protein residence time in the
ER. Proteins that remain misfolded after the GII enzyme removes the glucose are
trimmed by EDEMs and retrotranslocated by the lectin OS9 to the cytosol, where an Nglycanase removes the glycan and the protein is degraded. The enzyme UGGT can recatalyze the addition of this glucose, allowing for more folding time. Properly folded
proteins will be translocated to the Golgi apparatus as normal.
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Typically, proteins exported to the cis-Golgi contain 8-9 Man residues, depending
on whether or not they were acted on by ER α-mannosidase I (MAN1B1), which removes
the terminal Man from the central arm of the glycan [23]. In the cis- and medial-Golgi,
further trimming of high-mannose glycans (which contain anywhere between 5 and 9
terminal Man residues) is performed by α-mannosidases 1A and 1B (MAN1A1 and
MAN1A2), which ultimately leads to Man5GlcNAc2, a structure which can undergo
further processing to generate complex- or hybrid-type glycans or can remain on the final
exported protein [24]. Some proteins retain their high-mannose glycans, in particular
proteins that are destined to remain within the organelle compartments of the cell, as
these glycans are known to play a role in intracellular trafficking of proteins to the
lysosome through the binding of the mannose-6-phosphate receptor [1]. In most
circumstances, high-mannose glycans are processed to either of these advanced forms
prior to secretion or insertion of the mature protein into the plasma membrane. However,
in some cases cellular stress due to cancer, infection, or other disease can result in
inefficient processing leading to an increase in the proportion of these glycans on the cell
surface, the consequences of which are discussed in a subsequent section.

1.2.3: Processing of hybrid and complex glycans
Further processing of glycans (Figure 4) is initiated in the cis/medial-Golgi by the
N-acetylglucosaminyltransferase MGAT1, which adds a β1,2-GlcNAc residue to the α3
arm of the trimannose core forming the hybrid glycan GlcNAcMan5GlcNAc2 [25]. The
remaining Man residues (apart from the trimannose core) are trimmed away by the
enzymes MAN2A1 and MAN2A2, which can only act on glycan substrates that have
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been acted on by MGAT1 [24]. In plants and some invertebrates, the action of MGAT1
can be reversed by a hexoseaminidase in the Golgi forming what are referred to as
paucimannose structures (Man3-4GlcNAc2) [26]. While some hybrid glycans appear on
exported proteins, most have both the α3 and α6 arm of the trimannose core extended by
GlcNAc, the second of which is added by the enzyme MGAT2. This structure,
GlcNAc2Man3GlcNAc2 (or GnGn for short), can have additional GlcNAc residues added
by other enzymes in the MGAT family (MGAT3, MGAT4A/B, MGAT5/5A/5B, and
MGAT6), which generate large multi-antennary and bisecting structures (Figure 6) [1].
These terminal GlcNAc residues form the starting points for N-glycan maturation, which
consists of the further addition of sugar residues to the core, elongation of the GlcNAc
residues, and capping of these elongated branches. Most mammalian complex glycans
contain an α1,6-linked Fuc residue on the innermost core GlcNAc that is added by the
enzyme Fuc-TVIII (encoded by the FUT8 gene) [27]. In plants, this core fucose is
attached with an alternative α1,3 linkage by an α1,3-fucosyltransferase. Plant glycans
also commonly contain a β1,2-xylose residue attached to the central mannose residue of
the trimannose core [26]. The presence of plant-derived core xylose and fucose is
controversially implicated in hypersensitivity reactions to plant allergens and is
hypothetically a safety concern for recombinant therapeutic proteins manufactured in
plant-based platforms, though the safety (or lack thereof) of plant glycans is much
debated [28, 29].
The number of possible mature N-glycoforms is extensive. The majority of
complex and hybrid glycans begin with the addition of Gal to the terminal GlcNAc
residues forming Galβ1-4GlcNAc, or type 2 N-acetyllactosamine (LacNAc). Under
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certain circumstances, LacNAc sequences are repeated to create poly-LacNAc glycans,
which have many different structures and separate biosynthesis pathways that are beyond
the scope of this work [30]. The most important sugars in mammals for capping are Fuc,
Gal, GlcNAc, and the sialic acids (Sia). These sugars are almost always α-linked, which
causes them to point away from the main glycan structure and allows them to interact
with lectins and antibodies more easily [31]. The Sia family of sugars are particularly
abundant on mature glycoproteins and have diverse structures [32]. The most common
sialic acid in humans is 5-N-acetylneuraminic acid (Neu5Ac), and unlike other
monosaccharides these can be repeatedly extended with additional sialic acid residues to
create polysialic acid chains [33]. Sialic acids impart a number of biological functions to
glycans, and polysialic acids in particular are abundant on cellular adhesion molecules
like NCAM where they mediate intercellular interactions and regulate neuronal
development [34]. Among other functions, sialic acids protect the underlying glycan or
glycoprotein from degradation or recognition by host-cell receptors or proteases and
pathogen-associated receptors or toxins [31]. The abundance of sialic acids on
mammalian glycoproteins, however, has led to many animal pathogens evolving to
recognize these residues. A notable example of this is influenza virus hemagglutinin
(HA), which agglutinates erythrocytes by binding to sialylated receptors on their surface
[35].
In summary, N-glycosylation is a complex yet integral part of cell physiology that
is necessary for protein maturation, structure, and function. N-glycans are incredibly
diverse, and the impact of individual glycan structures on the function of the underlying
protein is in most cases still being elucidated. However, one thing that is becoming
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increasingly clear is that changes to the typical glycoforms produced by the cell can be
induced by cellular stress such as that from viral infection, inflammation, and cancer.
Changes to the normal glycan structures therefore represent potential glycobiomarkers of
disease that could be targeted for diagnostic or therapeutic purposes, to be discussed
further.
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Figure 4. General outline of N-glycosylation in mammals.
The precursor glycans assembled in the ER and transferred onto NXS/T-containing
proteins by OSTA are trimmed by a series of glucosidases and mannosidases in the ER
and cis-Golgi, ultimately forming GlcNAc2Man5. The enzyme MGAT1 catalyzes the
addition of the first GlcNAc to the α3 arm of the trimannose core, forming a hybrid
glycan structure. Further trimming by mannosidases is followed by the addition of a
second GlcNAc to the α6 arm of the trimannose core, which begins the synthesis of the
complex glycans in the medial- and trans-Golgi. A series of sugar “capping” and core
modifications is then performed to generate the final diversity of N-glycan structures, in
particular through the addition of galactose, sialic acids, and core α1,6-fucose. The
number of different complex N-glycans that can be synthesized is very large, and the
relative proportions of each structure can change under certain cellular conditions.
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Figure 5. General outline of N-glycosylation in plants.
N-glycosylation in plants proceeds along much the same path as it does in mammals,
albeit with different enzymes and different final glycan structures. The major differences
occur after the addition of the second GlcNAc residue to the α6 arm of the trimannose
core in the medial-Golgi, forming the so-called “GnGn” glycoform. In mammals, this is
typically followed by the addition of a core α1,6-fucose residue and extension of the
GlcNAc residues by galactose and other sugars. In plants, however, the generation of the
GnGn glycan is followed by the addition of a core β1,2-linked xylose residue to the first
core mannose and a α1,3-linked fucose residue to the innermost core GlcNAc. These
sugars, in this particular arrangement, are generally considered to be plant-specific. As
with mammals, the number of complex N-glycans from plants is large and can change
depending on the cellular conditions.
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1.3: N-glycosylation and disease
Changes to the normal patterns of N-glycans produced by cells or the introduction
of rare and cryptic glycans have been identified as hallmarks of diseases such as cancer
and viral infection [13, 36]. Indeed, aberrant glycoforms have been explored and
identified for their potential use as biomarkers and druggable targets, and some of the
relevant findings will be discussed here with a particular focus on high-mannose glycans.

1.3.1: N-glycosylation of viral glycoproteins
Changes to the normal pattern of N-glycosylation described above can often be
the consequence of viral infection. The surface glycoproteins of enveloped viruses are
often used for cellular attachment and membrane fusion leading to infection of the target
cells, and as such the proper folding and function of these proteins is integral to virus
replication and survival. As N-glycosylation is a critical determinant for the final
structure and function of any glycoprotein, so it is also for viruses. Many glycoproteins
belonging to enveloped viruses are heavily decorated with N-glycans, which have
evolved over time to modulate the affinity of viral entry proteins to their cognate
receptors on the host cell as well as mask the underlying protein epitopes from the
immune system [36, 37]. This high glycan density places significant stress on the cellular
glycosylation machinery resulting in aberrant glycosylation not only on host proteins but
on the viral glycoproteins themselves [37]. It is this property that allows for potential
discrimination of virally-infected tissues from non-infected, making these glycan changes
potentially druggable or diagnostic targets.
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One of the most commonly observed glycan changes observed on the surface of
highly glycosylated viral glycoproteins is an overabundance of high-mannose glycans.
This phenotype has been identified on a wide range of viruses including influenza virus
[38], human immunodeficiency virus (HIV) [39], hepatitis C virus (HCV) [40], the
human coronaviruses (MERS, SARS, SARS-2, HKU1, and 229E) [41-43], West Nile
Virus [44], Lassa virus [45], the Ebola viruses [46], herpes simplex virus 1 and 2 [47],
and many others. While it is not known for certain why these glycans are overrepresented
on these viruses, there are at least two hypotheses. The first is that the infection itself and
resulting inflammatory signaling may cause changes in cellular metabolism that promotes
the production of high-mannose glycans, and that they may constitute a type of danger
signal that allows for the mounting of an appropriate immune response by cells bearing
mannose-recognizing C-type lectins (mrCLRs) [14, 48]. A recent study also suggested
that IFNα, an important mediator of the antiviral response, may alter host glycosylation
patterns including the upregulation of high-mannose glycans [49]. Similarly, infection of
cells by influenza virus was found to activate the ER unfolded protein response, which
results in improper glycan processing and upregulation of high-mannose glycans on the
cell surface which can then be recognized by the mannose-binding lectin leading to
inflammation [50]. The second hypothesis is that the overexpression of viral
glycoproteins produces steric hindrance and saturation of the N-glycosylation pathway,
preventing the trimming of certain occluded glycans and forcing the rapid movement of
proteins through the secretory pathway [37]. This could certainly be the case for viruses
like HIV, whose spike glycoprotein gp120 exists as a trimer on the surface of the virus
and can contain as many as 30 N-glycans per monomer, the majority of which are high-
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mannose glycans [39]. This huge density of glycans and their rapid production during
viral replication places tremendous stress on the glycosylation machinery and combined
with the lack of access by mannosidases to their substrates, may help explain the
abundance of high-mannose glycans [51]. Other enveloped viruses such as West Nile
virus are not abundantly glycosylated (with only 1 or 2 glycans per envelope protein) yet
also display high-mannose glycans, allowing them to infect cells through the mannosebinding lectins DC-SIGN and DC-SIGNR, though the mechanism for this is less clear
[52]. What is clear is that high-mannose glycans are a common viral glycobiomarker, one
which can potentially be taken advantage of as a druggable target. Indeed, a number of
antibody-based and lectin-based therapeutics have been developed for this purpose [53,
54].

1.3.2: Aberrant N-glycosylation in cancer
While much work remains to elucidate the exact role that N-glycans play in
oncogenesis and metastasis, aberrant changes associated with cancer have been described
for decades and have provided targets for diagnostic and therapeutic strategies [13]. As
mentioned previously, N-glycans are incredibly diverse structures whose compositions
are largely determined by intrinsic factors such as substrate availability,
glycosyltransferase and glycosidase expression levels, and compartmentalization of these
enzymes within the cell. Two broad processes have been identified which define the
tumor-associated changes to glycan structures and can be used to generally classify the
aberrant changes: the incomplete synthesis and neo-synthesis processes [55]. Incomplete
synthesis of glycans refers to the impairment of normal glycan synthesis and the
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upregulation of truncated or immature structures. Alternatively, glycan neo-synthesis
involves the expression of glycosyltransferases and other genes that result in the
generation of novel carbohydrates. These processes however are simply descriptive terms
that describe the outcome of glycosylation changes, and don’t necessarily provide a
framework for how they occur. Realistically, shifts away from normal glycosylation
patterns during oncogenic transformation are the result of a number of intrinsic and
extrinsic factors. The first of these is the altered expression (over or under) of the various
glycosyltransferases and glycosidases, which may occur due to transcriptional or
translational disruption [56, 57]. Altered glycan expression can also be the result of
changes to the availability of the various sugar nucleotide donors and enzymatic cofactors
as a result of metabolic disturbance [58]. Lastly, normal glycan structures can be
disrupted by changes to the localization of glycosyltransferases and glycosidases,
especially those that are present in the Golgi apparatus where the complex N-glycans are
mostly formed [59].
For N-glycans, the most consistently observed alterations in cancer are increased
core fucosylation and the upregulation of branching and poly-LacNAc structures (Figure
6) [13, 60]. As described previously, many complex mammalian glycans are decorated
with the addition of an α1,6-linked fucose residue to the innermost GlcNAc of the Nglycan core. The increase in core fucosylation is due to overexpression of the FUT8 gene,
which encodes the Fuc-TVIII enzyme that catalyzes the addition of the sugar. Abundant
core fucosylation is a well-established phenomenon in lung, liver, and breast cancers, and
can even be used to diagnostically differentiate between hepatocellular carcinoma and
other chronic liver disorders [61-64].
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Figure 6. Structure of poly-LacNAc and generation of branched, bisected, and
fucosylated N-glycans.
Branched and bisected structures are generated through the action of the Nacetylglucosaminyltransferases MGAT4A, MGAT4B, MGAT5, MGAT5B, and MGAT6.
Each GlcNAc residue, except for the bisecting GlcNAc, can be modified with additional
galactose, GalNAc, and sialic acid residues creating large and complicated structures.
Increases in the proportions of branched N-glycans and Poly-LacNAc is commonly
observed in cancer.
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The increase in expression of complex branching structures is primarily due to the
upregulation of the MGAT5 gene, which encodes the N-acetylglucosaminyltransferase
GnT-V. GnT-V catalyzes the addition of β1,6-linked GlcNAc to the trimannose core
which leads to the generation of tri- and tetra-antennary structures that are further
decorated with LacNAc residues. Interestingly, MGAT5 expression appears to be
regulated by the RAS/RAF/MAPK signaling pathway, which itself is activated in many
cancers [60]. The principal consequence of this is the increased generation of polyLacNAc chains that are the primary ligands for the S-type galectins, which bind to these
glycoproteins and form large lattice complexes in the extracellular matrix. Galectins
contribute to the transformation to cancer possibly by helping to regulate the process of
angiogenesis, which is critical for tumor survival and ultimately metastasis [65]. In
addition, branching N-glycans seem to play a significant role in regulating the function of
some receptors and adhesion molecules including E-cadherin, integrins, and EGFR. In
several in vivo studies, upregulation of MGAT5 resulted in the loss of contact inhibition
of cancer cells and increased tumor formation [66, 67], while downregulation suppressed
tumor growth and metastasis [66]. A seminal publication by Granovsky et al. in 2000
effectively demonstrated this effect through the generation of Mgat5-/- mice, which
significantly suppressed viral oncogene-induced breast cancer production and metastasis
[68]. Overexpression of MGAT5 also negatively impacts E-cadherin structure and
function, resulting in significant loss of functional protein and loss of effective cell
adhesion [69]. Conversely, the addition of bisecting GlcNAc, catalyzed by GnT-III
(MGAT3), precludes the generation of branching structures by enzymatic competition and
acts as a tumor suppressor, significantly limiting the lung metastasis of B16 cells and
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delaying the recycling of E-cadherin at the cell surface (which may help to suppress the
epithelial-to-mesenchymal transition, or EMT) [69-71].
One change to the normal N-glycosylation pattern of cancer cells that has been
more recently elucidated is an increase in the proportion of high-mannose glycans. As
described previously, high-mannose glycans are immature glycoforms that are generally
processed by mannosidases and modified into complex forms prior to the secretion of the
glycoprotein from the cell or its insertion into the plasma membrane. Their presence on
the cell surface, therefore, is indicative of a disruption to glycan processing that prevents
complete glycan maturation. Increases in the expression of high-mannose glycans have
been found in breast cancer [72], colorectal cancer [73-75], hepatocellular carcinoma [76,
77], cholangiocarcinoma [78], lung adenocarcinoma [79], pancreatic cancer [80], ovarian
cancer [81, 82], prostate cancer [83], and some skin cancers [84]. Interestingly, highmannose glycans are also overrepresented on the surface of human embryonic stem cells,
an observation that may be linked to their appearance in cancer as cancer cells often take
on a more stem-cell-like phenotype during EMT [85]. The mechanism by which cancer
cells produce greater numbers of high-mannose glycans are not clearly established, and
different mechanisms likely exist in cancers from different cell and tissue types. The
mannosidase MAN1A1, which is a key enzyme responsible for trimming Man8 to Man5,
has been implicated as the culprit in a number of cancer cells. For instance, MAN1A1
was found to be downregulated in metastatic cholangiocarcinoma cells and differentially
localized to Golgi compartments in aggressive prostate cancer cells [78, 86-88].
Downregulation of mannosidases was also speculated as the reason for increased
abundance of high-mannose glycans on colorectal cancer cells [89]. Interestingly,
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expression of high-mannose glycans could be modulated through expression of certain Oglycans, in particular O-GlcNAc, suggesting that regulation of the two processes may be
linked [88].
The biological consequences of the overexpression of high-mannose glycans on
the cell surface are not well understood. In 2011, de Leoz et al. demonstrated that highmannose glycans expression levels correlated with the progression of breast cancer,
suggesting that they may play a broad role in tumor migration, invasion, and metastasis
[72]. Subsequently, more mechanistic studies showed that the increase in high mannose
glycans resulted in the increased migration and invasion of cholangiocarcinoma cells, the
effect of which could be masked through the use of high-mannose glycan-binding lectins
such as Pisum sativum Agglutinin [88]. Inhibition of MAN1A1 in metastatic
cholangiocarcinoma cells through the use of the chemical inhibitor kifunensine resulted
in significant increases in migration and invasion, activity which may have been
mediated by the mannosylation of specific membrane receptors including the transferrin
receptor (TFR1), integrin α-V (ITGAV), and nicastrin (NCSTN) [78]. An increase in
Man9 on the TFR1, for instance, resulted in a significant increase in homodimer stability
and transferrin affinity, suggesting that high-mannose glycans affect cell-surface protein
dynamics in a way that may promote cancer growth [78]. Another well-established
example of this is the presence of high-mannose glycans on EGFR, which has long been
known to be prognostic in lung cancer patients [90, 91]. A recent study by Alonso-Garcia
et al. has shed some light on a possible biophysical mechanism to explain the enhanced
invasiveness of high-mannose glycan-bearing cells [92]. In this study, knockdown of
MAN1A1 in mesenchymal stromal cells (MSCs) using shRNA constructs resulted in
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increased cell migration. Similarly, the use of kifunensine resulted in both enhanced
migration and structural changes to the cells that may lead to enhanced motility and tissue
invasion, including a decrease in cell contact area and a reduction of cell stiffness [92]. In
summary, while it is increasingly clear that the increase in cell-surface high-mannose
glycans is a potentially useful and broad glycobiomarker of cancer that may not only
constitute a diagnostic marker but a druggable target, the functional consequences of that
increase are still not clear.

1.4: Avaren-Fc, a novel high-mannose-binding agent
The search for therapeutic carbohydrate-binding agents targeting diseaseassociated glycobiomarkers has remained somewhat elusive. The vast majority of mAb
therapeutics are IgGs, as they are capable of high-affinity binding and inducing immunemediated effector functions while maintaining a long serum half-life. IgGs targeting
glycans are notoriously hard to generate, however, as glycans alone make poor epitopes
and do not typically present on MHC-class molecules, which precludes isotype switching
and affinity maturation [93]. To date, the GD2 ganglioside-binding mAb dinutuximab
remains the only FDA-approved cancer therapeutic targeting a carbohydrate epitope [94].
Furthermore, antibodies specifically targeting cancer-associated high-mannose glycans
are practically nonexistent. One such antibody, TM10, was found to bind selectively to
cancer cells but was completely devoid of activity in vivo. The most likely due to the fact
that TM10 is an IgM-class antibody, which are large, low-affinity antibodies that lack
effector functions [95].
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Lectins, which are proteins that specifically bind to carbohydrates, are an
incredibly diverse set of proteins found across the tree of life and offer a powerful
alternative to mAbs for therapeutic carbohydrate binding. They not only play important
roles in biological processes – from cell signaling to immune cell trafficking and
pathogen defense – they have found use in biotechnological applications including in
microarrays, chromatography, and medical diagnostics and imaging [96]. Furthermore,
some lectins have been found to have antimicrobial and anticancer activity, suggesting
that they may have therapeutic utility by targeting disease-associated glycobiomarkers
[53, 97]. Unfortunately, lectin therapeutic development has been somewhat limited due to
toxicity, off-target effects, and lack of producibility. Thus, there is considerable room in
the field for novel lectin agents that overcome these downsides.
To that end, our lab has pioneered the development of a novel lectin-Fc fusion
protein, or lectibody, called Avaren-Fc (AvFc). AvFc is a first-in-class antibody-like
carbohydrate-binding agent that has high affinity for clusters of high-mannose glycans, a
type of immature N-glycan that is enriched on the surface of some highly-glycosylated
viral glycoproteins as well as on the surface of many types of cancer (as described in
section 1.3.1 and 1.3.2). In addition to exhibiting high-affinity binding to these glycans,
the inclusion of the Fc region allows for the induction of immune-cell-mediated effector
functions including antibody-dependent cell-mediated cytotoxicity (ADCC), antibodydependent phagocytosis (ADP), and complement-dependent cytotoxicity (CDC).
Interestingly, unlike other mannose-binding lectins such as concanavalin A (ConA),
AvFc demonstrates a high degree of selectivity for high-mannose glycans, is not
cytotoxic or mitogenic to normal cells in vitro, and has not shown any signs of toxicity in
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vivo [98, 99]. This combination of sugar binding and antibody-like functions in the
immune system make AvFc a unique and powerful molecule. This section will detail its
structure and activity.
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Figure 7. The predicted 3D structure of Avaren-Fc.
The 3-dimensional structure of AvFc was predicted using AlphaFold. The lectin Avaren
(green) is linked by a GGGS linker to the hinge region (blue) of the Fc region from a
human IgG1 molecule (purple).
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1.4.1: Design and antiviral activity
The design and anti-HIV activity was summarized by Hamorsky, Kouokam, and
Dent et al. in 2019. Key points from this manuscript are reiterated herein. The lectin
Avaren is a mutant derived from the actinomycete lectin actinohivin (AH), which was
discovered by screening microorganisms for novel anti-HIV compounds using a
standardized syncytium-formation assay [100]. AH was capable of neutralizing multiple
strains of HIV without inducing toxicity or mitogenicity to human blood cells by binding
to terminal α1,2-linked mannose residues, which are found on high-mannose glycans
[101-104]. However, a major drawback with AH is its lack of manufacturability in
recombinant systems, owing to its high hydrophobicity and propensity for aggregation
[102]. In order to improve the biochemical properties of AH, a number of variants were
generated and tested in the Nicotiana benthamiana-based transient overexpression
platform. Structurally, AH consists of 3 near-homologous repeated domains of
approximately 38 amino acids, each of which is capable of binding a single highmannose glycan [101, 103]. 11 variants of AH were generated by structure-guided
mutation of one or two domains to corresponding residues in the others with the intention
of neutralizing its surface charge variation. One of these variants retained much of the
parent molecule’s gp120-binding ability while significantly improving its solubility and
producibility. This variant was termed “Avaren” (actinohivin variant expressed in
Nicotiana) and was subsequently fused to the fragment crystallizable (Fc) region of
human IgG1, which had the dual purpose of dimerizing the lectin and introducing the
ability to induce immune-mediated effector functions (Figure 7). The resulting molecule
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retained its sugar-binding specificity while greatly improving its affinity to high-mannose
glycans and binding to Fc-receptors.
Dimerization of the lectin Avaren in AvFc improved upon the anti-HIV activity of
the parent lectin. Cross-clade neutralization of HIV strains (from groups M and O as well
as HIV-2) was observed with a mean IC50 value of 20 ng/mL (259 pM) in pseudovirus
neutralization assays. AvFc was also capable of neutralizing simian immunodeficiency
virus (SIV) and could recognize infected mesenteric lymph node cells isolated from
rhesus macaques. Significant anti-HIV activity was also observed using the antibodydependent cell-mediated virus inhibition assay with primary human PBMCs, indicating
that AvFc could neutralize virus by both binding and through Fc-mediated functions.
Furthermore, co-incubation with PBMCs did not induce activation of immune cells nor
did it result in cytokine release, and its administration was well tolerated in rats and
macaques, indicating a lack of major toxicity. These data together suggest that AvFc has
potent antiviral activity while lacking the toxicity typically associated with other lectins,
which warranted additional exploration of its therapeutic use against HIV and other
highly-glycosylated viruses. The activity of AvFc against hepatitis C virus (HCV) is
described in Chapter 4.

1.4.2: Anti-cancer activity and possible mechanism of action
As mentioned previously, high-mannose glycans are often enriched on the surface
of cancer cells and have been identified as aberrantly overrepresented in a number of
human cancer types (see section 1.3.2). This fact led us to hypothesize that in addition to
its antiviral activity, AvFc may selectively recognize cancer cells and exhibit anticancer
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activity, and some of the preliminary work on this indication has been described by Oh et
al. in 2021, which is currently undergoing secondary review [105]. Indeed, AvFc was
found to bind at low nanomolar concentrations to many established human cancer cell
lines from a number of tissues and could selectively discriminate between human lung
tumor tissues and adjacent tissues. This binding was dependent on the presence of highmannose glycans as digestion of the cell surface with the enzyme endoglycosidase H
(EndoH), which cleaves high-mannose glycans from proteins, nearly eliminated the
ability of AvFc to bind to A549 lung cancer cells. Further analysis of AvFc’s activity
against A549 and H460 non-small-cell lung cancer (NSCLC) revealed that by binding to
the cell surface AvFc could both induce ADCC as well as bind to and inhibit cell-surface
glycoproteins, in particular the receptors EGFR and IGF1R. This combined activity led to
AvFc exhibiting potent anticancer activity in vivo in A549 and H460 flank tumor
xenograft models, as treatment with 25 mg/kg of AvFc slowed tumor growth
substantially over time. Conversely, the FDA-approved cancer immunotherapeutic
cetuximab, which targets EGFR, only had activity against A549 tumors, illustrating the
broader range of activity of AvFc caused by binding to a glycan as opposed to an
individual receptor. Questions remain, however, as to what the predominant mechanism
of action of AvFc is, and what the relative contributions of receptor binding and ADCC
may be to this. The anticancer activity of AvFc is expanded upon in Chapters 5 and 6.

1.5: Antibody-mediated immune effector functions in cancer
Therapeutic mAbs with anticancer activity express this activity through a number
of direct and indirect mechanisms. Direct inhibition mechanisms are mediated by the

33

interaction of the antigen-binding fragment (Fab) with the target antigen on the cell
surface. A well-known example of this is the FDA-approved therapeutic cetuximab,
which targets the epithelial growth factor receptor (EGFR) found to be overexpressed in
several carcinomas. Other anticancer antibodies such as bevacizumab act by inhibiting
host processes such as angiogenesis by binding to and inhibiting the vascular endothelial
growth factor (VEGF). Antibodies also exhibit anticancer activity through their Fc
regions by interacting with complement and Fc receptor-bearing cells of the immune
system, leading to cellular activation, degranulation and phagocytosis, and target cell
death. Immune-mediated mechanisms are increasingly being recognized as major
mechanisms of action for mAb therapeutics and contribute heavily to their clinical
success. This section will discuss the three major Fc-mediated effector functions that are
generally considered integral to therapeutic antibody function in vivo.

1.5.1: The classical complement pathway
The complement system is an ancient protein-based antimicrobial system that
evolved as a part of the innate immune system and is localized to the bloodstream. It has
three major functions: induction of inflammation, the opsonization of pathogens to
facilitate uptake by phagocytic cells, and the synthesis of the membrane attack complex
to kill infected or malignant cells. The system is a complicated cascade composed of a
number of inactivated proteases called zymogens, all bearing the letter C and a number,
that are sequentially activated by proteolytic cleavage from other enzymes in the
pathway. The initial activation of the cascade is triggered following recognition of
pathogens or malignancies by pattern recognition receptors or by specific antibodies. As
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such, three pathways to complement activation have been described: the classical or
antibody-dependent pathway, the alternative pathway, and the lectin pathway. No matter
the mechanism of activation, all complement pathways lead to the generation of a C3
convertase complex on the surface of targeted cells and pathogens.
The classical pathway, so named for it being the first discovered and not because
it is the most evolutionarily ancient, is activated by the C1 protein complex (Figure 8A).
The C1 protein complex is composed of the hexameric C1q subunit, which specifically
recognizes the Fc region of antibodies (mostly IgG3), and the proteases C1r and C1s.
Upon activation these proteases cleave C2 and C4 into the C2a/b and C4a/b fragments.
The binding of C2a and C4b generates the C3 convertase complex, which rests on the
surface of the targeted cells and pathogens. As the name implies, the C3 convertase
complex cleaves C3 into C3a and C3b fragments, which the latter of which forms a
complex with C2aC4b to form the C5 convertase complex on the membrane surface. This
complex then cleaves C5 to C5a and C5b. C5b remains on the membrane surface and
recruits C6, C7, C8, and C9, which insert themselves into the membrane to form a pore
called the membrane attack complex (MAC) that causes rapid loss of membrane potential
and cell lysis. The soluble fragments C4a, C3a, and C5a are referred to as the
anaphylatoxins, named due to their ability to create an anaphylactic-like shock reaction if
overactivated. These proteins are extremely potent mediators of inflammation and do so
by enhancing phagocytic uptake of antigens and pathogens for lysis and presentation to
lymphocytes and by recruiting immune cells (in particular neutrophils) to sites of
infection or cancer.
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The complement system is an important system in the inflammatory response,
which is heavily involved in the various stages of tumor progression and oncogenesis.
The evidence however suggests that complement activation is mostly pro-tumor, which is
a counterintuitive notion given its anti-pathogenic properties [106]. For instance, C3deficient mice were shown to be protected against chemically-induced carcinogenesis
while mice lacking PTX3, an important negative regulator of complement activation,
causes susceptibility to carcinogenesis through increased inflammation [107]. One
potential explanation for this is that tumor cells evade immune surveillance by the
complement system by expressing complement receptor proteins that limits complement
activation in the tumor microenvironment [108]. Tumor cells also appear to express
anaphylatoxin receptors like C5aR and C3aR, which promote cell survival and the EMT
transition [109, 110]. There is also evidence to suggest that complement activation does
not play as much of a role in the antitumor effects of monoclonal antibody therapeutics
such as rituximab as previously thought. Deposition of complement protein C3b on B
cells was shown to completely inhibit the activity of rituximab, while its antitumor
activity was enhanced in complement-deficient mice [111, 112]. Overall, these results
seem to suggest that complement-mediated lysis is not a major mechanism of action for
therapeutic mAbs, and indeed complement activation may have significant protumor
effects.

1.5.2: Antibody-dependent phagocytosis
Antibody-dependent phagocytosis (ADP) of tumor cells primarily occurs
following the activation of FcγRI on immune cells by antibodies, but can also be induced
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by the other activating FcγRs II and IIIa in humans and IV in mice (Figure 8C) [113].
While macrophages and monocytes are the primary mediators of this phenomenon, some
evidence suggests that neutrophils also play a role in tumor phagocytosis [114]. Antibody
decoration of tumor cells results in their uptake by phagocytosing cells, which deposit
them into a specialized vacuole called a phagosome that matures and fuses with
lysosomes, which then become highly oxidative and acidic resulting in destruction of the
contents of the vacuole [115]. ADP has been demonstrated to be an important mechanism
of action for some therapeutic mAbs including the anti-CD38 mAb daratumumab, and
many tumor-associated antigens are known to induce high levels of ADP [116, 117].
Macrophage phagocytosis of tumor cells also leads to greater tumor antigen presentation,
enhancing the antitumor immune response by inducing cytotoxic T lymphocytes [118]. A
number of strategies have been developed to improve ADP functions of mAb therapies,
including CD47 blockade (inhibiting the so-called “don’t eat me” signal), FcγRIIb
blockade, and improvement of the affinity of the Fc region for FcγRI and reduction of its
affinity for the inhibitory receptor FcγRIIb [119]. Removal of the lone CH2 glycan and Fc
modification of trastuzumab, for instance, was shown to greatly enhance ADP by
increasing affinity for FcγRIIa over the inhibitory receptor [120]. Overall, the evidence
suggests an important role for macrophages in cancer therapy in the removal of
circulating tumor cells and the induction of cytotoxic responses, and antibodies that make
use of this function can potentially have greater therapeutic impact.
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1.5.3: Antibody-dependent cell-mediated cytotoxicity
Antibody-dependent cell-mediated cytotoxicity (ADCC) is a well-known
mechanism of action inducing cell death by mAbs and plays a key role in the anticancer
activity of antibodies like rituximab and trastuzumab [121, 122]. Anticancer mAbs that
target tumor-associated antigens activate ADCC by forming immune complexes that
interact with and cross-link FcγRIIIa on the surface of natural killer (NK) cells, which
results in the phosphorylation of immunoreceptor tyrosine-based activation motifs by src
kinases (Figure 8B) [123]. Activation of NK cells in this manner results in the
phosphorylation of the transcription factor NFAT, which upregulates pro-inflammatory
cytokine expression (in particular IFNγ) and induces degranulation, releasing granzymes
and perforins that permeabilize the target cell membrane and induce apoptosis by
cleaving caspase pro-enzymes [123]. The level of induction of ADCC is dependent on
both the density of the target antigen on the cell and the affinity of the Fc region for the
Fc receptor. While the density of the target antigen is largely dependent on the nature of
the antigen and of the cancer, much research by both industry and academia has been
dedicated to improving the affinity of the Fc region for FcγRIIIa as these modifications
allow for significant improvements in clinical efficacy of mAb therapeutics.
There are two major approaches to improving Fc affinity to FcγRIIIa: engineering
of the Fc region through amino acid substitutions and glycoengineering of the Fc Nglycan [124, 125]. The FcγRIIIa binds to the Fc region of IgGs (primarily IgG1) by
interacting with the hinge region between CH1 and CH2 and with the CH2 N-glycan, and
removal of this glycan obviates Fc receptor binding [126, 127]. One well-established Fc
modification that affects this interaction is the GASDALIE
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(G236A/S239D/A330L/I332E) mutation, which exhibits higher affinity for the receptor
by increasing electrostatic interactions between it and the Fc and has increased effector
functions in vivo [128, 129]. However, removal of the core α1,6 fucose from the CH2 Nglycan by host glycoengineering is the most widely recognized modification and is the
most effective approach to enhance ADCC activity [125]. Mechanistically, this may be
due to the generation of several hydrogen bonds between the normally occluded core
GlcNAc residues and the Fc receptor [126]. This concept is illustrated beautifully in the
HIV field, as naturally generated antibodies with reduced fucosylation are observed in
many HIV-specific antibodies and are generally associated with improved antiviral
activity and control of HIV replication [130]. Defucosylation can be achieved in
mammalian recombinant manufacturing platforms by knockdown or knockout of the
FUT8 gene, which as discussed previously catalyzes the addition of the core α1,6 fucose
to the inner GlcNAc residue [131]. Similar results can be achieved in plants using RNAi
to knockdown or CRISPR/Cas9 to knockout the related core-modifying
glycosyltransferases α1,3-fucosyltransferase and β1,2-xylosyltransferase (Figure 5) [132,
133]. With these modifications, therapeutic mAbs can be manufactured and
defucosylated to a high homogeneity, significantly impacting their effectiveness in vivo
and beyond.
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Figure 8. Simplified diagram of various Fc-mediated effector functions.
A) The classical complement pathway is initiated by the binding of C1q to
antibody:antigen complexes. Associated C1r and C1s proteases cleave C4 and C2 to form
the C3 convertase C2aC4b, which then cleaves C3 to form C2aC4bC3b. This complex,
also called the C5 convertase, then cleaves C5 to form C5a and C5b, the latter of which
embeds itself into the target cell membrane and recruits C6-9, forming the membrane
attack complex (MAC). B) ADCC occurs when NK cells (and other FcγRIIIa-expressing
cells, rarely) encounter antibody-opsonized target cells or pathogens, which can be
infected cells or tumors. Cross-linking of FcγRIIIa with these antibody:antigen
complexes leads to the release of cytotoxic granules containing perforin and granzymes,
which permeabilize and cause induce apoptosis in the target cell. Activation of FcγRIIIa
also activates the NFAT transcription factor, leading to pro-inflammatory cytokine
production. C) ADP occurs when phagocytes encounter antibody-opsonized target cells
or pathogens, which similarly can be infected cells or tumors. Cross-linking of FcγRI or
FcγRIIa with antibody:antigen complexes leads to envelopment and phagocytosis of the
target.
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CHAPTER 2: CANCER BIOLOGICS MADE IN PLANTS

2.1: Introduction 1
The 1997 approval of rituximab, which was the first anti-cancer monoclonal
antibody (mAb) approved for use in the U.S., began a biologic explosion that has
transformed the landscape of cancer therapy and dramatically altered and improved
patient survival and quality of life. According to the U.S. National Cancer Institute, this
broad category of pharmaceuticals includes immune checkpoint inhibitors, immune cell
therapy, therapeutic mAbs and other immune system molecules, therapeutic vaccines and
immune system modulators, which now combined make up the majority of total
pharmaceutical sales globally (with a market value of approximately 1 trillion dollars in
2016) [135]. Since 1997 hundreds of biologic drugs have been approved or clinically
evaluated, and the development of mAbs targeting immune checkpoints like PD-1 and
CTLA-4 was even the subject of the 2018 Nobel Prize in Medicine or Physiology, a
testament to the impact that biologics have had on medicine. Despite their promise,
biologic drugs remain expensive due to manufacturing costs and the lack of significant
generic competition from biosimilars (the first was only approved in 2015) [136]. Cell-
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The following chapter was reproduced for this dissertation from “Cancer Biologics
Made in Plants”, by Dent et al., with modifications made for presentability and
formatting of text. The original manuscript was published in Current Opinion in
Biotechnology in 2020 [134]. The right to reproduce for a thesis/dissertation is retained
by the author, as per publisher guidelines.
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culture based manufacturing systems are also slow to implement for initial screening and
proof-of-concept (POC) studies, prolonging preclinical development of novel drugs,
though alternative methods have some important advantages.
Cancer biologic production in plants has a long history, beginning with the early
production of mAbs against tumor-associated antigens (TAAs) like CO17-A [137]. In
contrast to transgenic plants, the recent advent of transient overexpression vectors allow
relatively short time for novel biologic drugs to be produced at scale and tested, making
plants an ideal platform for preclinical biologic development [138]. A large number of
recent advances in the field have come from the area of plant virus nanoparticles (PVNs),
particularly those derived from cowpea mosaic virus (CPMV), tobacco mosaic virus
(TMV), and potato virus X (PVX), which have shown efficacy as both
immunostimulatory agents/therapeutic vaccines and as drug delivery modalities capable
of delivering chemotherapy payloads to tumor sites in vivo. While much of the literature
is dominated by these advancements, steps have also been made towards the development
of recombinant cancer vaccines based on tumor antigens and anti-cancer lectins. This
review sets out to catalog recent advancements in plant-made cancer biologics and their
future.

2.2: Cancer vaccines and immunotherapy
The goal of cancer vaccination is to induce tumor-specific immunity and activate
immune cells in the tumor microenvironment to elicit anti-cancer activity. Cancer
vaccines are immunostimulatory agents that often make use of TAAs, which are antigens
capable of distinguishing cancer and non-cancer tissue or antigens that are overexpressed
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in cancer tissues compared to normal tissue, such as epidermal growth factor receptor
(EGFR) and its family in some cancers. One such example is human prostatic acid
phosphatase, or PAP, which is a secreted glycoprotein used historically as a marker for
prostate cancer. A recombinant PAP fused to granulocyte-macrophage colonystimulation factor (GM-CSF) is used as a part of spuleucel-T (Provenge®) vaccine, an
FDA-approved autologous cellular immunotherapy for prostate cancer [139]. To enhance
immunogenicity and expression, Kang et al. has successfully expressed PAP-fused to the
Fc region of human IgM in transgenic tobacco (Nicotiana tabacum) [140]. Other tumor
antigens that have been expressed in plants include the colorectal cancer antigen GA7332-Fc fusion with an additional KDEL receptor, which was reported to have increased
immunotherapeutic effects [141], and idiotypic antibody-keyhole limpet hemocyanin (IdKLH) conjugate vaccines for Non-Hodgkin’s Lymphoma [142-144]. More recently, a
phase I safety and immunogenicity trial of Id-KLH conjugate vaccines in 11 patients
showed that immunization resulted in a vaccine-induced, idiotype-specific cellular and
humoral immune response without any serious adverse events reported [142].
Some chronic infections are known to be risk factors for cancer. A recent report
estimated that approximately 15% (2.2 million) of 14 million worldwide new cancer
cases in 2012 were attributable to infectious agents, including Helicobacter pylori,
human papillomavirus (HPV), hepatitis B virus, hepatitis C virus and Epstein-Barr virus
[145]. Thus, vaccines against these infections have significant implications for cancer
prevention, and a number of efforts have been made for the development of plant-made
vaccines against cancer-causing pathogens. However, these vaccines are beyond the
scope of this review as they are not strictly categorized as “cancer biologics” with the
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exception of therapeutic vaccines against HPV E6 and E7 oncoproteins. HPV infection is
the cause of approximately 5% of all human cancers, in particular, malignancies of the
genitalia (penile, vulval, anal, and cervical cancers) and oral cavity [145]. The E6 and E7
proteins are ideal targets because they are constitutively expressed in HPV-associated
malignant cells and thus may be more effective at generating an immune response to
infected cells than L1-based vaccines [146]. One interesting vaccine candidate that has
been produced by transient expression in N. benthamiana is LALF32-51-E7, which is a
fusion of the HPV E7 protein to the bacterial cell-penetrating peptide LALF [147].
LALF, or Limulus polyphemus anti-lipopolysaccharide factor, can penetrate mammalian
cell membranes and has immunomodulatory properties. While plant-made LALF32-51-E7
has not been evaluated in animals, it does form the appropriate protein body-like
structures in leaf tissue and can be purified to a high degree and may be a cost-effective
therapeutic vaccine candidate [148].
Extensive work in the plant-made pharmaceutical (PMP) research field has been
dedicated to the use of PVNs as in situ vaccination/immunostimulatory agents with or
without the delivery of tumor antigen epitopes, beginning with the first POC study in
2006 with TMV-peptide fusion vaccines [149]. This strategy ultimately aims at the
reactivation of tumor-suppressed immune cells in the tumor microenvironment and the
induction of systemic anti-cancer immunity. The most well-studied of these PVNs are
derived from CPMV, which have demonstrated efficacy in murine 4T1 breast, CT-26,
colon, B16F10 melanoma, GL261 glioma, and ID8 ovarian cancer models [150-155].
The icosahedral structure of CPMV appears to be more efficiently taken up by antigen
presenting cells (APCs), resulting in higher APC activation and better transport of PVNs
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to and retention in lymph nodes than high-aspect-ratio viruses like PVX [151, 156].
Additionally, as has been recently demonstrated, in situ vaccination can result in the
conversion of immunosuppressive cells like M2 macrophages and N2 neutrophils to their
M1 and N1 counterparts, helping to break tumor immunotolerance [153]. What remains
to be seen is the potential efficacy of these particles in humans, as mouse models in these
studies used immunodeficient mice for human cancer xenograft, which may have a
limited predictive value for immunotherapeutic effects in humans. Nevertheless, the
results obtained in recent years hold much promise for their development.
Plants have long been used as production platforms for cancer-targeting
immunotherapeutics, including mAbs and cytokines. One such example is the production
of CCL21 in tomato, which may potentially be used as an anti-metastatic agent for many
cancer types [157]. Recently, several groups have published the production of anti-cancer
mAbs including the anti-HER2 mAb trastuzumab [158], the anti-GA733 mAb C017-1A
[159], and the anti-CD20 mAbs ofatumumab and rituximab [160, 161], as well as an antiHER2 single chain variable fragment-Fc (scFv-Fc) fusion [162]. Importantly,
trastuzumab and rituximab were produced in glycoengineered plants and showed greater
anti-cancer activity owing to the lack of core fucose on the single N-glycan in the Fc
region, which increases the affinity for FcγRIIIa and potently elicits antibody-dependent
cell-mediated cytotoxicity [163]. Similar increases in Fc effector functions were also seen
for a plant-produced anti-CD20-hIL-2 immunocytokine, made by the fusion of an antiCD20 mAb and human IL-2 [164]. The resulting immunocytokine was also highly
efficient at activating T cells, potentially resulting in greater cytotoxic T cell responses
against malignant cells. The relative ease of plant glycoengineering compared to
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mammalian or insect cell culture systems make them a useful alternative for mAb
production [133].

2.3: Drug delivery and imaging
Considerable research has been conducted into novel drug delivery systems, with
the goal of improving the pharmacokinetics and pharmacodynamics of small molecule
and biologic drugs by affecting their absorption and distribution in the body. PVNs have
been particularly attractive owing their ability to deliver larger payloads than antibodydrug conjugates, the relative ease at which they can be decorated with targeting ligands
for tissue-specific delivery of drugs, the wide array of possible chemistries, and the ease
of manufacturing them in planta. So-called high-aspect-ratio viruses, like TMV and
PVX, are particularly useful as they are not taken up as easily by phagocytosis and may
have a prolonged serum half-life compared to icosahedral viruses. Several recent reports
have described PVNs for chemotherapeutic and imaging reagent delivery, including those
derived from TMV [165-170], PVX [171-173], red clover necrotic mosaic virus
(RCNMV) [174], Pepino mosaic virus (PeMV) [173], and Johnsongrass chlorotic stripe
mosaic virus (JgCSMV) [175, 176].
Much of the recent work regarding PVNs as drug delivery modalities has focused
on the use of high-aspect ratio, or filamentous, viruses. Among these, TMV PVNs have
been extensively researched and used in medical imaging and animal models of cancer.
Notably, Franke et al. demonstrated that the conjugation of cisplatin to tobacco mosaic
virus PVNs restored the efficacy of the chemotherapeutic to OVCAR3 cells, which are
typically cisplatin resistant [169]. Because resistance to cisplatin is common among
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patients with recurrent ovarian cancer [177], the results justify further preclinical
validation. Similarly, PVX particles loaded with doxorubicin or presenting tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) have also shown to be
efficacious in mice xenografted with the human breast cancer cell line MDA-MB-231
[171, 172]. PVX however may have less desirable pharmacokinetic and tumor homing
properties compared to another filamentous virus, PeMV [173]. Overall, much work
remains to demonstrate how these particles end up at the tumor site and how that can be
improved, in addition to further demonstration of efficacy in animal models.
A number of icosahedral viruses have also been used as drug delivery systems,
including RCNMV and JgCSMV. While icosahedral virus particles have short serum
half-life as efficiently taken up by the immune system, these PVNs appear to have
excellent tumor penetration and drug carrying capacity. For example, RCNMV particles
loaded with doxorubicin showed more efficacy at a lower dose in an SKOV3 human
ovarian cancer xenograft model than the pegylated liposomal form of the drug, indicating
a greater degree of tumor targeting by the PVNs [174]. Alemzadeh et al. also recently
demonstrated the loading of JgCSMV particles with doxorubicin and their efficacy in the
MCF-7 human xenograft breast cancer model in mice [175, 176]. Interestingly,
encapsulation of drug in JgCSMV particles led to increased uptake of doxorubicin in the
breast cancer tissue and actually led to decreased cardiotoxicity [175].
Many recent advances have come in the area of medical imaging. TMV PVNs
have, for example, been successfully conjugated to the contrast agent dysprosium and
used to image prostate cancer cells in mice using both ultra-high-field magnetic
resonance and near-infrared fluorescence imaging [167]. Serum-albumin-coated particles,
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which may reduce the potential immune response to the TMV, have also been
characterized and used to deliver doxorubicin and the contrast agent gadolinium in mouse
models of human breast cancer. Dubbed a “theranostic”, this approach successfully
combined treatment and MRI imaging, demonstrating the dual capacity of PVNs and
their superiority over conventional drug-delivery modalities.

2.4: Anti-cancer lectins
Lectins are a diverse group of carbohydrate-binding proteins that have garnered
much interest for their potential immunomodulating and cancer-targeting abilities. In
recent years, a great number of fungal and plant lectins with anti-cancer activity have
been isolated, characterized, and described in the literature [178, 179]. Plant lectins in
particular have been historically important as alternative or adjuvant therapies for cancer
especially in Europe, where arguably the most well-known is a lectin-containing extract
from European mistletoe (Viscum album). One of the active ingredients in the extract,
viscumin (also called mistletoe lectin or ML), is a holotoxin consisting of a single
ribosome-inactivating A chain and a single sialic acid-specific lectin B chain covalently
linked with a disulfide bond [180, 181]. Though a comprehensive systematic review of
the use of mistletoe extract in addition to chemotherapy concluded that it offered no
additional benefit in terms of survival or quality of life, isolated viscumin may still have
useful anti-cancer activity in vivo [182-184]. To this end, Gengenbach et al. recently
published the expression and purification of recombinant viscumin in N. benthamiana,
with a yield of ≈ 7 mg/kg fresh weight. The plant-derived lectin exhibited greater
cytotoxicity to THP-1 cells than E. coli-made viscumin and was significantly more cost
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effective to produce [185]. While promising, further in vitro and in vivo studies are
warranted to demonstrate efficacy in multiple models and to demonstrate the selectivity
of viscumin for cancer over healthy tissue. Additionally, improvements in yield are
necessary to facilitate preclinical development.
Cholera toxin B subunit (CTB) is a non-toxic lectin component of the holotoxin
that recognizes the Galβ1–3GalNAc moiety of GM1 ganglioside found on the surface of
intestinal epithelial cells (where the toxin normally exerts its activity). We have recently
demonstrated that oral administration of a CTB variant (containing a KDEL endoplasmic
reticulum retention motif) produced in N. benthamiana can facilitate mucosal healing and
reduce tumorigenesis in a colitis-associated colorectal cancer mouse model [186].
Epidemiological evidence has pointed to an increase in colorectal cancer incidence in
inflammatory bowel disease patients [187, 188]. Thus, the plant-made CTB variant as a
treatment for chronic intestinal inflammation may also have anti-cancer properties that
should be investigated further.
Lastly, aberrant glycosylation has been recognized a hallmark of cancer, and in
particular high-mannose glycans have been demonstrated to be over-represented in the
glycocalyx of many human cancers [189, 190], making them a potentially useful
biomarker or druggable target [191]. Our lab has recently developed Avaren-Fc, a plantproduced “lectibody” targeting a cluster of high-mannose glycans that are widely found
on the surface of enveloped viruses and malignant cells [98, 192]. While originally
developed as an anti-HIV agent, we observe that Avaren-Fc also has strong anti-cancer
activity in vitro and in human cancer cell xenograft and syngeneic mouse models (Dent
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and Matoba, unpublished), highlighting the druggability of HIV- and tumor-associated
high-mannose glycans.

2.5: Conclusions
Transient expression of proteins in plants is a powerful method for the rapid,
robust production of recombinant proteins, which will significantly facilitate the
preclinical development of biosimilar, biobetter and innovator anti-cancer proteins as
well as vaccines. PVNs show promise as immunostimulatory agents, drug delivery
platforms and imaging probes. Since aberrant protein glycosylation is a hallmark of
cancer [2, 193], plant-derived lectins and their derivatives such as “lectibodies” may have
unique potential as cancer biologics.
As regulatory frameworks for plant-based biomanufacturing system are
becoming well established [142, 194-197], the technology has finally come of age. In
addition to transient expression, other technologies based on transgenic plants and plantcell culture offer some potential advantages that may facilitate the commercialization of
plant-made biologics. Transgenic plants, for instance, offer greater scalability and simpler
upstream processing, while plant-cell culture is similar to existing platforms that are wellestablished in the pharmaceutical industry, allowing for the adaptation of conventional
chemical engineering and regulatory approaches. Though there are still challenges to be
addressed in regard to plant growth conditions, transgene expression regulation, posttranslational modifications, and product isolation and recovery, we will soon witness
some plant-made cancer biologic products being tested for their clinical efficacy – the
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most important step that will further cement plants as a viable alternative to other more
established production methods.
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CHAPTER 3: METHODS AND MATERIALS

Animal studies
The use of animals throughout this dissertation was approved by the University of
Louisville’s Institutional Animal Care and Use Committee (protocols 20714, 21910,
18910, and 15009). Studies conducted by PhoenixBio Co., Ltd., in their facilities were
approved by its internal Animal Ethics Committee (resolution 2281). Regardless of study
location, all animals were given a standard diet and water ad libitum and were housed in
a temperature- and humidity-controlled facility with a 12-hour day/night cycle. Prior to
the beginning of each study, animals were acclimated to their environment for one week.

Cell culture
B16F10, Huh-7, HEK-293T, CAOV3, SKOV3, A2780, and SW626 cells were
acquired from the American Type Culture Collection (Manassas, VA) and cultured in
high-glucose Dulbecco’s Modified Eagle Medium (DMEM) containing L-glutamine and
sodium pyruvate supplemented with 10% fetal bovine serum and 1X
penicillin/streptomycin. The engineered Jurkat cells used in the ADCC reporter assay,
which constitutively express human FcγRIIIa as well as firefly luciferase downstream of
an NFAT response element, were obtained from Promega (Madison, WI) and cultured
according to the manufacturer’s protocol. The murine ovarian cancer cell lines ID8 and
ID8-luciferase were a generous gift from the labs of Dr. Zong Seng at the University of
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Pittsburgh School of Medicine and Dr. Steven Fiering at the Geisel School of Medicine at
Dartmouth University. ID8 cells were cultured in DMEM containing L-glutamine and
sodium pyruvate supplemented with 4% FBS, 1X insulin-transferrin-selenium solution,
and 1X penicillin and streptomycin. ID8-luciferase cells were additionally maintained
with 1 μg/mL blasticidin. Each cell line was tested for mycoplasma using ATCC’s
Universal Mycoplasma Detection Kit, and to prevent contamination between tests the
antibiotic Normocin™ (Invivogen, San Diego, CA) was routinely added to the culture
medium according to the manufacturer’s specifications. All cell lines were maintained at
37°C with a 5% CO2 atmosphere.

Plant growth
Nicotiana benthamiana was grown in a temperature-controlled room kept at a low
humidity, with fluorescent lighting timed to a 16/8-hour day/night cycle. Plants were
seeded into new 4-inch pots containing damp Jiffy Coco Mix, with 3-5 seeds per pot.
Following seeding, plants were fertilized with diluted Peters Peat-Life Special 17-3-17
(nitrogen-phosphate-potash) fertilizer, covered with plastic wrap and allowed to
germinate for 12 days, after which they were thinned and separated to a lower growth
density. Fertilization and watering continued every other day until 4 weeks of age, at
which point plants were ready for agroinfiltration.

Expression in and purification of Avaren-Fc and variants from N. benthamiana
Table 1 summarizes the variants of AvFc used throughout this dissertation. Each
variant was expressed in and purified from wild type N. benthamiana plants with the
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exception of AvFcΔXF, which was expressed in a glycoengineered line of plants
containing RNAi knockdowns of β1,2-xylosyltransferase and α1,3-fucosyltransferase,
which are hereafter referred to as ΔXF plants. Recombinant expression in plants was
performed by agroinfiltration using the deconstructed tobacco-mosaic-virus-derived
three-component vector system magnICON® and purified with Protein A and ceramic
hydroxyapatite (CHT) resins on an ÄKTA Pure fast protein liquid chromatography
(FPLC) system (Cytiva Life Sciences, Marlborough, MA). The three-component vector
system consists of 3 modules: a 5’ plasmid that contains promoter elements, a 3’plasmid
that contains the gene of interest (in this case AvFc) as well as terminator elements, and
an integrase plasmid which combines the two in planta to create an RNA replicon which
drives the high-level expression of the target gene. Each of these plasmids is maintained
in separately transformed Agrobacterium tumefaciens GV3101 lines, which are combined
prior to agroinfiltration of leaf tissue. In addition to this, each variant of AvFc has an Nterminal signal peptide derived from rice α-amylase to direct nascent peptides to the ER
for processing in the endomembrane system.
For agroinfiltration, 3 transformed A. tumefaciens GV3101 1 mL frozen stocks,
each containing one of the aforementioned plasmids, were individually cultured
overnight at 30°C in 150 mL of LB medium containing rifampicin (50 μg/mL) and
carbenicillin (100 μg/mL). The following morning, bacteria were collected by
centrifugation at 6000 xg for 10 minutes, and the culture medium was decanted and
replaced with 15 mL of MES agroinfiltration buffer (10 mM MES hydrate, 10 mM
MgSO44 heptahydrate, pH 5.5). The concentration of bacteria in this buffer was
determined by measuring the optical density at 600 nm (OD600) on a Nanodrop One C
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(Thermo Fisher Scientific, Waltham, MA). Each of the three bacterial solutions was then
diluted in 5 L to a final OD600 value of 0.03, making the total OD600 of the final
agroinfiltration solution ≈ 0.1. This mixture was then introduced to N. benthamiana leaf
tissues using the vacuum method [198]. Briefly, plants were submerged in the
agroinfiltration buffer inside a vacuum tank under a vacuum for 3-5 minutes to draw air
out of the leaf tissues, at which point the chamber was slowly repressurized to force the
buffer into the interstitial spaces. Infiltrated plants were placed back into the growth
chamber and maintained as described above for 7 days.
After incubation in the growth chamber, leaf tissues were harvested, weighed, and
homogenized in an extraction buffer (20 mM NaPi, 40 mM ascorbic acid, pH 7) at a ratio
of 2 mL of buffer per gram of tissue weight using a stainless-steel blender. Crude extract
was first filtered using a layer of cheesecloth and miracloth, then the pH of the filtrate
was lowered to ≈ 5.2 using HCl and clarified by centrifugation at 15,000 xg for 10
minutes at 4°C. The clarified supernatant was decanted and neutralized with NaOH, then
clarified again in the same manner before being filtered through a 0.2 μm vacuum filter.
This material was then applied to a protein A column at a flow rate calculated to allow
for a 2-minute residence time with the resin. Unbound material was washed away using
10 column volumes (CVs) of 5 mM NaPi at pH 7 and elution was performed using 10
CVs of 2 M arginine at pH 3, which was applied to the column in a single step and
collected into 5 mL fractions and neutralized with 1 M tris base.
Elution fractions containing protein, as determined by the FPLC system’s
spectrophotometer, were combined and diluted 20x with deionized water before being
applied to a CHT column at a flow rate calculated to provide a 2-minute residence time
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with the resin. The columns were washed with 10 CVs of 5 mM NaPi at pH 7 and eluted
with a gradient from 5 mM NaPi and no salt to 5 mM NaPi with 1 M NaCl over 10 CVs,
collected into 5 mL fractions. Columns were stripped with 5 CV of 5 mM NaPi and 2 M
NaCl before being cleaned with and stored in 0.1 M NaOH. Fractions containing protein
were then combined and concentrated on a 30 KDa MWCO centrifuge filter (Millipore
Sigma, Burlington, MA) before endotoxin removal by phase separation (see below).
Endotoxin-free protein was then formulated into a histidine buffer (30 mM histidine, 100
mM sucrose, 100 mM NaCl, see below for details) on a 30 KDa MWCO centrifuge filter
before being filter sterilized and stored at -80°C. The purity of the protein was confirmed
by SDS-PAGE and densitometry analysis (see below).
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Variant
AvFcWT

AvFcΔXF

AvFcCHO

Description of variant
Normal AvFc expressed in wild type N. benthamiana
plants. Displays plant-specific glycans containing β1,2xylose and α1,3-fucose at the CH2 N-glycan site (N200).
Expressed in a stable ΔXylT/ΔFucT RNAi knockdown
line of N. benthamiana plants (ΔXF) [133]. Contains
primarily terminal GlcNAc residues (GnGn) and lacks
plant-specific glycans.
Expressed and purified from Chinese hamster ovary
(CHO) cell culture. Contains mammalian glycans
(importantly, core α1,6-fucose).

Function
“Normal”
function
Increased ADCC
activity
“Normal”
function

Disables Fcmediated
AvFcΔgly
effector
functions
A series of three point mutations in the lectin Avaren
Removes highAvFcΔlec (Y32A, Y70A, Y108A). May also be referred to as
mannose binding
lecAvFc .
activity
Table 1. Definition and description of AvFc variants used in these studies.
A single asparagine to glutamine substitution (N200Q)
which renders the CH2 domain of AvFc aglycosylated.
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Endotoxin separation by phase separation
Endotoxin was removed from proteins using triton X-114 phase separation. The
detergent was first added to the protein solution to a final concentration of 2%, mixed
vigorously, and then incubated on ice for 30 minutes. Samples were then incubated at
37°C for 10 minutes and centrifuged at the same temperature at max speed for 20-30
minutes. The aqueous endotoxin-poor layer was removed by careful pipetting. To remove
residual detergent, 5 g of Bio-Beads (Bio-Rad Laboratories, Hercules, CA) per 25 mL of
solution was then added and incubated at room temperature for 2 hours. The protein
sample was then removed by pipetting and endotoxin levels were measured using the
Limulus Amebocyte Lysate test on an Endosafe PTS system (Charles River, Wilmington,
MA).

Glycan analysis
The N-linked glycans were released from 1 mg of purified recombinant AvFc by
hydrazinolysis (Fujiyama et al., 2006). After N-acetylation with saturated sodium
bicarbonate and acetic anhydride, the hydrazinolysate was desalted using Dowex 50 × 2
(Muromachi Kagaku Kogyo Kaisya, chuo-ku, Tokyo, Japan), and lyophilized. The
oligosaccharides obtained were pyridylaminated (PA) as described previously (Kondo et
al., 1990; Fujiyama et al., 2006). PA-sugar chains were purified by HPLC and monitored
on the basis of the fluorescence intensity (λexc = 310 nm, λem = 380). For RP-HPLC,
PA-sugar chains were eluted from a Cosmosil 5C18-AR-II column (Nacalai Tesque,
Nakagyo-ku, Kyoto, Japan) by linearly increasing the acetonitrile concentration in 0.02%
trifluoroacetic acid (TFA) from 0% to 4% for 35 min at a flow rate of 1.2 mL/min. For
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SF-HPLC, using an Asahipak NH2P-50 4E column (Showa Denko), the PA-sugar chains
were eluted by linearly increasing the water content of the water–acetonitrile mixture
from 26% to 50% for 20 min at a flow rate of 0.7 mL/min.

SDS-PAGE analysis of AvFc
Purity of AvFc was determined by SDS-PAGE using 4-20% Bio-Rad MiniPROTEAN™ gels and Coomassie Brilliant Blue (CBB) staining. 10-15 μg of protein was
mixed with Laemmli sample buffer and run in a tris-glycine-SDS running buffer (25 mM
tris, 192 mM glycine, 0.1% SDS, pH ≈ 8.5) at 200 V for 35 minutes under denatured and
reducing or non-reducing conditions (with or without 1% 2-mercaptoethanol). After gels
were removed from their cassettes they were washed with water and stained for 20
minutes with Coomassie stain (0.3% Coomassie Brilliant Blue, 45% methanol, 10%
acetic acid). Stained gels were washed and placed in a destaining buffer (12% ethanol,
10% acetic acid), heated for 1 minute in a microwave, and left to destain with gentle
agitation until the background was clear. Gels were imaged on an Amersham Imager 600
(Cytiva Life Sciences). Densitometry analysis to estimate purity was performed using Gel
Analyzer software (www.gelanalyzer.com, by Istvan Lazar, Jr., and Istvan Lazar, Sr.).

Hepatitis C neutralization assay
To produce cell-culture-derived hepatitis C virus (HCVcc), we used a modified
version of the plasmid encoding a genotype 2a virus JFH1 genome backbone provided by
Dr. Takaji Wakita from the National Institute of Infectious Diseases in Tokyo, Japan
[199]. The H77/JFH1 genotype 1a/2a chimeric virus was generated as described by
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Maurin et al. [200]. Chimeras from genotype 4a (ED43/JFH1), genotype 5a
(SA13/JFH1), and genotype 6a (HK6a/JFH153) were provided by Dr. Jens Bukh from
the University of Copenhagen in Copenhagen, Denmark [201-203]. Viral
pseudoparticles (HCVcc) using an HIV-derived lentivirus backbone and bearing the
envelope glycoproteins from genotype 2a JFH1 strain, as well as expressing the Firefly
luciferase reporter gene, were produced in HEK-293T as previously described [204]. The
inhibitory effects of AvFc were determined by quantifying its impact on infectivity with
indirect immunofluorescence of infected Huh-7 cells, using the anti-E1 monoclonal
antibody A455 or an anti-NS5A polyclonal antibody kindly provided by Dr. Mark Harris
from the University of Leeds in Leeds, UK to identify and count infected foci. IC50
values were calculated by 4 parameter non-linear regression.

Optimization of AvFc formulation buffer
In order to determine a more suitable buffer for drug stability and in vivo studies,
we performed an initial buffer screening of AvFc in 30 mM glutamate, acetate, citrate,
succinate, histidine, tris, and phosphate buffers with pH values ranging from pH 4.5-7.5.
These buffers are summarized in Table 3. All buffer agents were acquired from
Millipore-Sigma (Burlington, MA). For each buffer, AvFc was diafiltrated using a 30
KDa MWCO centrifuge filter and adjusted to a final concentration of 1 mg/mL (≈ 13
μM). Stability in these initial conditions was determined by SDS-PAGE after incubation
for 2 weeks at 37°C. Melting temperatures of AvFc were determined by differential
scanning fluorimetry (DSF) which was performed on an Applied Biosystems
StepOnePlus qPCR system. Using a 96-well template, AvFc in various buffers was made
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to a concentration of 50 μM and mixed with 50x SYPRO Orange dye (Thermo Fisher
Scientific) before slowly heating to 98°C, which exposes hydrophobic regions in the
protein and allows the fluorescent dye to bind. The melting temperature was defined as
the vertex of the first derivative of the relative fluorescence values in the resulting melt
curves. To compare the stability of AvFc in the optimized histidine buffer and in PBS,
the drug was formulated in each buffer to a concentration of 10 mg/mL (≈ 130 μm) and
incubated at 4°C or room temperature. Measurements of the absorbance at 280 nm and
600 nm were made prior to incubation, at 16 hours, and again after 72 hours. A280
measurements were made after centrifuging any precipitates. Accelerated degradation
was assessed by overnight incubation of AvFc in either buffer at 56°C and SDS-PAGE.

Pharmacokinetic analyses
A pharmacokinetic profile for AvFcΔXF was generated following a single 25
mg/kg intraperitoneal injection in male and female C57bl/6 mice (The Jackson
Laboratory, Bar Harbor, ME). Equal numbers of males and females were used, with n=4
animals per time point. Blood was sampled at 0.5, 1, 2, 4, 8, 12, 24, and 48 hours after
injection by either submandibular vein or cardiac puncture. The pharmacokinetics of
AvFcWT were separately assessed in both male and female C57bl/6 mice using a modified
version of the protocol described by Joyce et al. [205]. AvFc was administered
intravenously at a dose level of 10 mg/kg followed by blood sampling via tail vein at
regular intervals (0.5, 1, 3, 9, 24, and 72 hours). For serial tail blood sampling, animals
were warmed under a heat lamp and a 25 G needle was used to prick the vein beginning
at the most distal end of the tail and moving more proximally for each subsequent
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sample. Using a glass microcapillary tube (Drummond Scientific Company), 10 μL was
collected and mixed into 90 μL of an anticoagulant solution containing DPBS and 1.5
mg/ml Na2EDTA. Diluted blood was then spun down at 1500 g for 10 minutes. The
concentration of AvFc in the serum for both variants was then determined by gp120
ELISA (described below) using purified AvFc as a standard. Pharmacokinetic parameters
for both were calculated from these measurements using PK Solver [206].

Hepatitis C challenge and toxicological analysis of AvFc in PXB-mice®
The mouse model of toxicological analysis and HCV infection and toxicological analysis
was performed in PXB-mice® (cDNA-uPAwild/+/SCID, cDNA-uPAwild/+: B6;129SvEvPlau, SCID: C.B-17/Icr-scid/scid Jcl; reviewed in: [207]) by PhoenixBio Co. These mice
contain transplanted human hepatocytes with a replacement index of greater than 70% as
determined by blood human albumin (h-Alb) measurements prior to virus inoculation
[208]. Blood h-Alb levels indicate the level and integrity of human hepatocyte
engraftment in the mouse liver. Mice were separated into 3 treatment groups: AvFclec- (25
mg/kg, n=5) for 11 doses, or AvFc (25 mg/kg, n=5 each) for 8 or 11 doses. The initial
treatment was co-administered i.p. with virus inoculation (5 x 105 copies/kg) on day 0
with a genotype 1a strain (PBC002), and treatment continued every other day thereafter.
The general conditions and body weights of the animals were monitored every other day,
while serum HCV RNA and blood h-Alb were measured every 7 days by RT-PCR and
latex agglutination immunonephelometry (LZ Test “Eiken” U-ALB, Eiken Chemical Co.,
Ltd.) respectively. The HCV RNA RT-PCR assay was developed based on a method
described by Takeuchi et al. [209] with modifications and validated by PhoenixBio for
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use in this animal model. The lower limit of quantification was determined to be 4.0 x 104
copies/mL. Serum alanine aminotransferase 1 (ALT) levels were determined either using
a Fujifilm DRI-CHEM NX500sV clinical chemistry instrument or by ELISA (Institute of
Immunology Co., Ltd., Tokyo, Japan). At the study termination on day 35, animals were
euthanized and subject to gross necropsy and general health. Blood was also drawn via
cardiac puncture and used for ALT, HCV RNA, and h-Alb analyses.

Histopathologic analysis of liver tissues
Hematoxylin and eosin-stained liver sections from 3-4 mice per group were
generated by Nara Pathology Research Institute Co., Ltd. (Nara, Japan) and evaluated by
pathologists at SkyPatho, LLC. All slides were examined by a blinded, board-certified
veterinary pathologist under a light microscope (BX43, Olympus Corporation, Tokyo,
Japan). The tissues were assigned a severity score for a number of characteristics based
on the 5-point scoring system of the CDISC SEND Controlled Terminology where 0:
unremarkable, 1: minimal, 2: mild, 3: moderate, 4: marked; 5: severe; and P: present.

Detection of AvFc using a gp120-coated capture ELISA
Recombinant envelope glycoprotein gp120 from HIV-1 (strain CM235, NIH Aids
Reagent Program) was coated overnight at 4°C at 0.3 μg/mL in carbonate buffer, pH 9.5.
After coating, wells were blocked with PBST containing 5% dry milk for 1 hour at 37°C.
AvFc variants were then incubated on the plate beginning at 13 nM with 1:5 serial
dilutions for 1 hour at 37°C, followed by detection with a goat anti-human IgG-HRP
(Southern Biotech 2040-05, Birmingham, AL). Plates were developed for 5 minutes with
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TMB substrate (VWR 95059-286), with development stopped with an equal volume of 2
N sulfuric acid and plates read at 450 nm. To measure the concentration of AvFc in
serum, purified AvFc at 13 nM with 1:5 serial dilutions was used as a standard curve and
compared to serial 1:10 dilutions of serum. Dose-response curves were fit with 4parameter non-linear regression in GraphPad Prism which were used to calculate EC50
values or to interpolate unknown values.

Flow cytometry to assess cancer cell binding
B16F10 and other cancer cells were harvested and stained with AvFc variants at
150, 15, and 1.5 nM followed by detection with a goat anti-human Fc FITC secondary
antibody (Abcam, Cambridge, UK) at 1:200 and fixation in 4% formalin. Unstained cells
incubated with the secondary antibody only and AvFcΔlec (150 nM) were used as controls
to determine background. To detect anti-tumor antibodies, B16F10 cells were stained
with a 1:10 dilution of animal serum followed by detection with a 1:1000 dilution of a
goat anti-mouse Fc FITC secondary (Abcam) and fixation with 4% formalin. Flow
cytometry was performed on a BD FACSCalibur and all data were analyzed in FlowJo.
Statistical comparisons were made with One-way ANOVA followed by multiple
comparisons with Tukey’s multiple comparison test.

ADCC reporter assay
B16F10 and other cancer cells were plated at 10,000 cells/well on a solid white
96-well plate and incubated overnight at 37°C to allow attachment. The following day
AvFc or its variants were serially diluted (from 650 nM to 8.32 pM in 1:5 steps) in
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ADCC assay buffer, which consisted of RPMI-1640 medium supplemented with 1%
Ultra Low IgG Fetal Bovine Serum (VWR) and added to the wells. To determine the
effect of ADA-containing serum on ADCC activity, serum was added to the assay buffer
to a concentration of 5%. To determine ADCC activity of ATAs in serum, 1:5 serial
dilutions of serum were made beginning from 5%. Jurkat effector cells, which were also
suspended in ADCC assay buffer, were then added to each well to give a total
effector:target cell ratio of 15:1 (150,000 cells) and incubated overnight. After
incubating, culture medium was carefully removed, and luminescence was measured on a
BioTek plate reader using the Britelite Plus Reporter Gene Assay System (Perkin Elmer,
Waltham, MA). Each assay included a no drug control and a cell only control, with and
without 5% serum as necessary. Fold luminescence induction was plotted against the log
drug concentration and was calculated as the ratio between the relative luminescence
units (RLUs) of the wells containing drug and the average RLU values for the no drug
control. The resulting dose-response curves were fit with a 4-parameter non-linear
regression model in GraphPad Prism to calculate the EC50.

MTS cell viability assay
B16F10 cells were plated at 5,000 cells per well and incubated with AvFc
(beginning at 650 nM with 1:5 serial dilutions) for 48 hours. The toxic mannose-binding
lectin Concanavalin A was used in equimolar concentrations as a positive control. After
incubation, 20 μL of MTS reagent (Abcam) was added to each well and incubated for 4
hours, at which point the reaction was stopped by adding 10 μL of 10% SDS. Plates were
then read in a BioTek plate reader at 490 nm. Percent viability was calculated relative to
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untreated controls and plotted against concentration. Dose-response curves were fit using
non-linear regression in GraphPad Prism to calculate IC50 values.

Annexin V/propidium iodide staining of apoptotic cells
B16F10 cells (1.5x105 cells/well) were seeded into 6 well plates with AvFc
variants or concanavalin A at 650 nM and incubated for 48 hours at 37°C. Following
incubation cells were harvested and stained with an annexin V-488A (ANXV) conjugate
and propidium iodide (PI) according to Rieger et al. [210]. Briefly, cells were stained
with 2.5 μg/mL annexin V conjugate and 2 μg/mL PI for 15 minutes each at room
temperature in the dark. Following fixation with a 1% formalin solution, cells were
incubated with 50 μg/mL RNase A and measured on a BD FACSCalibur flow cytometer.
Apoptotic cells, in the early and late stages, were defined as ANXV+/PI- and
ANXV+/PI+, respectively, with unstained cells used to define the quadrant gates. Data
were processed and analyzed using FlowJo, and statistical comparisons between groups
were made with 2-way ANOVA with p=0.05 as the threshold of significance.

Surface plasmon resonance for FcγR binding
Surface plasmon resonance experiments were performed on a Biacore T200
(Cytiva Life Sciences). Binding affinity of AvFc for human FcγRIIIa (hFcγRIIIa) and
mouse FcγRIV (mFcγRIV) was assessed using a 6xHis-capture approach. To achieve
this, an anti-6xHis-tag monoclonal antibody (Thermo Fisher Scientific) at 50 μg/mL was
conjugated via amine linkage to two parallel flow cells on the surface of a CM5 chip at ≈
10,000 response units (RUs). Recombinant Fc receptors obtained from R&D Systems
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were captured by flowing them over the chip surface at 5 μg/mL for 60 seconds with a
flow rate of 10 μL/min. A second flow cell was used for reference subtraction and was
not used to capture the receptors. AvFc variants (ΔXF, WT, Δgly) were flowed over both
cells at multiple concentrations with a flow rate of 30 μL/min, using an association time
of 240 seconds and a dissociation time of 600 seconds. For both hFcγRIIIa and
mFcγRIV, 5 concentrations of AvFc were used to measure affinity starting at 2 μM with
1:2 serial dilutions, repeating the middle concentration and including a blank cycle.
Regeneration was performed by washing the chip surface for 60 seconds at a flow rate of
30 μL/min with glycine at pH 1.5. Sensorgrams were fit with a 1:1 binding model with
Rmax set to fit local using the Biacore Evaluation software.
For hFcγRI, recombinant receptor was captured on the surface of an NTAconjugated chip following a 60 second injection of Ni2+ at 0.5 mM. The receptor was
captured by flowing at 10 μL/min at a concentration of 1 μg/mL for 100 seconds to
achieve a capture level of ≈ 200 RUs. A second flow cell was left blank for reference
subtraction. 5 concentrations of AvFc were used to measure affinity starting at 324 nM
with 1:3 serial dilutions, repeating the middle concentration and including a blank cycle.
Regeneration was performed by washing the chip surface for 60 seconds at a flow rate of
30 μL/min with 350 mM EDTA. Sensorgrams were fit with a 1:1 binding model with
Rmax set to fit local using the Biacore Evaluation software.

PET/CT imaging
The in vivo tumor-targeting property of AvFc was determined with radiolabeled
AvFc (64Cu-NOTA-AvFc) in B16F10 melanoma-bearing C57bl/6 mice using small
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animal PET/CT. The mice (n = 2) were each subcutaneously inoculated with 1x106
B16F10 cells on the right flank to generate tumors. The animals were submitted to
imaging when tumor weights reached approximately 0.2 g at 10 days post-cell
inoculation. Approximately 3.7 MBq of purified 64Cu-AvFc was injected into each mouse
via the tail vein. The mice were scanned with small animal PET and CT at 24 h postinjection. A ten-minute CT scan (MicroCAT II) was immediately followed by 30 min
PET imaging on MicroPET (Siemens R4) using the same animal bed. The PET and CT
data obtained were reconstructed and merged by the Siemens IRW software.

B16F10 flank tumor challenge model
On day 0, 100,000 B16F10 cells in 100 μL of DPBS was injected subcutaneously
into the hind left flank of each C57BL/6 mouse. Intraperitoneal administration of 200 μL
of AvFc, AvFcN200Q, or vehicle (AvFc formulation buffer, see above) at the indicated
dose level began on day 5 and continued Q2D until day 16. Tumor measurements were
taken every other day from day 1 using digital calipers, and tumor volume was estimated
as: tumor width x tumor height2.
To determine the impact of anti-drug antibodies on the efficacy of AvFc in this
model, groups of animals were pre-pretreated with 6 doses of AvFc at 25 mg/kg Q2D
followed by tumor implantation 11 days after the final dose (day 21). Treatment with
AvFc was then performed as before, beginning on day 5 and continuing Q2D for a
maximum of 6 doses. The primary endpoint was survival, defined as the time until
animals reached a tumor volume of 1500 mm3, at which point the animal was euthanized.
Blood was collected to determine anti-drug antibody titers on day -1 and day 20 via
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submandibular vein before pretreatment and before B16F10 implantation, and again via
cardiac puncture at the time of euthanasia. Survival curves were compared using the
Mantel-Cox test in GraphPad Prism. Multiple comparisons of individual survival curves
were made using the Mantel-Cox test, which was corrected using the Bonferroni method
(corrected p value threshold was 0.0083).

Immunophenotyping of B16F10 tumor-infiltrating immune cells
Immunophenotyping was performed with the assistance of Dr. Noel Verjan
Garcia, who also performed the gating. B16F10 melanoma cells (1x105) were injected
subcutaneously into the hind left flank of C57BL/6 (n=6/group) mice pre-treated with
AvFcΔXF at 25 mg/kg or vehicle (AvFc formulation buffer). Tumor measurements were
taken every day by using digital calipers until the tumor volume reached 500 mm3, at this
time the animals were euthanized, and the tumors dissected, weighed, and minced for cell
isolation. The minced cell suspension was digested in complete RPMI medium
containing 2.5 mg/mL of Collagenase type IV (ThermoFisher Scientific) and 40 µg/mL
of DNase I (MilliporeSigma, Saint Louis, MO) at 37 °C for 20 min under shaking
conditions (200 rpm). Subsequently, the cells suspension was passed through a 40 µm
cell strainer and the cell pellet resuspended and washed twice with FACS buffer, the cells
were counted and incubated with 20 µg/mL of mouse gamma globulins to block FCgamma receptors. A total of 1 x 106 Cells were stained for 30 min with 2 µg/mL of
different combination of the following fluorochrome-labeled antibodies: antiCD45eFluor450 or anti-CD45-FITC (30-F11), anti-CD3-FITC (17A2), anti-CD3-APC
(17A2), anti-CD161 (NK1.1)-BV605 (PK136), anti-CD49b-PE (DX5), anti-CD107-
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AlexaFluor700 (1D4B), anti-CD335 (NKp46)-BV650 (29A1.4), anti-CD16.2-PE-Dazzle
594 (9E9), anti-CD11b-APC-Cy7 (M1/70), anti-CD11c-PE (N418), anti-IA-IE-BV421
(M5/114.15.5), anti-F4/80-PE-Cy7 (BM8), anti-Ly6G-APC (1A8), antiLy6CAlexaFluor700 (HK1.4), anti-CX3CR1-BV605 (SA011F11), anti-CD206-BV650
(C068C2), anti-CD103-PE-Dazzle 594 (QA17A24), anti-CD80-BV605 (16-10A1), antiCD69-BV650 (H1.2F3), anti-CD68-AlexaFluor700 (FA-11), anti-CDC86-PE-Dazzle 594
(GL-1), anti-CD4-BV605 (RM4-5), anti-CD8-BV650 (53-6.7), anti-IFNγRβ-APC
(MOB-47), anti-CD69-FITC (H1.2F3), anti-IL-33R-PE-Dazzle 594 (DIH4), anti-CD62LAPC-Cy7 (MEL-14), anti-TCRβ-PE-Cy7 (H57-597), anti-IL23R-BV421 (12B2B64) and
anti-TCRγ/δ-PE (UC7-13D5). After two washing steps the cells were incubated with 7aminoactinomycin D for 15 minutes and analyzed with a BD LSRFortessaTM flow
cytometer. Data were processed with FlowJo software.

Calculation of anti-drug antibody titers
Anti-drug antibody titers were measured by ELISA. AvFc was coated on a 96well plate at 1 μg/mL overnight at 4°C, followed by blocking for 1 hour with 3% BSAPBST at room temperature. Mouse serum was plated at a minimum dilution of 1:50 and
serially diluted further with 1:10 dilutions, followed by a 2-hour incubation at room
temperature. Bound serum antibodies were then detected with a goat anti-mouse IgGHRP secondary antibody (Southern Biotech, Birmingham, AL) at 1:10,000 for 1 hour at
room temperature. Lastly, plates were developed with TMB substrate for 5 minutes and
stopped with 2 N sulfuric acid prior to measuring the absorbance at 450 nm on a BioTek
plate reader. Titers were interpolated using non-linear regression in GraphPad Prism,
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with the cutoff value set at the limit of quantification for the assay (average absorbance of
the blanks + 10 standard deviations). Statistical comparisons between groups were made
using a Two-way ANOVA, while multiple corrections were made with the Tukey
multiple comparisons test.

B16F10 metastasis challenge model
On day 0, 250,000 B16F10 cells suspended in 100 μL of DPBS was administered
into each C57BL/6 mouse intravenously via the tail vein using a heat lamp to facilitate
the injections. Intraperitoneal administration of 200 μL of AvFc, AvFcΔlec, or vehicle
(AvFc formulation buffer, see above) at the indicated dose level began concurrently with
tumor implantation and continued Q2D for a total of 6 doses (ending on day 10). Animals
were monitored until day 21, at which point they were euthanized and their lungs
removed for analysis. The tumor burden was calculated as the number of tumor nodules
per lung per mouse. Statistical comparisons between treatment groups were made using
the Kruskal-Wallis test, while multiple comparisons were made using Dunn’s test.

Immunohistochemistry of human cancer tissues with AvFc
IHC was performed on Ventana Discovery Ultra automated immunostainer
(Ventana Medical Systems, Tucson, AZ) by US Biomax Inc. On-board antigen retrieval
was performed with CC1, pH 8.0 for 56 minutes at 95C (Cat#950-124). Biocare
Background Sniper was used for the blocking reagent (Cat #BS966, Biocare, Pacheco,
CA) for 4 minutes and endogenous peroxidase was blocked by Discovery inhibitor
(Cat#760-4840, Ventana) for 4 minutes. 5.0 ug of the primary antibody was tagged with
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digoxigenin using a Biocare Human-on-Human HRP-Polymer kit according to the
manufacturer's instructions (Cat #BRR 4056K, Biocare). The tagged antibody was
applied at a dilution of 1:100 and incubated for 36 minutes at 37°C.
Mouse anti-Digoxigenin from the Biocare kit was applied as the secondary
antibody for 12 minutes at 37C. This was followed by Anti-Mouse HQ (Cat#760-4814,
Ventana) for 12 minutes at 37C and Anti-HQ HRP (Cat#760-4820, Ventana) for 12
minutes at 37C. Visualization was performed using ChromoMap DAB (Cat#760-159,
Ventana). Nuclear counterstaining was applied with Ventana Hematoxylin II for 12
minutes followed by a Bluing reagent for 8 minutes. Slides were dehydrated, cleared, and
mounted as in routine processing.

Identification of putative binding partners of AvFc on cancer cells
Co-immunoprecipitation was used to isolate potential binding partners of AvFc on
the surface of two human OVCA cell lines (SW626 and SKOV3) and one murine line
(ID8). Co-immunoprecipitation was performed on AvFc- or AvFcΔlec-conjugated resins
using the Pierce™ Co-Immunoprecipitation Kit (Thermo Fisher Scientific) according to
the kit instructions. A single 75 cm2 flask of cells were lysed using a buffer containing
1% NP-40 and 1X Halt™ protease and phosphatase inhibitor (Thermo Fisher Scientific)
and centrifuged to separate debris from the lysate. The lysate was then pre-cleared with
unconjugated agarose resin to remove any proteins that may bind non-specifically to the
resin. It was then incubated with the conjugated resins for 2 hours at 4°C, after which the
spin-tubes containing the mixture were placed in a spin column and washed 5 times with
a neutral buffer provided by the manufacturer. Proteins bound to AvFc were eluted from
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the column using a low pH buffer. Several elutions were performed, and each fraction
was pooled together and neutralized with 1 M tris base prior to submission to the
University of Louisville proteomics core for protein identification.
Protein samples were digested with trypsin (1:50 ratio) in a filter-aided sample
preparation approach following reduction and alkylation with 100mM dithiothreitol and
50mM iodoacetamide. The tryptic digests (0.5µg) were separated using a Proxeon EASY
n-LC (Thermo-Fisher Scientific) UHPLC system and Dionex (Sunnyvale, CA) 2cm
Acclaim PepMap 100 trap and a15cm Dionex Acclaim PepMap RSLC (C18, 2µm, 100Å)
separating column. The eluate was introduced into an LTQ-Orbitrap ELITE (ThermoFisher Scientific) using a Nanospray Flex source and MS2 data collected in a data
dependent fashion in a top-20 rapid CID method. All MS1 data were acquired using
Fourier transform ion cyclotron resonance MS at 240,000 resolution and MS2 data using
the linear ion trap. MSn data were searched using Proteome Discoverer 1.4 (Thermo
Scientific) with Sequest HT (SageN) and Mascot, version 4.0 (Matrix Science) in a decoy
database search strategy against UniProt Knowledgbase, Homo sapiens reference
proteome. The searches were performed with a fragment ion mass tolerance of 1.0 Da
and a parent ion tolerance of 50 ppm. The search data results file was imported into
Scaffold, version 4.3.4 (Proteome Software Inc.) and filtered using a 2ppm mass error
filter, removal of decoy hits, to control for <1.0% false discovery rates with
PeptideProphet and ProteinProphet (Institute for Systems Biology). Peptide and protein
identifications were accepted at >95.0% probability by the PeptideProphet or
ProteinProphet algorithm. A comparison of protein abundance among the sample sets
was conducted in Scaffold using the intensity based absolute quantification (iBAQ)
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method or by normalizing the total spectra. Results were further refined using Gene
Ontology (GO) terms to extract the most abundant membrane receptors, transporters, and
adhesion molecules bound by AvFc and not AvFclec-. The number of N-glycan sites for
each protein were predicted using the NetNGly server from the Technical University of
Denmark.

Orthotopic murine ID8-luciferase EOC challenge model
The ID8-luciferase challenge model was performed using ID8-luciferase cells,
which constitutively express the luciferase enzyme and are useful for bioluminescent
monitoring of disease development. On day 0, 1 or 2x106 cells were injected in 200 μL of
DPBS intraperitoneally to establish tumors. Intraperitoneal treatment of animals with
either AvFcΔXF at 25 mg/kg or a vehicle (AvFc formulation buffer, see above) began on
day 7 and continued Q2D for 28 days. Disease progression was monitored through
weekly measurements of abdomen circumference and body weight as well as by
bioluminescent imaging, performed by the In vivo Molecular Imaging Core at the
University of Louisville. Images were taken after injecting 150 mg/kg luciferin
intraperitoneally and waiting 10 minutes for the substrate to disperse and generate signal.
Animals were to be euthanized upon reaching 35 g or when moribund. The primary
endpoint for these studies was survival. Survival curves were plotted and compared using
the Gehan-Breslow-Wilcoxon test in GraphPad Prism. Multiple comparisons between
curves were corrected for using the Bonferroni method, if necessary. Other statistical
comparisons between body weights and abdomen circumferences were made with 2-way
ANOVA.
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CHAPTER 4: SAFETY AND EFFICACY OF AVAREN-FC LECTIBODY
TARGETING HCV HIGH-MANNOSE GLYCANS IN A HUMAN LIVER CHIMERIC
MOUSE MODEL

4.1: Introduction 2
Hepatitis C virus (HCV) is an enveloped monopartite positive sense ssRNA virus
in the family Flaviviridae and the causative agent of hepatitis C disease. Its genome
encodes three structural (core, E1, E2) and seven non-structural proteins (p7, NS2, NS3,
NS4A, NS4B, NS5A, NS5B) [212]. HCV is highly heterogenous and globally
distributed, consisting of seven genotypes each further subdivided into multiple subtypes.
Genotype 1 and 2 are the predominant genotypes worldwide and particularly
concentrated in high-income and upper-middle income countries, whereas genotype 3
and 4 are more common in lower-middle and low-income countries [213]. In the United
States, injection drug use represents the primary risk factor for contracting HCV infection
[214, 215]. Around 15-25% of people acutely infected with HCV will clear the virus,
while the remainder will develop chronic infection that can persist largely unnoticed for
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decades. Indeed, many HCV carriers discover their chronic infection after they have
developed cirrhosis [216]. Chronic HCV infection is also associated with the
development of hepatocellular carcinoma, and those with the disease are more likely to
develop cryoglobulinemia and non-Hodgkin’s lymphoma [217].
There is no vaccine currently available for HCV. Prior to 2011, the standard
chronic HCV treatment was a non-specific antiviral medication using ribavirin combined
with a pegylated interferon-α, which was associated with significant toxicity and limited
treatment efficacy [218]. In 2011, the U.S. Food and Drug Administration approved the
first generation of direct-acting antivirals (DAAs) for HCV: boceprevir and telaprevir,
both of which inhibit the viral protease (NS3/4A) but required cotreatment with ribavirin
and peginterferon [219, 220]. Further approval of more potent DAAs, such as NS3/4A,
NS5B and NS5A inhibitors led to the development of oral ribavirin/peginterferon-free
regimens [216]. Multi-DAA regimens achieve sustained virologic response (defined as a
period of time with no viral RNA detection) rates as high as 100% and are less toxic and
more tolerable than their predecessors [221-224]. While the cure rates are remarkable,
there exist populations of patients who may not benefit from DAA therapy [225],
especially patients with decompensated cirrhosis due to chronic HCV infection, for
whom liver transplantation may be a last resort [226]. Moreover, recurrent infection
occurs universally and rapidly post liver transplantation [227, 228], which increases the
risk of accelerated cirrhosis, graft failure and death [229]. DAAs, by their nature, cannot
prevent recurrent infection. Therefore, alternative or complementary therapies to DAAs
that can block viral entry to target cells, such as antibodies or other molecules acting
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alike, may need to be considered in these circumstances [229, 230]. However, there is
currently no entry inhibitor approved for HCV treatment.
The HCV envelope proteins E1 and E2 are heavily glycosylated and, like
glycoproteins of other enveloped viruses (HIV and the coronaviruses, for instance), have
a high proportion of high-mannose-type N-glycans on their surface [40, 231, 232]. These
glycans are typically processed to hybrid and complex forms on glycoproteins secreted
by healthy cells [233]. Thus, the high-mannose glycans on the surface of HCV may be
considered a druggable target. We have previously described the development of an highmannose glycan-targeting lectin-Fc fusion protein, or “lectibody”, called Avaren-Fc
(AvFc), which was shown to bind with high affinity to clusters of high-mannose glycans
on the HIV envelope protein gp120 and effectively neutralize multiple HIV clades and
groups including HIV-2 and simian immunodeficiency virus [98]. Further analysis
indicated that AvFc can bind to HCV E2 protein [98]. Therefore, in this study, we aim to
investigate the anti-HCV therapeutic potential of AvFc in in vitro neutralization assays
and an in vivo HCV challenge study using PXB-mice®, a chimeric uPA/SCID mouse
model transplanted with human hepatocytes (reviewed in: [207]).

4.2: Results
4.2.1: AvFc exhibits broad anti-HCV activity in vitro
Building on our previous observation that AvFc has affinity to a recombinant
HCV E2 envelope protein [98], we first examined whether AvFc inhibits HCV infection
in vitro using multiple genotypes of cell culture-produced virus (HCVcc) or pseudotyped
virus (HCVpp). AvFc significantly blocked the infection of the human liver cell line
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Huh-7 by HCVcc from genotypes 1a, 2a, 4a, 5a, and 6a, with 50% inhibitory
concentration (IC50) values in the low nanomolar range (Table 2 and Figure 9A).
Compared to Avaren monomer, AvFc overall showed approximately 2-log higher
activity, while no inhibitory effect was observed for a plant-produced anti-HIV broadly
neutralizing antibody VRC01 that shares the same human IgG1 Fc region with AvFc
[234]. Additionally, Avaren and AvFc, but not VRC01, effectively neutralized HCVpp
harboring a murine leukemia virus backbone, suggesting that the lectin and the lectibody
act as an entry inhibitor (Figure 9B).
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Virus
JFH1/H77
JFH1
JFH1/ED43
JFH1/SA13
JFH1/HK6a

Genotype
1a
2a
4a
5a
6a

Avaren IC50 (nM)
529.28 ± 158.78
484.62 ± 109.16
204.27 ± 1.65
148.86 ± 2.48
114.95 ± 52.93

Average:
269.39 ± 65.00
Table 2. IC50 values for AvFc and Avaren against HCVcc.

AvFc IC50 (nM)
1.69 ± 0.39
1.69 ± 0.78
2.85 ± 0.91
2.33 ± 0.13
1.95 ± 0.78
2.10 ± 0.60

IC50 = 50% inhibitory concentration derived from 4 parameter non-linear regression.

Figure 9. In vitro HCV inhibition assays.
(A) Avaren and Avaren-Fc (AvFc) inhibit cell culture derived HCV. JFH1 virus was
preincubated with Avaren, AvFc or the control antibody VRC01 for 30 min at 37°C
before incubation with Huh-7 cells. At 48 h post-infection, infected cells were quantified
by indirect immunofluorescence with an HCV-specific antibody. Results are expressed as
percentage of infection compared to a control infection in the absence of compound.
Error bars indicate standard errors of the mean (SEM) values from at least three
independent experiments. (B) Avaren and AvFc inhibit HCV entry. Retroviral
pseudotypes bearing HCV envelope glycoproteins of JFH1 virus (HCVpp) were
preincubated with Avaren, AvFc or the control antibody VRC01 for 30 min at 37°C
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before incubation with Huh-7 cells. At 48 h post-infection, cells were lysed to quantify
the luciferase activity. Results are expressed as percentage of infection compared to the
control infection in the absence of compound. Error bars indicate SEM values from at
least three independent experiments.
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4.2.2: Formulation of AvFc into a biocompatible buffer for in vivo studies
Previously, we found that AvFc has limited solubility in phosphate-buffered
saline (PBS) at concentrations greater than 1 mg/mL (unpublished observation). To
facilitate in vivo studies, we screened for an optimal liquid formulation for systemic
administration that can impart improved stability and solubility to AvFc at higher
concentrations. Initial buffer screening showed that AvFc is prone to degradation at and
below a pH of 6.5, suggesting that AvFc is not stable in acidic pH conditions (Figure 10,
Table 3). Further preformulation studies led us to identify an optimal buffer composed of
30 mmol/L histidine, pH 7.0, 100 mmol/L sucrose, and 100 mmol/L NaCl. Although
AvFc showed comparable melting temperature in the histidine buffer and PBS in
differential scanning fluorimetry (62.49°C ± 0.13°C vs 62.68°C ± 0.25°C) (Figure 11A),
sodium dodecyl sulfate–polyacrylamide gel electrophoresis analysis showed that the
lectibody holds superior stability in the histidine buffer upon accelerated stability testing
via overnight incubation at 55°C (Figure 11B). When concentrated to approximately 10
mg/mL, AvFc remained stable in solution in the histidine buffer over 72 hours at 4°C and
room temperature, while showed a significant concentration decrease concomitant with
increasing turbidity in PBS (Figure 11C), further showing the histidine buffer’s
superiority for AvFc formulation.
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Figure 10. Stability of AvFc in various buffers.
The initial buffer screening was performed by incubating 1 mg/mL of AvFc at 37°C for 2
weeks in various buffers without any excipient (listed in Table 3), followed by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis analysis. The image shows a
Coomassie Brilliant Blue–stained gel resolving 10 μg of AvFc from respective buffers,
including glutamate at pH 4.5 (lane 1) and 5.0 (lane 2); acetate at pH 4.5 (lane 3) and 5.5
(lane 4); citrate at pH 5.0 (lane 5) and 6.0 (lane 6); succinate at pH 5.5 (lane 7) and 6.5
(lane 8); histidine at pH 6.0 (lane 9) and 7.0 (lane 10); phosphate at pH 6.5 (lane 11), 7.0
(lane 12), and 7.5 (lane 13); Tris at pH 7.5 (lane 14); and PBS (lane 15). At pH 6.0 and
less (buffers 1–9), AvFc showed significant degradation after 2 weeks at 37°C. AvFc did
not significantly degrade in buffers 10–15, and therefore these were chosen for further
preformulation analysis. MW, molecular weight marker; S, standard AvFc control. SDSPAGE was run by Dr. Krystal Hamorsky.
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Buffer
30 mM glutamate
30 mM glutamate
30 mM acetate
30 mM acetate
30 mM citrate
30 mM citrate
30 mM succinate
30 mM succinate
30 mM histidine
30 mM histidine
30 mM
phosphate
30 mM
phosphate
30 mM
phosphate
30 mM tris-HCl
PBS

Formulation
5.61 g/L sodium glutamate monohydrate
5.61 g/L sodium glutamate monohydrate
2.46 g/L sodium acetate
2.46 g/L sodium acetate
350 mL 0.1 M citric acid monohydrate, 650 mL 0.1
M trisodium citrate dihydrate
115 mL 0.1 M citric acid monohydrate, 885 mL 0.1
M trisodium citrate dihydrate
4.86 g/L disodium succinate
4.86 g/L disodium succinate
4.65 g/L L-histidine
4.65 g/L L-histidine
2.89 g/L sodium phosphate monohydrate, 2.42 g
disodium phosphate heptahydrate
1.75 g/L sodium phosphate monohydrate, 4.64 g
disodium phosphate heptahydrate
0.78 g/L sodium phosphate monohydrate, 6.53 g
disodium phosphate heptahydrate
3.63 g/L tris base
0.144 g/L potassium phosphate, 9 g/L sodium
chloride, 0.795 g/L disodium phosphate

*

pKa
4.15
4.15
4.76
4.76

pH
4.5*
5.0*
4.5*
5.5*

4.76

5.0

4.76

6.0

5.60
5.60
6.04
6.04

5.5*
6.5*
6.0*
7.0*

7.21

6.5

7.21

7.0

7.21

7.5

8.07 7.5*
7.21

pH adjusted with NaOH or HCl
Table 3. Buffers used in the initial screening of AvFc preformulation analysis.
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7.2

Figure 11. Liquid formulation development for AvFc.
(A) Differential scanning fluorimetry for melting temperature measurement. AvFc was
prepared in 30 mmol/L histidine buffer, 100 mmol/L NaCl, 100 mmol/L sucrose
(histidine, black line), or PBS (grey line) at a concentration of 1 mg/mL and analyzed in
triplicate in the presence (solid line) or absence (dashed line) of the fluorescent dye
SYPRO Orange (ThermoFisher Scientific, Waltham, MA). Melting temperature values
were 62.49°C ± 0.13°C in the histidine buffer and 62.68°C ± 0.25°C in PBS, as
determined by the vertex of the first derivative of the relative fluorescence unit values.
(B) Accelerated stability testing of AvFc in the histidine buffer and PBS. AvFc, prepared
at 1 mg/mL in the histidine buffer or PBS were incubated overnight at 55°C, and 10 μg of
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the protein from each formulation was analyzed by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis under nonreducing conditions. A representative
Coomassie-stained gel image is shown. The band at around 75 kilodaltons corresponds to
AvFc. Note that after overnight incubation, PBS shows less band intensity for AvFc and
more large-size aggregate bands than the histidine buffer. (C) Time course of
concentration change and the turbidity of AvFc solution in the histidine buffer and PBS.
AvFc was formulated at 10 mg/mL in respective buffers and incubated at 4°C or room
temperature (RT). After 16 and 72 hours, the concentration was measured using a
theoretical extinction coefficient at 280 nm of 1.6493 (mg/mL)-1 cm-1, whereas turbidity
was assessed by absorbance at 600 nm. Representative data are shown for samples
analyzed in triplicate.

86

4.2.3: Pharmacological and toxicological analysis of AvFc in mice
To determine an optimal dosing regimen for an HCV challenge experiment, a
pharmacokinetic analysis of AvFc was conducted in C57bl/6 mice. After a single i.p.
injection of AvFc at a dose of 25 mg/kg, peak drug concentration was observed between
2 and 4 h, with a half-life of 24.5 h in male and 18.5 in female animals (Figure 12). After
48 h, in both male and female animals the plasma concentration of AvFc remained above
a target trough concentration of 130 nM (10 μg/mL), at which AvFc showed >90%
neutralization effects against HCV (see Figure 9). Consequently, these results suggested
that administration of the drug every other day (Q2D) might be sufficient to keep the
virus under control in a murine HCV challenge model.
We then assessed the safety of Q2D administration of AvFc in PXB-mice®. To
effectively discern potential toxicity associated with AvFc’s high-mannose glycanbinding activity, we included an AvFc variant lacking high-mannose glycan-binding
activity as a control (AvFclec-; Figure 13A, B). PXB mice received either the vehicle (the
histidine buffer described above) Q2D for 11 total doses, AvFc at 25 mg/kg Q2D for a
total of 8 or 11 doses, or AvFclec- at 25 mg/kg Q2D for 11 total doses. As shown in Figure
14A-C, no significant differences in either body weights, blood h-Alb levels or serum
ALT activity were observed. Additionally, no significant differences in relative liver
weight were seen (Figure 14D). These results indicate that AvFc, formulated in the
histidine buffer, is well tolerated in the immunocompromised mice engrafted with human
hepatocytes.
Histopathology was performed to evaluate any potential toxicity to the human
liver grafts due to AvFc administration (Table 1 and Figure 15). In the human hepatocyte
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area, slight to moderate (score 2 to 3 in Table 4) macrovesicular fatty change, a
characteristic change of human hepatocytes in the PXB-mouse, was observed in all mice
including the vehicle-treated group (Figure 15A-C). Minimal inflammatory cell
infiltration around vacuolated hepatocytes (Score 1) was seen in one mouse each from the
11 dose AvFc and AvFclec- groups (Figure 15D, E); however, this was unlikely treatmentrelated as a similar change is occasionally seen in PXB-Mice (PhoenixBio, unpublished
observation). No AvFc treatment-specific change was observed, except for an incidental
build-up of pigmentation found in the Glisson’s sheath in the liver of one mouse (Figure
15F). Collectively, it was concluded that there was no treatment-related adverse effect in
the liver tissue.
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Figure 12. Pharmacokinetics of AvFc in Mice.
AvFc pharmacokinetics were evaluated in C57bl/6 mice following a single i.p. injection
of 25 mg/kg with blood sampled at various time points. Data are expressed as mean ±
SEM from 4 mice per group. The average half-life was 24.5 h and 18.5h in male and
female mice, respectively, as determined by the PKSolver Microsoft Excel Add-on. The
peak concentration occurred between 2 and 4 h post administration. The target trough
concentration of 130 nM (corresponding to 10 μg/mL) is indicated by a dashed line.
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Figure 13. Characterization of the non-sugar-binding mutant AvFclec-.
A variant of AvFc that does not bind to high-mannose glycans was generated by mutating
a tyrosine residue in each of the three binding pockets of Avaren. (A) SDS-PAGE gel
showing purified AvFc and AvFclec- under reducing (R) and non-reducing (NR)
conditions. Under R conditions, AvFc monomer is seen at 38.5 kDa and, whereas under
NR conditions, AvFc dimer (via inter-polypeptide disulfide bonds in the Fc region)
appears at 77 kDa. (B) Surface plasmon resonance analysis of HCV E2-binding affinity
of AvFc and AvFclec-. A recombinant E2 protein (Immune Technology Corp.) was
immobilized to a CM5 chip using amine coupling to a surface density of ≈ 200 RU. AvFc
or AvFclec- was then injected over the chip surface at a rate of 30 μL/min for 120 seconds
followed by a 600 second dissociation period, with concentrations ranging from 10 to
0.625 μM. Binding affinity was calculated using steady-state analysis and was
determined to be 2.34 ± 0.18 x 10-6 M (2.34 ± 0.18 μM) for AvFc. Binding affinity could
not be determined for AvFclec- due to lack of measurable binding.
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Figure 14. Toxicological analysis of systemically administered AvFc in the PXB®
human liver chimeric mouse model.
PXB mice were administered i.p. with AvFc or AvFclec- at 25 mg/kg (n=4 each), or the
histidine buffer vehicle control (n=3) every 2 days (Q2D) and monitored for body
weights, blood human albumin (h-Alb) levels and serum alanine aminotransferase (ALT)
levels over 42 days. (A) Percent change of body weights from the initial day of dosing
(Day 0). (B) Blood h-Alb levels. (C) Serum ALT levels. (D) Ratio of the liver weight to
the body weight of individual mice at necropsy. Each data point represents mean ± SEM
(A-C) and individual data with mean ± SEM (D) in each group. No significant changes in
any of the safety endpoints were noted between the groups (A-C: two-way analysis of
variance (ANOVA); D: one-way ANOVA). Experiment was conducted by PhoenixBio
Co, Higashi-Hiroshima City, Japan.
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Vehicle
101 102

Mouse
0
hepatocytes
Human hepatocytes
Fatty change,
2
macrovesicular
Infiltrate,
inflammatory
0
cell, around
vacuolated
hepatocyte
Portal canal and others
Hepatocellular
carcinoma,
trabecular, with P
extramedullary
hematopoiesis
Metaplasia,
0
osseus
Pigmentation,
brown,
0
histiocyte,
Glisson’s
sheath, focal
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AvFclec201 202

203

204

AvFc, 11 doses
301 302 303

304

AvFc, 8 doses
401 402 403
0
0
0

404
0

0

0

0

0

0

0

0

0

0

0

3

3

3

3

3

3

3

3

3

3

3

3

3

3

0

0

0

1

0

0

0

1

0

0

0

0

1

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

2

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1

0

0

0

Table 4. Histopathology of chimeric mouse liver tissue.
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Figure 15. Histopathological examination of PXB mouse liver tissues.
Representative hematoxylin/eosin-stained liver tissue section images corresponding to
histopathological findings in Table 4 are shown. Liver tissues are from the toxicological
study in Figure 14. (A) A 4x image from an animal in the vehicle control group (mouse
ID: 103 in Table 4) showing low magnification of vacuolated hepatocytes. (B) A 10x
image from a portion of panel A, containing many human hepatocytes with a large, welldefined rounded vacuole. (C) Higher magnification (40x) of panel B. (D) A 10x image
from an animal in the AvFclec- group (ID: 202 in Table 4), showing small foci of
inflammatory cell infiltration in the human hepatocyte area. (E) Higher magnification
(40x) of panel D. Inflammatory cells appear to surround vacuolated hepatocytes. (F) A
20x image from an animal in the AvFc group (8 total doses; ID: 401 in Table 4).
Histiocytic brown pigmentation in the Glisson’s sheath is noted only in this mouse.
Histopathological analysis was conducted by Nara Pathology Research Institute Co., Ltd.
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4.2.4: AvFc protects against HCV infection in vivo
Lastly, we assessed AvFc’s protective efficacy against HCV infection in vivo
using the treatment regimen described above. PXB mice were inoculated i.p. with a
genotype 1a virus along with initial treatment with 25 mg/kg of AvFc or AvFclec- on day
0. As shown in Figure 16A, AvFclec--treated mice showed high serum HCV RNA levels
from day 7 post challenge through the end of the study on day 35. In sharp contrast,
animals treated with both 8 and 11 doses of AvFc did not show any quantifiable level
(4.0 x 104 copies/mL) of HCV RNA in sera, indicating that the lectibody prevented the
infection of human liver grafts by the virus. Similar to the results in Figure 14, overall no
major toxicity signal was noted in body weights, h-Alb or h-ALT levels between the test
groups although there was a temporal drop in body weight and h-Alb in one of the AvFctreated group at an early timepoint, indicating that the liver grafts remained functional
over the course of the study (Figure 16B-D).
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Figure 16. The protective effect of AvFc against HCV challenge in PXB mice.
(A) Study design. PXB mice were challenged i.p. with an HCV genotype 1a virus on Day
0 simultaneously with an initial treatment i.p. with either 25 mg/kg of AvFc or AvFclec-.
Treatment was continued Q2D for a total of 8 or 11 doses for AvFc and 11 doses for
AvFclec- (n=5 each). The general conditions and body weights of the animals were
monitored every other day, while serum HCV RNA and blood h-Alb were measured
every 7 days. (B) Serum HCV RNA levels. AvFc treatment (both 8 and 11 doses) showed
no detectable HCV RNA at any time point. The gray line indicates the lower limit of
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quantification (LLOQ), which was 4 x 104 copies/mL in this assay. **, ***p < 0.01,
0.001 (AvFclec- vs. both AvFc 8 and 11 doses); two-way ANOVA with Tukey’s multiple
comparison test. The graph in the inset shows the same data with y-axis on a linear scale.
(C-E) Time course of body weight change from day 0 (C), blood h-Alb levels (D) and
serum h-Alt concentrations (E). Each data point represents mean ± SEM in each group.
*p < 0.05 (AvFclec- vs. AvFc 8 doses in C and AvFclec- vs. AvFc 11 doses in D]; two-way
ANOVA with Tukey’s multiple comparison test. No significant difference between
groups at any timepoint was noted in E. Experiment was conducted by PhoenixBio Co,
Higashi-Hiroshima City, Japan.
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4.3: Discussion
In this study we demonstrated that the high-mannose glycan-binding lectibody
AvFc exhibits broad genotype-independent anti-HCV activity. Additionally, systemic
administration of AvFc effectively protected chimeric human-mouse liver mice from
infection with a genotype 1a virus without apparent toxicity, providing the first in vivo
proof-of-concept for the lectibody’s antiviral potential.
The mechanism of HCV neutralization by AvFc is likely through binding to highmannose glycans on the E1/E2 envelope protein dimer, which blocks their interaction
with host cell receptors and viral entry. Unlike HIV envelope glycoproteins, whose
glycan content can vary widely between strains, the number and position of glycosylation
sites on E1/E2 are highly conserved, indicating their critical role in HCV’s infectious
processes [235]. The notion that AvFc functions as an entry inhibitor is supported by the
facts that the lectibody has affinity to the E2 protein [98] and that other mannose-binding
lectins, such as Griffithsin or Cyanovirin-N, inhibit entry in this manner [236, 237]. AvFc
inhibited multiple genotypes of HCV with an average IC50 over 100-fold lower than that
of the monomer Avaren lectin (Table 2), indicating that the multivalent recognition of
high-mannose glycans on the surface of the virus, brought about by the dimerization of
Avaren via Fc fusion, led to greater entry inhibition. Unlike other antiviral lectins,
however, the inclusion of the human IgG1 Fc region implicates the possibility of Fcmediated effector functions, such as antibody-dependent cell-mediated cytotoxicity,
against infected cells. In fact, Fc-mediated effector functions greatly contributed to the
antiviral potency of AvFc against HIV, as determined by a primary cell-based inhibition
assay and an antibody-dependent cell-mediated viral inhibition assay [98]. Accordingly,
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the remarkable efficacy seen in the present in vivo HCV challenge study may be partially
Fc-mediated. Further investigations are necessary to address this possibility.
The present study also demonstrated that AvFc therapy is well tolerated in mice
and human hepatocytes, as Q2D i.p. administration of 25 mg/kg of AvFc up to 11 doses
did not show any obvious toxicity in PXB mice by gross necropsy or histopathology of
engrafted human hepatocytes, nor did it result in significant changes in body weight, hAlb, or ALT levels (Figure 14, Figure 15). This corroborates our previous observation
that AvFc administration, both i.p. and intravenously, was well tolerated and produced no
toxicity in mice, rats, and rhesus macaques [98]. We hypothesize that the lack of any
significant toxicity is attributable to AvFc’s unique high-mannose glycan-binding
mechanism, whereby it requires multivalent interaction with several high-mannose
glycans in proximity to exhibit high affinity binding to a glycoprotein target. In line with
this hypothesis, Hoque et al. demonstrated that the three binding pockets of the parent
lectin actinohivin can bind up to three independent high-mannose glycans, providing high
affinity binding when the high-mannose glycans are in relatively close proximity [104].
This implies that AvFc may not effectively interact with healthy normal cells and tissues
that do not usually exhibit clusters of high-mannose glycans on their surfaces. In contrast,
glycoproteins of many enveloped viruses display a high proportion of these immature
forms of N-glycans [40, 231, 232]. While HCV E2 has fewer N-glycosylation sites
(around 11) than the HIV glycoprotein gp120 (which has between 20 and 30 depending
on the strain), E2 is likely present on the surface of HCV at a higher density and thus
provides higher local concentrations of high-mannose glycans [238]. Further studies are
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necessary to reveal a threshold high-mannose glycan concentration which enables
efficient interaction between AvFc and the surfaces of cells or viruses.
While alcoholic liver disease has now surpassed HCV infection as the number one
indication for liver transplantation in the US, a large number of procedures will continue
to be performed for the foreseeable future in patients with HCV-related decompensated
cirrhosis [239]. A major outstanding issue is the lack of effective treatment protecting the
allograft liver from recurrent infection by the virus that remained circulating in the
periphery at the time of transplant. As a consequence, reinfection of donor livers
universally occurs, as early as in the first 90 minutes upon reperfusion [228], and can
result in accelerated fibrosis and increased risk of graft failure, cirrhosis, and
hepatocellular carcinoma [240]. In fact, allograft failure due to reinfection is the leading
cause of secondary transplants and death in HCV-infected patients who have received
liver transplant [241]. Patients cured of HCV with DAAs after liver transplantation still
have a higher than normal risk of hepatocellular carcinoma [242], and the high cost of the
drugs represents a significant barrier to their widespread use. Furthermore, emergent drug
resistance even in DAA combination therapies, though rare, represents a particular
challenge for further treatment [243]. Unlike DAAs, entry inhibitors neutralize
circulating viruses and physically block the viral infection of target cells. The use of entry
inhibitors perioperatively upon liver transplantation, either alone or in combination with
DAAs, may significantly improve treatment outcomes [241, 244]. Thus, while the
effectiveness of DAAs is not in question, there are still unmet needs that may be
addressed through the use of entry inhibitors.
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As of yet, no entry inhibitor has been approved for the treatment or prevention of
HCV. Two major drug candidates, Civacir® and MBL-HCV1, have shown some promise
in clinical trials (NCT01804829, NCT01532908) [245, 246]. Though larger studies are
needed, it appears that entry inhibitors in combination with DAAs may represent a new
treatment paradigm for HCV patients receiving liver transplant. Despite that both MBLHCV1 and Civacir® are capable of neutralizing a broad range of HCV genotypes, viral
resistance can still develop through mutations in the envelope proteins E1/E2, in
particular through shifting glycan positions [247, 248]. In this regard, AvFc in its own
right could be less susceptible to amino acid mutations because it targets the glycan
shield of the virus rather than a specific epitope. Deletions of glycans, even if occurring
following prolonged exposure to a carbohydrate-binding agent like AvFc, may result in
significant decrease in viral fitness by decreasing E1/E2 incorporation into HCV particles
or increased susceptibility to humoral immunity due to breach in the glycan shield [235,
249]. Our results provide a foundation to test the above hypotheses and feasibility of the
high-mannose glycan-targeting anti-HCV strategy. Of note, a unique advantage of AvFc
over the two antibody-based entry inhibitor candidates described above is that the
lectibody has the capacity to neutralize both HIV [98] and HCV (present study).
Accordingly, AvFc may provide an effective means (e.g., pre-exposure prophylaxis) to
protect high-risk populations against HIV/HCV co-infection, such as health care workers
and injection drug users [250, 251].
In conclusion, the present study provided an important proof of concept for the
therapeutic potential of AvFc against HCV infection via targeting envelope highmannose glycans. In particular, the lectibody may provide a safe and efficacious means to
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prevent recurrent infection upon liver transplantation in HCV-related end-stage liver
disease patients. Other potential utilities of AvFc may be found in pre-exposure
prophylaxis against HIV/HCV co-infection in high-risk populations, as well as in the
context of transplantation of organs from HCV-infected donors to HCV-negative
recipients, which may help alleviate the severe shortage of donor organs available for
transplantation [252, 253]. Further studies are warranted to determine a dose-response
relationship, therapeutic window, and feasibility of intravenous or subcutaneous dosing
routes, as well as to assess the efficacy of AvFc against established infection.
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CHAPTER 5: THE ANTI-CANCER POTENTIAL OF AVAREN-FC AND ITS
MECHANISM OF ACTION

5.1: Introduction
Cancer immunotherapy with monoclonal antibodies (mAbs) targeting tumorassociated antigens (TAAs) has forever altered treatment paradigms and has vastly
improved patient survival and quality of life. MAbs exert their anti-cancer activities
through a combination of immune-mediated and non-immune-mediated mechanisms such
as direct receptor inhibition, antibody-dependent cell-mediated cytotoxicity (ADCC),
antibody-mediated phagocytosis, and the complement system. The initiation of
inflammatory responses by antibodies is largely dependent on the binding and activation
of Fcγ receptors (FcγRs), which are differentially expressed in several different immune
cell types, in particular natural killer (NK) cells, neutrophils, macrophages, and
monocytes [254]. Binding of the Fc region of an antibody to the activating FcγRs (FcγRI,
FcγRIIa, FcγRIIIa) results in the generation of signaling cascades through intracellular
ITAM domains, leading to cellular activation, degranulation, or phagocytosis depending
on the specific receptor and cell type expressing it [255]. Initiation of ADCC, for
instance, is accomplished primarily by recognition of antibody-opsonized cells by
FcγRIIIa on NK cells, which subsequently release cytotoxic granules containing
granzyme and perforin to initiate target cell death and begin to express IFNγ. As these
immune-mediated mechanisms play an important role in the effects of therapeutic mAb
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drugs, even those whose primary mechanism is receptor antagonization [256], much
research has been conducted into enhancing their ability to activate Fc functions by
improving their affinity to the various FcγRs with the goal of improving clinical
outcomes [257].
The strength of the Fc-mediated response reflects both the density of the target
TAAs on the cell surface as well as the affinity of the mAb to the FcγR [258]. The
affinity of this interaction is determined by both the IgG isotype of the antibody as well
as the composition of its N-glycans attached to the Asn297 within the Fc region [255,
259]. One method for improving the affinity of an Fc to the FcγRs is through point
mutation of the Fc region. A well-known example of this is the GASDALIE mutation,
which is a series of 4 amino acid substitutions in the CH2 and CH3 domains that
significantly increases the affinity of the Fc for FcγRIIIa [128, 260]. This mutation has
been trialed on a number of mAb therapeutics and has consistently resulted in increased
ADCC activity and in vivo efficacy in pre-clinical models of both viral diseases and
cancer [129, 261]. Host glycoengineering is another method commonly used to modify
FcγR affinity. N-glycosylation of mAbs occurs at a single conserved site on the CH2
domain of the Fc region, the composition of which can be altered through manipulation
of host glycosyltransferase enzyme expression [262]. This can be performed chemically
through exposure to compounds such as kifunensine, which inhibits mannosidase I and
results in an abundance of high-mannose-type glycans, or genetically through
knockdowns or knockouts of glycosyltransferase genes by RNAi or CRISPR-Cas9 [132,
133, 263, 264]. In plants, recombinant expression of antibodies results in the majority of
glycoforms containing β1,2-xylose and α1,3-fucose residues [265]. Expression in

103

glycoengineered N. benthamiana plants containing RNAi knockdowns of β1,2xylosyltransferase and α1,3-fucosyltransferase genes (ΔXylT/ΔFucT, or ΔXF), however,
results in a near total loss of plant-typical glycans with the predominant glycoform
consisting of the core trimannose and two N-acetylglucosamine residues [133].
Antibodies manufactured in these plants have significantly higher FcγR affinity, which is
similar to the effect achieved following removal of the core α1,6-fucose residue from
antibodies expressed in mammalian cells [265, 266]. Thus, removal of plant-derived
glycans is an attractive target to achieve for therapeutic antibody development, and
indeed a number of stable transgenic N. benthamiana lines for recombinant protein
expression have been generated with that goal in mind [132, 133, 267, 268].
Plants, in particular Nicotiana benthamiana, are quite amenable to
glycoengineering owing to the relatively lower complexity of the N-glycosylation
pathway compared to that of mammalian culture systems, which are currently the
industry standard for mAb manufacturing. This makes them an attractive alternative
platform that has already been used to manufacture dozens of antiviral and anticancer
mAb and Fc-fusion protein therapeutics with glycan or amino acid modifications [164,
269-273]. Previously, we have described the development in plants of a novel lectin-Fc
fusion protein, or lectibody, which targets cancer-associated high-mannose glycans called
Avaren-Fc (AvFc) [98, 105]. The presence of aberrant glycosylation patterns on cell
surface glycoproteins has been identified as a hallmark of cancer, and an overabundance
of high-mannose glycans has been found in numerous human cancers including
colorectal cancer [73-75], hepatocellular carcinoma [76, 77], cholangiocarcinoma [78],
lung adenocarcinoma [79], pancreatic cancer [80], ovarian cancer [81, 82], prostate
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cancer [83], and some skin cancers [84]. This suggests that display of these immature
glycans may be common in cancer due to an inherent property of the transformation to
malignancy, and this fact can potentially be exploited to create a new druggable target for
therapy. We have previously reported that AvFc recognizes a large number of cancer cell
lines through this mechanism, and that by binding to mannosylated forms of EGFR and
IGF1R derived from lung cancer cell lines and tissues in addition to inducing ADCC,
AvFc displays potent activity against A549 and H460 lung cancer both in vitro and in
vivo [105]. To further explore and examine the contribution of ADCC to AvFc’s
antitumor mechanism of action, we have generated a variant of AvFc by expression in
ΔXF plants (AvFcΔXF) that is devoid of plant-derived glycans and may hence exhibit
greater ADCC activity due to the lack of core fucosylation. In this study, we set out to
characterize this variant as well as investigate its activity by comparing it to an
aglycosylated variant, AvFcΔgly, and a variant lacking sugar-binding activity, AvFcΔlec,
using both in vitro assays as well as the syngeneic murine B16F10 melanoma model.
Additionally, we explored the impact of the generation of anti-drug antibodies (ADAs)
on the efficacy of AvFc in this model. The results demonstrate the importance of Fc
modification on the therapeutic efficacy of AvFc, as well as the utility of the plant
expression system for manufacturing glycoengineered AvFc variants.

5.2: Results
5.2.1: Analysis of CH2 N-glycans of AvFc
In order to demonstrate the effects of expressing AvFc in glycoengineered plants,
we first set out to characterize the composition of the lone N-glycan on the CH2 domain

105

of the human Fc of AvFc produced in WT or ΔXF plants (Table 5). HPLC analysis of Fc
glycans revealed that AvFc expressed in WT plants contains a relatively large proportion
of high mannose glycans (60.5%), with Man9 being the predominant form, followed by
the expected plant glycans containing β1,2-xylose and/or α1,3-fucose (33.0%), and a
small amount of complex glycans (6.5%, primarily GnGn). Conversely, AvFc expressed
in ΔXF plants was entirely devoid of plant glycans and instead contained mostly complex
glycans, particularly the expected GnGn glycoform (54.2%), and a similarly high
proportion of high mannose glycans (40.0%). The use of RNAi to knockdown expression
of the xylosyltransferase and fucosyltransferase was somewhat “leaky”, and the ΔXF
variant was found to contain small percentages of other complex glycans (a β1,3galactosylated glycoform) and some hybrid glycans (GNM3, GNM4, GNM5). As a point
of comparison, when expressed in CHO cells, AvFc displays not only the typical
mammalian glycoforms containing α1,6-fucose (primarily GN2M3F) but also a large
proportion of high-mannose and galactosylated glycans.
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Figure 17. Glycan analysis by HPLC.
(A) Identification of Fc glycans by HPLC of WT and ΔXF AvFc shows the large
presence of high-mannose glycans between both variants. WT AvFc also contains
significant amounts of plant glycans containing α1,3-fucose and β1,2-xylose while ΔXF
is devoid of them. (B) Glycan analysis by HPLC shows that AvFc produce in CHO cells
contains characteristic α1,6-fucose in addition to high-mannose glycans. Glycan analysis
was performed by Drs. Kajiura and Fujiyama at Osaka University, Japan.

107

Glycan type

Structure

WT
M3X
1.1
M3FX
11.9
Plant
GNM3FX
3.5
GN2M3X
2.5
GN2M3FX
14.1
M5
M6
M7A
2.4
High-mannose
M7B
5.0
M8A
18.0
M9
35.2
GNM3
Hybrid
GNM4
GNM5
GN2M3 (GnGn)
6.5
GN2M3F (α1,6)
Complex
Gal(β1,4-)GN2M3F
Gal(β1,3-)GN2M3
Plant
33.0
High-mannose
60.5
Totals
Hybrid
Complex
6.5
Table 5. CH2 glycan analysis of AvFc variants by LC-MS.

Ratio (%)
ΔXF
5.3
3.3
14.8
16.6
1.1
0.3
3.5
54.2
0.9
40.0
4.9
55.1

CHO
24.5
5.5
2.9
3.1
3.1
50.6
10.3
39.1
60.9

Glycan composition was determined by HPLC. AvFc expressed in WT plants contained
33% plant glycans (which contain β1,2-xylose, α1,3-fucose, or both), 60.5% highmannose glycans (primarily Man8 and Man9), and 6.5% complex glycans. Expression in
the glycoengineered N. benthamiana line ΔXF resulted in GnGn becoming the
predominant glycoform in addition to a large proportion of high-mannose glycans. Plant
glycans were not detected in AvFc derived from either line, however AvFc from ΔXF
plants displayed a small percentage of hybrid glycans (4.9%) and a β1,3-galactosylated
glycoform. Plant glycans were also not found in AvFc expressed in CHO cells, which
primarily displays the mammalian α1,6-fucosylated GnGn (GN2M3F) glycoform as well
as a β1,4-galactosylated form. Like the others, AvFcCHO contained a fairly large
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proportion of high-mannose glycans. Symbols: M = mannose; X = xylose; F = fucose;
GN = N-acetylglucosamine; Gal = galactose. Glycan analysis was performed by Drs.
Kajiura and Fujiyama at Osaka University, Japan.
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5.2.2: Expression, purity, and binding activity of AvFc variants
We have previously reported that AvFcWT is highly expressed in plants and has a
purified yield of ≈ 100 mg/kg [98]. Yields of purified protein were not found to be
significantly different between AvFcWT, AvFcΔXF, or AvFcΔlec, averaging between 100
and 150 mg/kg depending on plant conditions, as determined by A280 measurements of
purified proteins (ϵ = 1.635). Densitometry analysis of Coomassie-stained gels showed
that proteins could be purified up to ≈ 95% homogeneity (Figure 18B). On the other
hand, removal of the single N-glycan in the AvFcΔgly variant resulted in a more than 50%
decrease in yield, likely due to a decrease in stability in planta. All the variants were
identical according to molecular weight (≈ 38.6 kDa reduced, ≈ 77.1 kDa non-reduced,
Figure 18A), though the amounts of a frequently observed 50 KDa band, likely
corresponding to cleaved Fc dimer fragments, varied somewhat between the different
forms of AvFc. Another minor impurity was detected at ≈ 30 KDa in reducing samples of
each variant, and a faint ≈ 150 KDa band can be seen in the non-reduced Δgly variant,
possibly suggesting an AvFc dimer. Overall, we concluded that change in the plant
expression host did not significantly alter our manufacturing capability or the resulting
protein purity and that, with the exception of the AvFcΔgly variant, expression yields were
consistently high.
Next, we set out to determine whether or not altering the glycosylation pattern of
AvFc affected its ability to recognize cancer cells or induce Fc-mediated effector
functions in vitro. Flow cytometry of AvFc variants binding to B16F10 cells showed that
changes to the Fc glycans did not significantly impact cancer-cell binding kinetics
(Figure 18D-E), with saturation of the cell surface occurring at ≈ 15 nM for AvFcΔXF,
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AvFcWT, and AvFcΔgly. Similarly, Fc modifications did not significantly impact binding
to the highly-mannosylated HIV glycoprotein gp120 as determined by ELISA (Figure
18C), with EC50 values of 0.048, 0.051, and 0.061 nM for the ΔXF, WT, and Δgly
variants respectively. For the Δlec variant no binding to gp120 could be measured,
though minimal binding to B16F10 cells was observed at the highest concentration. The
results suggest that changes to the Fc glycan do not have an impact on sugar binding by
the Avaren lectin.
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Figure 18. Purity and binding activity of AvFc variants.
(A) SDS-PAGE analysis of AvFc variants under denaturing and reducing/non-reducing
conditions. Each lane contains 15 μg of protein for purity determination. AvFc appears
predominantly at 38.6 KDa under reducing conditions and 77.1 KDa under non-reducing
conditions and is mostly pure. Some impurities are observed, in particular an ≈ 50 KDa
fragment is seen with each variant in varying amounts, likely corresponding to dimerized
Fc-fragments. Another fragment at ≈ 30 KDa is visible in each variant under reducing
conditions, as well as a small amount of a possible dimer of AvFc at 150 KDa in the Δgly
variant. (B) Purity of AvFc in panel A using densitometry. Densitometry was performed
using GelAnalyzer and purity was calculated as the percentage of the total area of all
visible bands made up by the main AvFc band. All variants were found to be around 95%
purity (average of purity calculations under reducing and non-reducing conditions). (C)
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Binding of AvFc variants to HIV-1 gp120 by ELISA. All variants of AvFc, excluding the
non-sugar-binding mutant AvFcΔlec, bound to gp120 with nearly identical potency and
efficacy. EC50 values: AvFcΔXF = 0.048 nM; AvFcWT = 0.051 nM; AvFcΔgly = 0.062 nM;
AvFcΔlec = N/A. (D-E) Binding of AvFc variants to B16F10 cells by flow cytometry.
Bound AvFc was detected with a goat anti-human IgG FITC secondary antibody. Panel D
shows representative histograms for each, while E shows the quantification of binding
determined by the proportion of cells with fluorescence intensity above the background.
Binding was nearly equivalent for AvFcΔXF, AvFcWT, and AvFcΔgly, with saturation
occurring at ≈ 15 nM. The Δlec variant exhibited very weak binding at the highest
concentration tested (150 nM) but was mostly devoid of activity. All data shown are
mean ± SD.
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5.2.3: AvFcΔXF exhibits higher affinity to FcγRs from humans and mice
We then set out to determine the impact of glycoengineering on AvFc’s affinity to
FcγRs by performing a kinetic analysis of AvFc binding to FcγRs with surface plasmon
resonance (SPR). For this we chose to assess affinity to human FcγRI (hFcγRI),
hFcγRIIIa, and murine FcγRIV. The high-affinity receptor hFcγRI is most closely
associated with the activation and phagocytosis of antibody-opsonized pathogens and
cells by macrophages but is also expressed by eosinophils and neutrophils and has
nanomolar affinity for IgG1. The low-affinity receptor hFcγRIIIa, on the other hand, is
primarily associated with the induction of ADCC by NK cells and has micromolar
affinity for IgG1. We also measured affinity to mFcγRIV, which is a low-affinity
receptor roughly equivalent to FcγRIIIa in humans, as we wanted to determine whether or
not glycoengineering would have an impact in mouse models.
Kinetic analysis of binding to FcγRs by SPR showed that the ΔXF variant had
1.9-fold increased affinity to human hFcγRI (though this was non-significant), 3.8-fold
increased affinity to hFcγRIIIa, and 5.5-fold increased affinity to mouse FcγRIV
(mFcγRIV) compared to AvFcWT (Figure 19). Representative sensorgrams are shown in
Figure 19 along with a table summarizing the results. Table 6 shows representative
measurements of dissociation and association rate constants (kd and ka) as well as the
overall dissociation constant KD from an individual SPR experiment. For hFcγRI, the
increase in affinity of ΔXF appears to be mostly due to a lengthening of the dissociation
time, as indicated by a decrease in the kd values, even though the WT variant showed
slightly faster association (higher ka, Table 6). For hFcγRIIIa, the increase in affinity by
ΔXF seems to be both due to faster association (higher ka) and longer dissociation (lower
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kd), while interestingly the increase in affinity of ΔXF for mFcγRIV was due almost
entirely to an increase in association speed as the dissociation rate constants were nearly
identical. In general, AvFcΔXF also reached higher Rmax values, however this is to be
expected given its higher affinity for the receptors. No measurements could be made for
the Δgly variant and signals seen in the sensorgrams are due almost entirely to bulk shift
in the refractive index due to minor differences in running and sample buffer
composition. Thus, we concluded that glycoengineering of AvFc resulted in the
predictable increase in affinity for FcγRs, similar to what is observed for defucosylated
mAbs, and should result in increased activity both in vitro and in vivo.
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Figure 19. Representative sensorgrams of AvFc variant binding to FcγRs.
Shown are representative sensorgrams illustrating the association and dissociation
kinetics of AvFc to the various FcγRs. Kinetics of binding to the high-affinity receptor
hFcγRI are characterized by rapid association and slow dissociation, which results in low
nanomolar KD values. AvFcΔXF had 1.9-fold increased affinity to this receptor compared
to the WT variant. For hFcγRIIIa and mFcγRIV, binding kinetics were generally
characterized by rapid association and dissociation resulting in high nanomolar KD
values. AvFcΔXF had 3.8-fold higher affinity to hFcγRIIIa and 5.5-fold higher affinity to
mFcγRIV than the WT variant. No affinity could be measured for the Δgly variant.
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hFcγRI
kd (1/s)
0.001144
0.000213

KD (M)
7.77559E-09
4.03824E-09

Rmax (RU)
206.8
308.5

hFcγRIIIa
kd (1/s)
0.02487
0.00609

KD (M)
1.24649E-06
1.35264E-07

Rmax (RU)
21.6
30.4

mFcγRIV
Variant
ka (1/Ms)
kd (1/s)
KD (M)
WT
5188.43
0.01093
2.10717E-06
ΔXF
23801.737
0.01031
4.33267E-07
Table 6. Representative example of SPR kinetic data.

Rmax (RU)
70.3
129.9

Variant
WT
ΔXF
Variant
WT
ΔXF

ka (1/Ms)
147145.162
52669.55
ka (1/Ms)
19954.29
45040.63

Shown in this table is a representative data set showing ka, kd, KD, and Rmax
measurements from an individual SPR experiment for each receptor. For hFcγRI,
AvFcWT showed faster association than ΔXF as indicated by the increase in ka value.
However, this was offset by a significant increase in kd, which results in faster
dissociation and ultimately lower affinity (KD). For hFcγRIIIa, AvFcΔXF had both faster
association and slower dissociation, resulting in significantly higher affinity.
Interestingly, the increase in affinity for mFcγRIV was due almost entirely to an increase
in association rate constant as the dissociation rate constants between the two variants
were almost identical. No measurements could be made for the Δgly variant. Increased
Rmax values for ΔXF generally correspond to the increase in affinity.
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5.2.4: AvFc binding to B16F10 cells induces ADCC but not direct cytotoxicity
The impact of the increased affinity to hFcγRIIIa was demonstrated in an in vitro
ADCC reporter assay, wherein activation of hFcγRIIIa on engineered Jurkat effector cells
in the presence of an antibody and a target cell leads to the expression of luciferase,
serving as a surrogate for Fc-mediated cell death. In this assay, using B16F10 as the
target cell, neither the Δgly or Δlec variants of AvFc were capable of inducing luciferase
expression due to the lack of significant affinity to FcγRIIIa or to B16F10 cells (Figure
20A). As hypothesized, incubation with AvFcΔXF resulted in the highest level of
luciferase induction (≈ 5.5-fold over background, EC50 = 2.75 nM) while AvFcWT
showed only a moderate level of induction (≈ 2.9-fold over background, EC50 = 13.78
nM), indicating that increased hFcγRIIIa affinity has functional consequences that could
potentially impact AvFc’s activity in vivo. We further noted that AvFc, by binding to the
cell surface alone, fails to induce cell death or inhibit cell proliferation after 48 hours of
incubation with B16F10 cells as determined by an MTS viability assay (Figure 20B). Nor
does co-incubation with AvFc and B16F10 cells lead to the induction of apoptosis as
determined by annexin V/propidium iodide staining (Figure 20C-D). This is in direct
contrast to concanavalin A, which is a known cytotoxic lectin that results in significant
cell death when incubated with B16F10 cells (Figure 20B-D). Taken together, these
results indicate that AvFc could have potent anti-cancer activity in vivo against B16F10
tumors due primarily to immune-mediated effector functions. To evaluate this, we opted
to directly compare the ΔXF and Δgly variants in the flank tumor model as they
represented the extreme ends of the spectrum of Fc-mediated activities, which would
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allow us to demonstrate activity as well as infer the extent to which Fc-mediated
functions are necessary for said activity.
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Figure 20. Induction of ADCC but not cytotoxicity by AvFc.
(A) Induction of ADCC by AvFc variants assessed using a reporter-cell based luciferase
assay. AvFcΔXF showed the highest levels of induction, ≈ 5.5-fold above background with
an EC50 of 2.75 nM. The WT variant, on the other hand, showed moderate induction, ≈
2.9-fold over the background with an EC50 of 13.8 nM. The Δgly and Δlec variants did
not induce any luciferase expression, indicating lack of binding to the Fc receptor or to
the B16F10 cells, respectively. (B) Impact of AvFc incubation on cell viability by MTS
assay. B16F10 cells were co-incubated with AvFc variants or the cytotoxic lectin
concanavalin A for 48 hours with concentrations beginning at 650 nM. No effect on cell
viability was seen with the AvFc variants, while co-incubation with concanavalin A was
found to significantly decrease cell viability at the highest concentrations tested. (C)
Representative dot plots of annexin 5/PI staining following coincubation for 48 hours
with AvFc variants or concanavalin A. (E) Quantification of results shown in panel C.
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Nearly 100% of cells following treatment with any of the AvFc variants stained negative
for both annexin v and PI, while nearly all of the cells treated with concanavalin A were
in either early or late apoptosis (ANXV+/PI- and ANXV+/PI+, respectively), indicating
that binding of AvFc to B16F10 cells likely does not induce apoptosis. All treatment
groups were significantly different from concanavalin A in every quadrant except for
ANXV-/PI+ (indicating necrosis or advanced cell death), where few cells from any
treatment were found (2-way ANOVA). All data are shown as mean ± SD.

121

5.2.5: Fc-mediated effector functions are required for AvFc’s activity in the B16F10
flank tumor model
We first set out to demonstrate that AvFc recognizes B16F10 tumors in vivo using
PET/CT imaging of mice with established B16F10 flank tumors. Animals were injected
with 1x106 cells subcutaneously in the hind right flank and imaged after 10 days, at
which point 3.7 MBq of a radiolabeled 64Cu-NOTA-AvFc was administered
intravenously. Analysis of the imaging data shows that AvFc strongly accumulates with
the tumor (Figure 21D), though some additional signal was seen in the liver (Figure 21D,
subpanel 3), spleen (Figure 21D, subpanel 4), and bladder (Figure 21D, subpanel 5).
These organs are the primary sites of protein metabolism, and as such background signal
in these organs is commonly observed in live animal PET imaging using antibody probes
[274].
To assess treatment with AvFc in this model, 100,000 cells were injected
subcutaneously into the hind left flank of the animal and tumor sizes were measured
every other day beginning the day after implantation (Figure 21A). Intraperitoneal
treatment with 25 mg/kg of AvFcΔXF, begun 5 days post-implantation, significantly
slowed the growth of the tumors beginning from day 9, while showing no overt toxicity
as indicated by the lack of significant deviations in body weight (Figure 21B-C).
Aglycosylated AvFc, on the other hand, had no effect on tumor growth over time while
maintaining a similar safety profile. These results corroborate our in vitro observations
and show that not only does AvFc have activity in vivo, but that the activity of AvFc
against B16F10 seems to be dependent on Fc-mediated effector functions and not through
direct cytotoxicity.
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Figure 21. Activity of AvFc in the B16F10 flank tumor model.
(A) Study outline. Tumors were implanted into the hind left flank of C57bl/6 mice on day
0, with treatment beginning on day 5 and continuing Q2D until day 15. Treatment was
with 25 mg/kg (500 μg) of AvFcΔXF or AvFcΔgly administered intraperitoneally in 200 μL
of vehicle (n=5/group). Tumor volumes and body weights were measured every other day
from day 1 until day 16 when the study was terminated. (B) Change in tumor volumes
over time. Beginning on day 9, AvFcΔXF significantly delayed the growth of flank tumors
compared to the vehicle-treated group (*p<0.05 between ΔXF and vehicle). Conversely,
the Δgly variant was unable to delay growth and was not significantly different from the
vehicle (# p<0.05; ## p<0.01; ### p<0.001; #### p<0.0001; between AvFcΔXF and
AvFcΔgly). Data shown are mean ± SD. (C) Comparison of body weights between groups
during the study, shown as percent change from day 0 weight. No significant differences
were noted between groups. (D) Representative PET/CT image of C57bl/6 mice with
colocalization of radiolabeled 64Cu-NOTA-AvFc with B16F10 flank tumors. (D1) Whole
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body PET/CT, dorsal view. Signal is clearly visible within the tumor and in the liver.
(D2) Whole body CT, dorsal view. Tumor is indicated by white arrowhead. (D3) Whole
body PET/CT, lateral view. (D4) Coronal slide view, PET/CT scan. Tumor is indicated
by the green crosshairs, which also correspond to the transverse slide view in subpanel 5.
(D5) Transverse slide view, PET/CT scan.
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5.2.6: Protection against metastatic B16F10 challenge by AvFc requires high-mannose
binding
We set out to further characterize AvFc’s activity using a metastatic B16F10
melanoma challenge model, comparing AvFcΔXF with the non-sugar-binding mutant
AvFcΔlec. In this model, 250,000 cells were injected intravenously via the tail vein
followed by co-treatment with 25 mg/kg of AvFcΔXF, which began on day 0 and
continued Q2D for a total of 6 doses (Figure 22A). This dose was found to significantly
reduce the resulting lung tumor burden by more than 3-fold compared to the vehicle
(p=0.0009) while the non-sugar-binding mutant AvFcΔlec offered no protection at the
same dose (p>0.9999, Figure 22B). There was also a significant difference in tumor
counts between AvFcΔXF and AvFcΔlec at both dose levels (p=0.0469 and p=0.0366). As
described previously, repeated administration of AvFc was not associated with any overt
toxicity or body weight effects (Figure 22C). These data suggest that AvFc has potent in
vivo against B16F10 melanoma, and this mechanism appears to be both dependent on Fcmediated effector functions and high-mannose binding but not by direct cytotoxicity.
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Figure 22. Activity of AvFcΔXF in the B16F10 melanoma metastasis model.
(A) Study outline. On day 0, 2.5x105 cells were injected intravenously into C57bl/6 mice
followed by immediate treatment with vehicle, AvFcΔXF, or AvFcΔlec at 10 or 25 mg/kg
(vehicle n=39; ΔXF 10 mg/kg n=18; ΔXF 25 mg/kg n=28; Δlec 10 mg/kg n=10; Δlec 25
mg/kg n=10). Treatment continued Q2D for a total of 6 doses. Animals were euthanized
on day 21, at which point lungs were removed and tumor nodules were counted. (B)
Tumor counts. Treatment with AvFcΔXF resulted in a dose dependent reduction in tumor
number with significance at 25 mg/kg compared to the vehicle as well as both dose levels
of AvFcΔlec as determined by the Kruskal-Wallis test. Neither dose level of AvFcΔlec
showed any protective benefit. Data shown are mean ± SEM. (C) Changes in body
weight over time. No significant changes in body weight were observed as determined by
2-way ANOVA. Data shown are mean ± SD.
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5.2.7: Impact of pretreatment of mice with AvFc on its anticancer activity in vivo.
As a foreign protein, AvFc administration in mice results in the generation of antidrug antibodies (ADAs), which in theory can compromise the safety and efficacy of the
drug. In order to address the consequence of ADA generation on the activity of AvFc in
vivo, we repeated the flank tumor model and divided it into 2 phases: a pretreatment
phase, where groups of animals would receive either AvFc or a vehicle before tumor
implantation to generate ADAs, and a treatment phase, where groups of animals would
receive AvFc or vehicle following tumor implantation as described above (Figure 23A).
The primary endpoint for this study however would be survival, which would be defined
as the time from tumor implantation until they reached a volume of 1500 mm3, at which
point animals were euthanized and blood and other organs taken for analysis. Pretreated
animals received 6 doses of AvFc at 25 mg/kg Q2D followed by an 11-day waiting
period before tumor implantation (Figure 23A). To confirm the presence of ADAs, serum
titers were measured by AvFc-binding ELISA at three points: just prior to tumor
implantation, at the beginning of the treatment phase of the study, and following
euthanasia of the animals. The results of these assays are reported in Figure 23B. Before
the pretreatment, all animals had titers at or near the lowest dilution tested (1:50), likely
due to a small matrix effect caused by the mouse serum on the ELISA. By day 20, all of
the pretreated animals had measurable ADA titers, with values between 104-105 that
continued to increase through the end of the study at varying rates. Animals that received
AvFc only during the treatment-phase of the study also generated a robust ADA response
by the time of euthanasia, between 104 and 106. By far, the pretreated and AvFc-treated
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group generated the largest ADA response, albeit a more variable one, with titers
between 104 and 108 at euthanasia.
The effect of pretreatment on animal survival in this model are summarized in
Figure 23C-D. Pretreatment with AvFc had no effect on the survival of vehicle-treated
animals compared to non-pretreated animals (p=0.3049). As was previously observed,
treatment with AvFc of non-pretreated animals resulted in delayed tumor growth and
increased survival compared to vehicle-treated animals (p=0.0067 vs. non-pretreated
animals, p=0.0083 vs. pretreated animals). Interestingly, compared to the non-pretreated
AvFc-treated group, pretreatment with AvFc extended the median survival time by nearly
5 days (25 vs. 29.5), though this effect failed to reach statistical significance (p=0.0323).
These data reveal that ADAs generated against AvFc do not appear to neutralize the drug
and make it ineffective, nor did they present any obvious safety concerns over the course
of the study with no major adverse events or body weight effects noted. On the contrary,
it seems that the presence of ADAs may have increased the anti-tumor activity of AvFc,
which challenges the conventional wisdom surrounding ADAs and cancer
immunotherapy.
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Figure 23. Impact of pretreatment on the anticancer activity of AvFc in vivo.
(A). Study outline. The study was divided into a pretreatment and a treatment phase that
followed implantation of tumors. A set of 40 animals were divided into 4 groups, two of
which would receive pretreatment and two that would not. Of the two that were either
pretreated or not, one would receive vehicle as treatment during the second phase and the
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other would receive AvFcΔXF. Treatment was administered i.p. at 25 mg/kg, and blood
was taken at different time points to monitor ADA generation. Animals were monitored
by survival which was defined as the time necessary for tumors to reach ≈ 1500 mm3. (B)
ADA measurements. Animals were negative for ADAs at baseline (day -1). After
pretreatment (day 20), pretreated animals had measurable ADAs in the 104 to 105 range.
Following euthanasia (at survival endpoint), All animals that received AvFcΔXF during
either the pretreatment or treatment phase had measurable ADAs, the ranges of which
varied between groups and was highest with the animals that received both pretreatment
with AvFcΔXF and were treated with it additionally. (C) Impact of AvFc on tumor
volumes over time. Pretreatment with AvFcΔXF had no effect on tumor growth rate in the
vehicle treated groups, and tumors grew rapidly in both (black and red lines). Treatment
with AvFcΔXF was associated with slower tumor growth in the group that was not
pretreated (green line). With both pretreatment and treatment, the delay of tumor growth
was more significant (purple line). (D) Effect of pretreatment on survival. Pretreatment
did not improve or worsen survival for the vehicle-treated groups, which both had median
survival times of 20 days (black and red lines). Treatment of B16F10 tumors with
AvFcΔXF but without pretreatment resulted in a significant increase in median survival
(p=0.0067, log-rank test) from 20 to 25 days. Pretreatment strengthened this effect,
increasing median survival from 25 to 29.5 days though it was not statistically significant
(p=0.0323, log-rank test).
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5.2.8: Flow cytometry analysis of B16F10 tumor-infiltrating immune cells
One of the hallmarks of cancer is immune evasion and the conversion of the local
immune microenvironment from a pro-inflammatory, anti-tumor response to an antiinflammatory, pro-tumor response. Since AvFc is a foreign protein that provokes an
immune response (see section 5.2.7), we hypothesized that administration of the drug to
tumor-bearing mice may result in a shift towards a more inflammatory cell phenotype
and increased cell infiltrates, which may play a role in its anti-cancer mechanism of
action. To explore this hypothesis, we performed flow cytometry on immune cells
isolated from B16F10 tumors after vehicle or AvFc treatment to assess changes in the
composition due to drug treatment. In this experiment, tumors were implanted into the
hind-left flank of C57bl/6 mice on day 0, with intraperitoneal treatment with 25 mg/kg
AvFc or 200 μL vehicle beginning on day 5. A total of 3 doses were given before the
animals were euthanized on day 10 and tumors removed and digested for immune cell
isolation. Cells were stained with 4 panels of antibodies for immunophenotyping: one for
NK cells, one for myeloid cells, one for dendritic cells, and one for T lymphocytes. B
cells were not analyzed in this experiment. The complete list of markers used is
summarized in Table 7. Cell counts were normalized based on tumor weight. Consistent
with results from the previous study (Section 5.2.5, 5.2.7), tumors from AvFc-treated
animals were significantly smaller than those from the vehicle group (Figure 27A). In
addition, all cell populations analyzed had a slight but non-significant trend towards
increased cell numbers per gram tumor weight with the exception of non-classical Ly6Cmonocytes, which were all significantly increased in AvFc-treated tumors (Figure 27,
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Figure 30, Figure 34). These results suggest that part of AvFc’s mechanism of action may
be due to the increased recruitment of immune cells to the tumor site.
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NK Cells

Population

Lymphocytes
CD8 T cells
CD4 T cells
Th1 CD4 T cells
Th2 CD4 T cells
Th17 CD4 T cells
DCs
Classical DCs CD11b+
Classical DCs CD11bActivation/costimulatory markers

Markers
CD45+, CD3-, NK1.1+
CD8+, TCRβ+
CD4+, TCRβ+
As above, IFNγR+
As above, IL-33R+
As above, IL-23R+
MHCII+, CD11c+, CD103-, CD11b+
CX3CR1hi/CD206+
CX3CR1lo/CD206MHCII+, CD11c+, CD103-. CD11bCD68, CD69, CD80, CD86

Myeloid cells
Neutrophils
Macrophages
Classical Monocytes

CD11b+, Ly6G+
MHCII+, Ly6C+, F4/80hi
MHCII+, Ly6C+, F4/80CX3CR1hi
CX3CR1lo
CD206+
Non-classical monocytes
MHCII+, Ly6CF4/80-, CX3CR1lo
F4/80-. CD206+
CX3CR1lo, CD206CX3CR1hi
CX3CR1hi, CD206Table 7. Summary of cell-surface markers used in B16F10 tumor
immunophenotyping.
The marker panel was designed with the assistance of Dr. Noel Verjan Garcia.

133

Figure 24. NK cell gating strategy.
Differentiation between lymphocytes and tumor cells was not possible through FSC/SSC
gating, so all cells were chosen for further analysis. Live cells were defined as 7AAD-.
NK cells were defined as CD3-/NK1.1+. Gating was performed with the assistance of Dr.
Noel Verjan Garcia.
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Figure 25. CD4 T cell gating strategy.
Differentiation between lymphocytes and tumor cells was not possible through FSC/SSC
gating, so all cells were chosen for further analysis (not shown). Live cells were defined
as 7AAD- (not shown). CD4 T cells were defined as TCRβ+/CD4+. A second population
of increased CD4+ expression was identified but not analyzed. Double positive cells were
then separately analyzed for IFNγR (Th1), IL-23R (Th2), or IL-33R (Th17) expression
on the Y axis using TCRβ as the X axis marker. Gating was performed with the
assistance of Dr. Noel Verjan Garcia.
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Figure 26. CD8 T cell gating strategy.
Differentiation between lymphocytes and tumor cells was not possible through FSC/SSC
gating, so all cells were chosen for further analysis (not shown). Live cells were defined
as 7AAD- (not shown). CD8 T cells were defined as TCRβ+/CD8+. Gating was
performed with the assistance of Dr. Noel Verjan Garcia.
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Figure 27. Comparison of NK and T cell subsets within B16F10 tumors.
All statistical comparisons were made with the Student’s T test with Welch’s correction.
(A) Comparison of tumor weights at the time of excision from the animals. Tumors
removed from AvFc-treated animals were significantly smaller than those from vehicletreated animals. While there was a trend towards increased cell numbers, no statistical
significance was observed for each of the following populations: B, NK cells (CD3-
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/NK1.1+); C, CD8+ T cells (TCRβ+/CD8+); D, CD4 T cells (TCRβ+/CD4+); E, Th1
cells (TCRβ+/CD4+/IFNγR+); F, Th2 cells (TCRβ+/CD4+/IL-23R+); G, Th17 cells
(TCRβ+/CD4+/IL-33R).
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Figure 28. Dendritic cell gating strategy.
Differentiation between lymphocytes and tumor cells was not possible through FSC/SSC
gating, so all cells were chosen for further analysis. Live cells were defined as 7AAD-.
MHCII+/CD11c+ cells were subsequently analyzed for CD11b, CD103, CX3CR1, and
CD206 expression. Gating was performed with the assistance of Dr. Noel Verjan Garcia.
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Figure 29. Gating strategy for DC activation and costimulatory markers.
Analysis of the activation status and costimulatory molecule expression of
CD11b+/CD103- DCs from Figure 28 was performed by plotting CD68, CD69, CD80,
and CD86 against MHCII. Gating was performed with the assistance of Dr. Noel Verjan
Garcia.
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Figure 30. Comparison of classical dendritic cell subsets within B16F10 tumors.
All statistical comparisons were made with the Student’s T test with Welch’s correction.
No statistically significant increases were seen, however a trend towards increased
intratumoral classical DCs (cDCs) and increased activation/costimulatory molecule
expression was observed. A: cDCs (CD11c+/MHCII+/CD11b+/CD103-). B:
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CX3CR1hi/CD206+ subset of CD11b+ cDCs in A. C: CX3CR1lo/CD206- subset of
CD11b+ cDCs in A. D: CD11b- cDCs (CD11c+/MHCII+/CD11b-/CD103-). E: CD68+
cDCs (CD11b+/CD103-). F: CD69+ cDCs (CD11b+/CD103-). G: CD80+ cDCs
(CD11b+/CD103-). H: CD86+ cDCs (CD11b+/CD103-).
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Figure 31. Neutrophil gating strategy.
Differentiation between lymphocytes and tumor cells was not possible through FSC/SSC
gating, so all cells were chosen for further analysis (not shown). Live cells were defined
as 7AAD- (not shown). Neutrophils were defined as CD11b+/Ly6G+. Gating was
performed with the assistance of Dr. Noel Verjan Garcia.
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Figure 32. Classical monocyte/macrophage gating strategy.
Differentiation between lymphocytes and tumor cells was not possible through FSC/SSC
gating, so all cells were chosen for further analysis. Live cells were defined as 7AAD-.
Classical monocytes were defined as MHCII+/Ly6C+ cells. Macrophages are defined as
MHCII+/Ly6C+/F480+. Double positive cells were then analyzed for CX3CR1, F4/80,
and CD206 expression. Gating was performed with the assistance of Dr. Noel Verjan
Garcia.
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Figure 33. Non-classical monocyte gating strategy.
Differentiation between lymphocytes and tumor cells was not possible through FSC/SSC
gating, so all cells were chosen for further analysis. Live cells were defined as 7AAD-.
Non-classical monocytes were defined as MHCII+/Ly6C- cells. Double positive cells
were then analyzed for CX3CR1, F4/80, and CD206 expression. Gating was performed
with the assistance of Dr. Noel Verjan Garcia.
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Figure 34. Comparison of neutrophil, macrophage, and monocyte populations
within B16F10 tumors.
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All statistical comparisons were made with the Student’s T test with Welch’s correction.
No statistically significant changes were observed in neutrophils, macrophages, or
classical monocytes (A-F), however as with other cell populations a trend towards an
increase was seen. Statistically significant increases were observed in all subsets of nonclassical monocytes (G-K). A: Neutrophils (CD11b+/Ly6G+). B: Macrophages
(MHCII+, Ly6C+, F4/80hi). C: Classical monocytes (MHCII+/Ly6C+). D: CX3CR1hi
subset of classical monocytes. E: CX3CR1lo subset of classical monocytes. F: CD206+
subset of classical monocytes. G: Non-classical monocytes (MHCII+/Ly6C-/F480-). H:
CD206+ subset of non-classical monocytes in G. I: F4/80+ subset of non-classical
monocytes. J: CX3CR1+ subset of non-classical monocytes in G. K: CX3CR1+/CD206subset of non-classical monocytes in G.
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5.3: Discussion
Plant-based recombinant expression systems have found some success as rapid,
robust, and scalable alternative manufacturing platforms for pharmaceutical proteins
[275, 276]. A useful characteristic of many of the plants used for pharmaceutical
production, in particular N. benthamiana, is that they are generally readily amenable to
engineering using modern techniques including RNA interference (RNAi), transcription
activator-like effector nucleases (TALENs), zinc-finger nucleases, and CRISPR/Cas9
[277-280]. Therefore, N. benthamiana can be exploited to generate glycoengineered
variants of biologics that have higher levels of activity in vivo and may obviate some
safety concerns regarding the presence of plant N-glycans. Removal of either the human
α1,6- or plant α1,3-liked core fucose residues through genetic engineering of the
expression host has long been known to dramatically increase the affinity of monoclonal
antibodies for FcγRs, especially hFcγRIIIa, and improve their activity both in vitro and in
vivo [266, 281]. Thus, for therapeutic antibodies or other Fc-bearing molecules such as
AvFc where ADCC is a major mechanism of action, such a modification would be highly
valuable. In this study, we show that expression of our candidate anti-cancer
immunotherapeutic AvFc in glycoengineered ΔXF plants results in the total loss of plantderived glycans, with the predominant glycoform being the truncated, “humanized”,
GnGn form (Table 5, Figure 17). However, compared to mAbs expressed in WT or ΔXF
plants, AvFc displays some idiosyncrasies with regards to its glycan composition.
The first of these is that AvFcWT contains few plant-derived glycans, with
glycoforms containing β1,2-xylose and α1,3-fucose (XF) representing only 33% of the
total glycan population compared to upwards of 90% for most plant-expressed mAbs
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(Table 5) [265, 282-284]. The second is that both AvFcWT and AvFcΔXF display large
proportions of high-mannose glycans, which are typically only present on mAbs in very
small amounts when expressed in plants [265, 282-284]. These two observations may
indeed be somewhat linked, as an overabundance of high-mannose glycans on
recombinant proteins can be the result of extended residency or accumulation in the
endoplasmic reticulum, such as is seen when antibodies are tagged with the ER-retention
signal KDEL [285]. Given that AvFc is a high-mannose-binding lectibody, it is highly
possible that it forms complexes with itself or with other ER-resident glycoproteins
during expression, preventing export to the Golgi apparatus for further processing and
resulting in an accumulation of high-mannose glycans. Similarly high levels of highmannose glycans have been identified on mAbs with atypical structures such as monoand multivalent single-chain variable fragments, which are hypothesized to be retained in
the ER due to prolonged interaction with BiP in the absence of the light chain constant
region [282, 286]. However, similar findings have not been reproduced for Fc fusion
proteins produced in mammalian cells or in plants [287-293]. It should be noted that
AvFc manufactured in CHO cells also has increased levels of high-mannose glycans
compared to normal mAbs, though there are fewer, and the predominant form is Man5
(data not shown), indicating a greater degree of processing but also suggesting that the
increase is due to a property of AvFc and not the production host. The increased presence
of high-mannose glycans may also help to partially explain the relatively low half-life of
AvFcΔXF in mice and rhesus macaques (≈ 22 and ≈ 28 hrs, respectively, as reported in
[98, 211]) compared to normal mAbs, as antibodies and other Fc-bearing molecules
containing high-mannose glycans are more rapidly cleared from the organism by the

149

immune system [294]. AvFcΔXF also had a longer half-life in female mice than AvFcWT
(≈ 14 hours for the WT variant, data not shown vs. ≈ 18.5 hrs for the ΔXF variant, Figure
35 and [211]), possibly due to the reduction in high-mannose glycan content compared to
the WT (Table 5). Additionally, we have previously shown that AvFc has lower affinity
to FcRn compared to normal human IgG1, which also impacts half-life [98].
Improvements to half-life could be made through the introduction of amino acid
substitutions that improve FcRn affinity such as those described by Mackness et al. [295].
Work is being done to elucidate the cause of the increase in high-mannose, including by
assessing the glycan profile of the non-sugar-binding mutant AvFcΔlec, which may not
interact with itself or other proteins in the ER.
It is well known that removal of the core fucose residues increases the ADCC
activity of mAbs [163]. Our results show that AvFcΔXF, which lacks both core xylose and
core fucose, does indeed have higher affinity to both hFcγRIIIa (and its murine
equivalent mFcγRIV) and hFcγRI in addition as determined by SPR (Figure 19).
Functionally, removal of plant glycans made the ΔXF variant of AvFc nearly twice as
efficacious and 5 times more potent in the ADCC reporter assay against B16F10 cells,
while neither the Δlec nor Δgly variants were capable of inducing ADCC (Figure 20A).
AvFcΔXF also had a longer half-life in mice than AvFcWT (≈ 14 hours for WT vs. ≈ 22 hrs,
Figure 35 and [211]).
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Figure 35. Pharmacokinetic analysis of AvFcWT.
Pharmacokinetic profiles for WT AvFc were measured in male and female C57bl/6 mice
(n=3 per gender) following a single intravenous dose of 10 mg/kg. Serum concentrations
of AvFcWT were determined by gp120-binding ELISA at various time points and PK
parameters were calculated by PK Solver. These parameters were generally similar
between the two sexes. The half-life of AvFcWT was determined to be approximately 14
hours in both male and female mice.
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Results from the in vitro assays (Figure 20) and the B16F10 challenge model
(Figure 21) suggest that the antitumor activity of AvFc is almost exclusively attributable
to the induction of Fc-mediated effector functions, in particular ADCC. As shown in
Figure 20, AvFc induced high levels of ADCC without directly causing cell death as
determined by both an MTS assay and annexin V/propidium iodide staining, with the
AvFcΔXF variant producing a much higher ADCC response than AvFcWT. In addition, we
did not find that AvFc inhibited B16F10 migration (data not shown), demonstrating that
binding alone is likely not sufficient for AvFc to exert activity against B16F10 cells.
However, we have also recently reported that AvFc can inhibit the migration of H460 and
A549 human lung cancer cells in addition to inducing ADCC against these cell lines
[105]. The discrepancy between the findings in the present study with B16F10 cells and
the previous one with H460 and A549 may be partly explained by specific cell-surface
glycoproteins targeted by AvFc; for example, in the previous study we showed that the
lectibody’s binding to EGFR and IGF1R led to the inhibition of receptor phosphorylation
and downstream signaling [105]. Thus, we speculate that the collective antitumor
mechanisms of AvFc may be dependent on the characteristics of cancer cells targeted
although Fc-mediated activity is likely the lectibody’s primary mode of action. We also
reported in this study that administration of AvFcΔXF but not AvFcΔgly delayed the growth
of B16F10 flank tumors in vivo (Figure 21). AvFcΔXF was also found to significantly
reduce the number of tumor nodules in mouse lungs in the B16F10 metastasis model
while the non-sugar-binding mutant AvFcΔlec did not (Figure 22). Combined, these results
suggest that, at least in the B16F10 model, both sugar-binding activity and Fc-mediated
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effector functions are necessary for AvFc’s anti-cancer activity, and direct cell-killing
likely does not occur.
A potential concern when administering foreign proteins as therapeutics is
immunogenicity, which has the potential to limit drug efficacy after repeated dosing and
can result in serious adverse events related to hypersensitivities, owing to the induction of
ADAs and immunological memory to the drug [296]. One of the more striking findings
in this study was that pretreatment with AvFc and generation of ADAs did not negate
AvFc’s activity (Figure 23). On the contrary, it appears that the presence of ADAs may
have improved its activity, resulting in an increase in median survival time (defined as
the time from tumor implantation to the time the tumor reached a volume of 1500 mm3)
from 25 to 29.5 days compared to the AvFcΔXF-treated group without preexisting ADAs.
While this increase was not statistically significant after correcting for multiple
comparisons (p=0.0323), the data show a clear trend that at the very least indicates that
the ADA response to AvFc did not undermine the drug efficacy in this model. At most, it
demonstrates that the presence of ADAs may actually have some benefit, though the
reason for this is not known.
A concerning observation regarding animal safety came following the first
administration of AvFc during the treatment phase (on day 26, see Figure 23A) in the
group of animals that had previously received AvFc pretreatment. Approximately 2 hours
after i.p. administration 6 of the 10 animals developed symptoms consistent with either
anaphylaxis or a delayed-type hypersensitivity including labored breathing, closed eyes,
hunching, lack of movement, and lack of response to touch [297, 298]. This development
resulted in a medical case being opened by the veterinary staff, and the animals were
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monitored for several hours until it appeared that they had recovered by the late
afternoon. This reaction did not develop again after subsequent doses and was not seen in
any other group except for those that had received pretreatment. While it cannot be
conclusively determined whether or not the animals were having an anaphylactic reaction
to the drug from this experiment alone, the possibility that the animals may develop a
hypersensitive or anaphylactic response to AvFc certainly requires further investigation.
In recent years, it has become increasingly evident that tumors are highly adept at
managing the local immune microenvironment, converting it from an immunogenic to an
immunosuppressive environment [299-301]. This conversion makes tumors more
aggressive and allows them to better invade the surrounding tissues and metastasize,
leading to poorer clinical outcomes [302]. This fact has led to the institution of a novel
paradigm of cancer immunotherapy whose objective is to target not the tumor but the
host immune response, helping to convert immunologically “cold” tumors to
immunologically “hot” ones that can be better treated [303]. The most prominent
examples of this are the checkpoint inhibitors that target the inhibitory receptors PD-1
and CTLA-4 on T cells, preventing the tumor-initiated deactivation of cytotoxic T
lymphocytes in the local microenvironment leading to a better anti-tumor immune
response and better treatment outcomes [304]. Other approaches, such as vaccination
with TAAs or administration of immunocytokines, work by increasing the anti-tumor
antibody response as well as by stimulating the tumor immune microenvironment to
become more inflammatory [305, 306].
We initially hypothesized that AvFc, as a foreign protein that selectively
recognizes tumor cells, may work in a similar manner by stimulating the local immune
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response to the tumor and increasing tumor antigen presentation and generation of antitumor antibodies (ATAs). A preliminary flow cytometry experiment using B16F10 cells
stained with serum from pretreated and non-pretreated animals from this study and a goat
anti-mouse IgG-FITC conjugate demonstrated a slight but non-significant increase in
anti-tumor antibodies as inferred from the increased number of cells with a mean
fluorescence greater than the background. (Figure 36). We also performed a modified
ADCC assay by spiking AvFcΔXF into solutions of pooled serum obtained from animals
during the immunogenicity study shown in Figure 23 to assess whether or not ADAs or
ATAs impact ADCC induction in the reporter cell assay (Figure 36A-C). With this
method we found that while serum taken from any time point did not induce any
luciferase expression alone (Figure 36A-B), the addition of AvFcΔXF to the serum
resulted in an increase in activity significantly greater than is induced by AvFcΔXF alone
(Figure 36C). Furthermore, the effect on induction is greatest with AvFcΔXF spiked into
serum from animals that received both pretreatment and treatment with AvFcΔXF (Figure
36C). Taken together, these data suggest that perhaps the increased activity resulting
from pretreatment is not necessarily due to an increase in anti-tumor antibodies but by
both an additive or synergistic effect on ADCC between ADAs, ATAs, and AvFc in
addition to changes in the cellular composition of the immune microenvironment
following treatment. Such a phenomenon has been observed following the successful
treatment of murine ID8 ovarian cancer by cowpea mosaic virus-like particles, which was
similarly not affected by the generation of ADAs and resulted in substantial changes to
the immune cell composition towards a more inflammatory phenotype [153, 307].
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To explore this hypothesis, we have performed a preliminary flow cytometry
analysis of infiltrating immune cells isolated from B16F10 tumors in which we observed
a significant increase in the infiltration of non-classical monocytes (NCMs) (Figure 34GK) and a non-significant increase in other cell types. NCMs are a functionally distinct
subset of steady-state monocytes that express pro-inflammatory cytokines and FcγRs, in
particular FcγRIIIa, allowing them to both recruit immune cells to sites of injury or
cancer and undergo antibody-dependent phagocytosis (ADP) [308, 309]. While much of
the biology of these cells remains unknown, recent studies have shown that they exhibit
anti-cancer activity, especially in the control of metastasis, by scavenging and eliminating
tumor cells in the vascular beds [310, 311]. The broad increase in myeloid cell infiltration
as a result of AvFc administration, including by NCMs, macrophages, and neutrophils, as
well as the relatively small number of intratumoral NK cells, suggests that the mechanism
of action of AvFc against cancer may involve more than NK cell-mediated ADCC and
that the impact of FcγR-expressing myeloid cells should be evaluated. While some
myeloid cells can perform ADCC through FcγRIIIa, the primary goal of further studies
with these cells and AvFc should be to assess the induction of ADP against tumor cells.
Induction of ADP against B16F10 cells (or other cancer cells) can be assessed by
coincubating cells with fluorescently-labeled AvFc and FcγRI-expressing macrophage
cell lines (such as murine RAW 264.7 cells) or isolated intratumoral
macrophages/monocytes and assessing uptake with flow cytometry [312]. The latter
study would provide greater evidence for the role of ADP in AvFc’s mechanism of action
by showing uptake of cancer cells in absolute terms and allowing for comparison in ADP
activity between different glycovariants of AvFc and between cells isolated from
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treated/untreated animals. A combination of this assay and other ex vivo FcγR-dependent
assays, such as the CD107a NK cell ADCC assay, as well as further immunophenotyping
should be done to assess the relative role of each of the different Fc-mediated
mechanisms in greater detail. Even though these results are preliminary, they corroborate
our assertion that Fc-mediated functions are crucial to the anti-cancer activity of AvFc
and suggest that the recruitment of FcγR-bearing cells into the tumor microenvironment
may play a significant role in its mechanism of action.
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Figure 36. Impact of ADAs and anti-tumor antibodies on ADCC activity.
(A) ADCC assay in the presence of mouse serum from before pretreatment. Serum was
collected and pooled from mice prior to pretreatment with AvFcΔXF (see Figure 23A), and
the ADCC assay was performed as described previously with AvFcΔXF alone, AvFcΔXF
spiked into a solution of 5% serum, and 5% serum alone. No ADCC was induced by the
5% serum alone. Dose-response curves were nearly identical between AvFcΔXF alone and
AvFcΔXF spiked into 5% serum, with some slight steepening of the curve. (B) ADCC
assay in the presence of terminal mouse serum alone. Serum was pooled from blood
taken at euthanasia of each animal in each treatment group. Neither serum from animals
in the non-pretreated, vehicle-treated group nor serum from the animals in the pretreated,
AvFcΔXF-treated group was capable of inducing ADCC on its own beginning at a 1:20
dilution. (C) ADCC assay with AvFcΔXF spiked into terminal mouse serum. The ADCC
assay was performed as in panel B with purified AvFcΔXF spiked into pooled serum from
the non-pretreated, vehicle-treated group and the pretreated, AvFcΔXF-treated group.
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Compared to AvFcΔXF alone, spiking into serum from the non-pretreated, vehicle-treated
group resulted in an increase in the maximum fold induction from 6-fold to 9.2-fold and
an increase in EC50 from 0.53 nM to 1.94 nM. Spiking into serum from the pretreated,
AvFcΔXF-treated group resulted in an increase in the maximum fold induction from 6-fold
to 11-fold and an increase in EC50 from 0.53 nM to 6.44 nM. (D) Detection of anti-tumor
antibodies with flow cytometry. Staining of B16F10 cells with a 1:10 dilution of pooled
serum from each group followed by detection with a goat anti-mouse IgG FITC revealed
no significant difference in the number of cells bound.
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In conclusion, the present study has demonstrated the successful glycoengineering
and activity of a novel immunotherapeutic drug, AvFc, which is a lectibody targeting
cancer-associated high-mannose glycans. This glycoengineered AvFc, which lacks plantderived glycans (in particular the core α1,3-fucose), induces more a potent ADCC
response in vitro and delays the growth of murine B16F10 melanoma in both a flank
tumor model as well as a model of metastasis in vivo. Additionally, pretreatment with
AvFc and generation of ADAs did not negate AvFc’s activity and indeed may have
increased it through a yet undetermined mechanism. Lastly, treatment with AvFcΔXF
resulted in a significant increase in tumor-infiltrating non-classical monocytes, which
suggests that ADP may play an equally important role in AvFc’s mechanism of action.
Further studies need to be conducted to determine the extent that AvFc and its variants
can induce ADP by immune cells against cancer and to reproduce the findings in the
immunophenotyping and pretreatment experiments using negative controls (Δgly and
Δlec AvFc). Ultimately, these findings further substantiate the notion that high-mannose
glycans may be a useful druggable biomarker in cancer therapy, and that
glycoengineering is a powerful strategy to improve the antitumor activity of AvFc.
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CHAPTER 6: DEVELOPMENT OF AVAREN-FC AS AN IMMUNOTHERAPEUTIC
AGAINST OVARIAN CANCER

6.1: Introduction
One goal of this project was to assess the feasibility of developing AvFc as a
therapeutic for ovarian cancer (OVCA). OVCA, in particular epithelial ovarian cancer
(EOC), is the deadliest gynecological cancer, ranking fifth in cancer death among
women. EOC typically begins as small, borderline epithelial tumors on either the surface
of the ovary, the fallopian tubes, or the mesothelium lining of the peritoneal cavity. These
tumors grow and become well differentiated before metastasizing, primarily to the
abdominal cavity but rarely to the lungs, liver, and brain [313]. According to the NCI
Surveillance, Epidemiology, and End Results (SEER) Program, the overall 5-yearsurvival rate in the United States is 48.3% as of 2016, largely driven by the dismal
survival rate (30.5%) of late-stage disease [314]. The age-adjusted mortality rate and rate
of new cases of OVCA is 6.8 per 100,000 per year and 10.5 per 100,000 per year,
respectively, slightly above that of the next deadliest gynecological cancer, uterine
cancer, with a mortality rate of 5.0 per 100,000 per year [314]. This translates to an
increase in 2016 of 22,530 new patients and 13,980 deaths. While the numbers of new
cases and deaths are trending downwards slowly over the past 20 years, the prognosis of
patients, especially those with late-stage disease, remains poor. This is largely due to
ineffective population-based screening, innocuous presentation, and the lack of effective
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second line therapies for chemo-resistant disease. Although patients generally respond
very well to the primary treatment, the vast majority of women (75%) will experience
disease recurrence that is incurable due to chemo-resistance [315].
Primary debulking surgery followed by chemotherapy has been the first-line
standard of care for EOC for decades [315]. Surgery for advanced disease consists of
total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy,
though patients with low grade disease can opt for a fertility conservation strategy. The
vast majority of patients will also receive chemotherapy consisting of a platinum-based
drug, most often carboplatin, and a taxane, such as paclitaxel. No residual disease
following primary therapy is the most important prognostic indicator. While this is
achievable for most patients regardless of disease stage, nearly all will inevitably
experience fatal chemo-resistant disease. Treatment options at this stage are limited based
on the platinum-free interval (the length of time between platinum drug treatments) of the
patient and the amenability of the subsequent disease to secondary debulking surgery,
though the likelihood of survival is poor regardless. For patients who have gone through
the first-line standard of care, a greater benefit has been demonstrated with the use of
long-term maintenance therapy, which consists of chemotherapeutics or biologics given
after no residual disease is achieved to prolong survival. FDA approval of bevacizumab
and poly ADP ribose polymerase (PARP) inhibitors has expanded the availability of
maintenance therapy and improved progression-free survival; however, current clinical
data have not demonstrated significant increases in overall survival and these drugs are
associated with significant adverse events [316-320]. Furthermore, there is no FDAapproved targeted immunotherapy for EOC, and trials with checkpoint inhibitors have
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not been conclusive [321, 322]. Thus, EOC therapy would benefit greatly from novel or
complementary therapies that may cure the disease, prolong progression, and improve
overall survival in patients, especially novel immunotherapeutics targeting a unique
biomarker of EOC.
Aberrant glycosylation of cancer-cell surfaces is a well-described phenomenon
and is considered to be a hallmark of the disease [323] Recent advances in tumor
glycobiology have demonstrated that various tumor types display an increased level of
high-mannose glycans on their surface, and that these glycans may play a role in
malignancy and metastasis [323, 324]. High-mannose glycans occur early in the Nglycosylation pathway in the endoplasmic reticulum and are typically processed by
mannosidases and glycosyltransferases prior to leaving the secretory pathway, and thus
are not typically found on the surface of the cell under normal conditions[14]. However,
quantitative N-glycan analysis by mass spectrometry with formalin-fixed, paraffinembedded tissues show that high-mannose glycans are overexpressed on the surface of
OVCA tumors [82]. Additionally, high-mannose glycans were shown to be significantly
elevated in the membrane glycoproteins of EOC cell lines compared to non-cancerous
ovarian epithelial cells and may increase metastatic activity in SKOV3 cells [325, 326]. It
is becoming clear that high-mannose glycans may be a useful EOC biomarker and a
potentially druggable target, therefore we hypothesize that AvFc may offer a powerful
new option for EOC treatment by complementing or supplanting existing therapies for
primary, secondary, or maintenance use. Such a therapy capable of improving overall
survival in patients could potentially alter the paradigm of EOC management and
introduce a new standard of care.
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A number of studies were done to assess whether or not AvFc has activity against
OVCA in vitro as well as establish murine challenge models that can be used to evaluate
its efficacy in vivo. We first set out to confirm that AvFc indeed has selectivity for
OVCA tissues and cell lines, and whether or not it could effectively induce ADCC
against these lines. Next, we established the murine ID8 EOC challenge model in
immunocompetent mice to perform pilot efficacy studies. This model is a standard
orthotopic model in the field of ovarian cancer research and has been used for the
assessment of therapeutic candidates, in particular immunotherapies which require a
functional immune system, and results in the generation of ascites in the peritoneal cavity
which is a common complication from OVCA [327, 328]. The results of these studies are
summarized later in this chapter.

6.2: Results
6.2.1: AvFc recognizes human ovarian cancer tissues and cell lines and induces ADCC
We first determined whether or not AvFc could recognize OVCA tissues and cell
lines by immunohistochemical staining and flow cytometry. Immunohistochemical
analysis of 3 stage 1 high-grade serous ovarian carcinoma tissues from a 48-year-old, a
72-year-old, and a 55-year-old showed clear differentiation of malignant tissues by AvFc
compared to both normal adjacent tissues as well as the non-sugar-binding mutant
AvFcΔlec as determined by the degree of DAB staining (Figure 37). This striking result led
us to then evaluate AvFc’s binding by flow cytometry to a number of established human
and murine OVCA cell lines in order to build a better profile to guide future animal
studies. In all, we tested binding to the following lines: A2780 (epithelial endometroid
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carcinoma), CAOV3 (primary adenocarcinoma), SKOV3 (adenocarcinoma from ascites),
SW626 (primary adenocarcinoma), ID8 (murine ovarian surface epithelial cells), and an
engineered ID8 daughter cell line expressing murine VEGF and β-defensin 29 (ID8VEGF-DEFB29). Of the 6 lines tested, all but SW626 and CAOV3 experienced nearsaturation at a relatively low concentration of AvFc (15 nM, Figure 38A). AvFc bound
strongest to A2780 cells, with almost 100% of cells bound at 1.5 nM while binding to
CAOV3 was the weakest, with only ≈ 56.5% of cells bound at the highest concentration
tested (150 nM). As expected, AvFcΔlec exhibited negligible binding to each of the cell
lines, indicating that binding is high-mannose-glycan-dependent.
We then assessed AvFc’s ability to induce ADCC against OVCA cell lines, as we
believe this is the primary anti-cancer mechanism of action for the drug. In general, the
reporter-cell-based ADCC assay (Figure 38B-D) showed that AvFcΔXF induced the
highest levels of luciferase expression followed by AvFcWT, while the aglycosylated
variant showed no activity, consistent with previous results (see Chapter 4). Fold
induction by AvFcΔXF (Figure 38B) ranged from ≈ 3 to 7-fold and between ≈ 1.5 to 4-fold
by AvFcWT (Figure 38C) depending on the cell line. Based on these results, it appears that
binding by flow cytometry was a poor predictor for ADCC-induction, as the highest level
of induction was seen against CAOV3 cells, which were bound by AvFc the least, and
the lowest levels of induction were seen against A2780, which showed the strongest
degree of binding. Despite this observation, the levels of induction are consistent with
other cancer cell lines and provide evidence that AvFc may have anti-OVCA activity in
vivo, which we attempted to establish using the orthotopic murine ID8 EOC challenge
model.
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Figure 37. Recognition of human OVCA tissues by AvFc with
immunohistochemistry.
Immunohistochemistry (IHC) was performed on a tissue array by US Biomax, Rockville,
MD, which contained 3 Stage I HGSOC tissues from a 48-year-old (column a), 72-yearold (b), and a 55-year-old patient (c) and three adjacent normal ovary tissues (below).
AvFc clearly delineates malignant from normal adjacent tissue as seen by the level of
DAB staining, while AvFcΔlec recognizes neither tissue.
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Figure 38. AvFc binds to many OVCA cell lines and induces ADCC.
(A) Single-color flow cytometry to assess AvFc binding to OVCA cell lines from humans
and mice. The Y-axis shows percentage of FITC+ cells as determined by gating against
background fluorescence. The experiment reveals high levels of binding to A2780,
SKOV3, ID8, and ID8-VEGF-DEFB29 cells and intermediate binding to SW626 and
CAOV3 cells. Binding was dose dependent with saturation occurring at ≈ 15 nM for most
cell lines excluding SW626 and CAOV3. AvFcΔlec exhibited negligible binding to all cell
lines tested at 150 nM. Panels B-D show dose-dependent induction of ADCC by AvFc
variants against OVCA cell lines with a luciferase-based reporter cell assay. As expected,
AvFcΔXF induces the highest level of ADCC (average of 5.0 ± 0.9-fold, panel B) while
AvFcWT only induces modest amounts (average of 3.2 ± 1.1-fold, panel C). AvFcΔgly
induces no ADCC against any cell line tested (D). The highest level of induction was
seen against CAOV3 cells, while the lowest observed was for A2780 cells. All data
shown are mean ± SD.
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6.2.2: Establishment of the ID8-luciferase challenge model
The orthotopic murine ID8-luciferase EOC challenge model is a useful syngeneic
model for assessing the activity of immunotherapeutic drugs against OVCA. However, it
is a lengthy and multifactorial model with many possible endpoints and measures of
activity. Thus, it was necessary to perform pilot experiments in order to gauge which
parameters were necessary and sufficient to test AvFc’s activity, in particular the number
of cells used to establish disease. We initially compared the disease progression and
treatment effect of AvFc following intraperitoneal administration of either 1 or 2x106
cells per animal. For both studies, AvFcΔXF at 25 mg/kg or a vehicle was administered
intraperitoneally beginning on day 7 and continuing Q2D for 28 days (15 doses). When
using 2x106 cells per animal, disease became noticeable around the 6th week (≈ 42 days)
with the development of ascites and sudden increase in animal body weights and
abdomen circumference compared to healthy mice (Figure 39B-C). Bioluminescent
imaging performed on day 46 (Figure 39D) showed very low signal and no significant
difference between the treatment groups. A second round of imaging a week later showed
no signal at all (data not shown), precluding its usefulness as an endpoint measuring
disease severity. Additionally, by the end of the study it became clear that body weights
or abdomen circumference measurements were not reliable in determining the disease
state of the animal, as animals rarely reached the 35 g humane endpoint for euthanasia
before becoming extremely moribund. Using survival as the ultimate gauge of drug
activity, we did find that AvFcΔXF significantly prolonged the lives of the animals,
increasing the median survival from 46 to 63 days (Figure 39A, p=0.0061 by the Gehan-
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Breslow-Wilcoxon test). This was despite the fact that 2 of the vehicle-treated animals
never developed disease and were excluded from the analysis.
When using 1x106 cells per animal, the development of the disease was
noticeably slower with ascites not beginning to develop until after the 7th and 8th weeks.
Similarly, we found that body weights and abdomen circumferences were poor predictors
of the animals’ health, with most of the subjects never reaching the humane endpoints
(Figure 40B-C). Bioluminescent imaging was performed once at day 56, however no
signal could be generated, and no meaningful comparisons could be made (data not
shown), which most likely was due to an issue with the model or cell line. At this point,
animals were only monitored every other day for their general health. Once disease was
evident, indicated by the presence of ascites, animals decompensated and needed to be
euthanized relatively quickly. While AvFc treatment was able to prolong the survival of
the animals, the effect size was much smaller than in the previous study, as median
survival only increased from 60 to 66 days (p=0.0076, Gehan-Breslow-Wilcoxon test).
While the results show AvFc has some activity in this model, more work needs to be
done in order to optimize the parameters for reliability and reproducibility.
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Figure 39. ID8-luciferase challenge model with 2x106 cells/animal.
(A) For the first ID8-luciferase challenge model 2x106 cells were administered
intraperitoneally on day 0. Treatment began on day 7 and continued Q2D for 28 days
(n=8 healthy, n=5 vehicle, n=7 AvFcΔXF at 25 mg/kg). 2 animals in the vehicle group did
not develop disease by day 71 and were excluded from the final analysis. (B) KaplanMeier curve comparing survival between the three groups. AvFc significantly increased
survival (p=0.0061, Grehan-Breslow-Wilcoxon test) from a median of 46 to 63 days.
Lines indicate the first and last dose of drug or vehicle. (C) Changes in body weight over
time, calculated as percent change from day 0 weight. Animal weights in the vehicle and
AvFcΔXF-treated groups began to increase rapidly around day 42 with the development of
ascites. (D) Comparison of abdomen circumferences over time. Corresponding to the
development of ascites and increased body weights, circumferences in the vehicle and
AvFcΔXF groups began to increase around day 42. Healthy animals remained more or less
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at a constant weight for the duration of the study. (E) In vivo bioluminescent imaging of
animals at day 46 showed no significant differences in photons/second/cm2 emitted
between the vehicle and AvFcΔXF-treated animals (Kruskal-Wallis test). All data shown
are mean ± SD.
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Figure 40. ID8-luciferase challenge model with 1x106 cells/animal.
For the first ID8-luciferase challenge model 1x106 cells were administered
intraperitoneally on day 0. Treatment began on day 7 and continued Q2D for 28 days
(n=10 vehicle, n=10 AvFcΔXF at 25 mg/kg). (A) Kaplan-Meier curve comparing survival
between the two groups. Similar to the previous study, AvFc significantly increased
survival (p=0.0076, Grehan-Breslow-Wilcoxon test) albeit to a lesser degree, from a
median survival time of 60 to 66 days. Lines indicate the first and last dose of drug or
vehicle. (B) Changes in body weight over time, calculated as percent change from day 0
weight. Body weights increased slowly over the course of the study, to a lesser degree
than seen following injection of 2x106 cells/animal. Body weights were only monitored
until day 56. (C) Similar to the body weights, changes in abdomen circumference were
less severe than with the previous study (Figure 39). No significant changes were seen in
either measurement. All data shown are mean ± SD.
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6.2.3: Proteomics analysis of AvFc binding partners on ovarian cancer cells
We have previously used proteomics techniques to identify potential binding
partners on the surface of blood cancer and lung cancers, the latter of which were
reported by Oh et al. [105] (manuscript in review at the time of writing). In order to build
more evidence to suggest that AvFc may be useful as an anti-OVCA immunotherapeutic,
as well as to identify possible additional mechanisms of action, we performed coimmunoprecipitation by incubating fixed AvFc and AvFcΔlec agarose resins with cell
lysates from SW626, SKOV3, and ID8 cells in order to isolate bound glycoproteins
containing high-mannose glycans. Bound proteins were then identified using electrospray
UHPLC-MS and curated using GO terminology to separate integral membrane proteins
from other cytoplasmic and organelle-resident proteins. The number of N-glycan sites
was predicted using the NetNGlyc server. The results are summarized in Table 8. In
general, AvFc was found to recognize a broad selection of glycosylated transporters
(including SLC and ATP family transporters), receptors (such as EGFR, IGF1R, and
IGF2R), and adhesion molecules (integrins, cadherins). A number of proteins were found
on the surface of both SW626 and SKOV3 cells and may represent proteins that are
commonly modified with high-mannose glycans in cancer and whose interactions with
AvFc should be validated using other methods. Among those identified between them are
the epithelial growth factor receptor (EGFR), insulin-like growth factor receptor 2
(IGF2R), transferrin receptor (TFR1), integrin α-5 and α-2 (ITGA5 and ITGA2), and
sortilin-related receptor (SORL1). These proteins also generally contain large numbers of
N-glycans, increasing the likelihood that many of those glycan sites are indeed occupied
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by high-mannose glycans and can be recognized by AvFc. Further work is needed to
validate these interactions.
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SW626 putative binding partners
Accession Normalized
Protein
Gene name
number
iBAQ
Integrin alpha-1
ITGA1
P56199
242170
CUB domain-containing
CDCP1
Q9H5V8
191430
protein 1
Magnesium transporter
MAGT1
Q9H0U3
146460
protein 1
Cleft lip and palate
CLPTM1
O96005
90317
transmembrane protein 1
Neuroplastin
NPTN
Q9Y639
47158
Leucyl-cystinyl
LNPEP
Q9UIQ6
42250
aminopeptidase
Stromal interaction
STIM1
Q13586
31253
molecule 1
Integrin beta-4
ITGB4
P16144
29861
Integrin alpha-3
ITGA3
P26006
23124
Integrin beta-5
ITGB5
P18084
20369
Adhesion G protein-coupled
ADGRE5
P48960
14898
receptor E5
Protocadherin Fat 1
FAT1
Q14517
5,021.60
Sodium channel protein
SCN5A
Q14524
4,842.00
type 5 subunit alpha
Solute carrier family 12
SLC12A2
P55011
3,875.20
member 2
Contactin-1
CNTN1
Q12860
3,021.20
Disintegrin and
metalloproteinase domainADAM10
O14672
2,187.80
containing protein 10
Agrin
AGRN
O00468
1,509.20
SKOV3 putative binding partners
Accession Normalized
Protein
Gene name
number total spectra
Integrin beta-1
ITGB1
P05556
18
Cadherin EGF LAG sevenCELSR2
Q9HCU4
11
pass G-type receptor 2
Cluster of Polycystin-2
PKD2
Q13563
11
Integrin beta-3
ITGB3
P05106
6
VPS10 domain-containing
SORCS2
Q96PQ0
5
receptor SorCS2
Basigin
BSG
P35613
4
Adhesion G-protein coupled
ADGRG1
Q9Y653
3
receptor G1
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Predicted
N-glycans
21
11
2
6
6
13
3
4
11
7
8
23
15
4
8
4
4
Predicted
N-glycans
12
13
7
3
7
4
6

Neural cell adhesion
molecule L1
Adhesion G protein-coupled
receptor L2
Attractin
Cadherin EGF LAG sevenpass G-type receptor 1
Leukocyte surface antigen
CD47
Dystroglycan
Inactive tyrosine-protein
kinase 7
Poliovirus receptor
Lysosome membrane
protein 2
Neutral amino acid
transporter B(0)
CD44 antigen

L1CAM

P32004

3

16

ADGRL2

O95490

2

13

ATRN

O75882

2

16

CELSR1

Q9NYQ6

2

12

CD47

Q08722

1

6

DAG1

Q14118

1

5

PTK7

Q13308

1

9

PVR

P15151

1

8

SCARB2

Q14108

1

10

SLC1A5

Q15758

1

1

CD44

P16070

0

8

Shared binding partners (SW626 and SKOV3)
Protein
Tyrosine-protein kinase
receptor UFO
Basal cell adhesion
molecule
Basigin
Epidermal growth factor
receptor
Cation-independent
mannose-6-phosphate
receptor
Integrin alpha-2
Integrin alpha-5
Cation-dependent mannose6-phosphate receptor
Plexin-B2
Sortilin-related receptor
Transferrin receptor protein
1

Protein
Integrin beta-1

Gene
name
Itgb1

Gene name

Accession number

Predicted
N-glycans

AXL

P30530

7

BCAM

P50895

4

BSG

P35613

4

EGFR

P00533

10

IGF2R

P11717

14

ITGA2
ITGA5

P17301
P08648

8
10

M6PR

P20645

5

PLXNB2
SORL1

O15031
Q92673

10
22

TFR1

P02786

5

ID8 putative binding partners
Accession
Normalized iBAQ
number
P09055
1370000.00
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Predicted
N-glycans
11

Integrin alpha-3
Itga3
Q62470
629000.00
11
Ataxin-10
Atxn10
P28658
626560.00
1
Leukocyte surface
Cd47
Q61735
575000.00
6
antigen CD47
CD63 antigen
Cd63
P41731
545440.00
4
Neutral amino
acid transporter
Slc1a5
P51912
154120.00
1
B(0)
Integrin alpha-6
Itga6
Q61739
91600.00
6
Lysosomeassociated
Lamp1
P11438
82112.00
17
membrane
glycoprotein 1
Transferrin
TFR1
Q62351
59400.00
3
receptor protein 1
Dynamin-3
Dnm3
Q8BZ98
28688.00
4
Tight junction
Tjp1
P39447
27796.00
8
protein ZO-1
Plexin-B2
Plxnb2
B2RXS4
15673.00
11
Exocyst complex
Exoc1
Q8R3S6
7081.00
3
component 1
Epidermal growth
Egfr
Q01279
4743.00
11
factor receptor
Table 8. Identification of putative cell-surface binding partners of AvFc on human
and murine OVCA cell lines.
Co-immunoprecipitation was performed with lysates from SW626, SKOV3, and ID8
cells using AvFc- and AvFcΔlec-conjugated agarose resins. Bound proteins were then
identified with LC-MS, and those that were identified in both the negative control
samples were removed from the final analysis, as were any proteins identified not
considered to be integral plasma membrane proteins (as determined by Gene Ontology
keywords and literature searches). N-glycan sites were also predicted with the NetNGly
server. AvFc was found to bind to a number of highly glycosylated transmembrane
receptors, transporters, and adhesion molecules.
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6.3: Discussion
The results described in this chapter demonstrate the potential utility of AvFc as
an immunotherapeutic against OVCA. We found that AvFc can convincingly delineate
malignant from normal-adjacent tissues from OVCA patients and that it binds strongly to
a number of human and murine OVCA cell lines. Furthermore, AvFc shows signs of
activity in vivo in our preliminary ID8-luciferase challenge experiments, significantly
extending the survival of animals with intraperitoneal ID8 tumors. Lastly, we have
identified a number of cell-surface receptors that may interact with AvFc and, in addition
to ADCC, may contribute to its mechanism of action.
Consistent with the results from the flow cytometry and ADCC assays, AvFc
displayed some activity in the orthotopic murine ID8-luciferase challenge model,
significantly extending the median survival with an effect size dependent on the initial
number of cells implanted. However, this is a lengthy and somewhat complicated model,
and our results demonstrate that further optimization is necessary. One observation that
was consistently made between the two experiments (with 1 or 2x106 cells implanted)
was that body weights and abdomen circumferences were poor predictors of the health of
the animal, with many becoming moribund long before reaching the established humane
endpoints (35 g and 10 cm). A potential explanation for this lies in the differential
development of ascites between animals, which occurs when the tumor burden reaches a
certain threshold and results in the filling of the peritoneal cavity with a bloody, serous
fluid. Individual animals can accumulate as much as 15 mL of this fluid, which adds a
tremendous amount of weight to the animal in some instances and seems to correspond to
serious disease. In many cases however it was found that even a small amount of ascites
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could greatly interfere with the health of the animal, causing them to become moribund
long before accumulating enough weight to be euthanized. This generation of ascites may
also help to explain why bioluminescent imaging of the animals failed to generate any
usable data, as the injected luciferin was likely rapidly diluted to unusable levels in the
ascitic fluid. Other studies have also suggested that regular removal of the ascites is
necessary for bioluminescent imaging and prolongs the survival of animals in this model
[329]. Lastly, generation of ascites may be incompatible with intraperitoneal treatment as
dilution of the drug in the fluid may render it ineffective. Our results agree with this
assessment, and it is clear that regular removal of the ascites is necessary in order to
assess the tumor burden and the effect of treatment more accurately by body weight
measurements and bioluminescent imaging. Recording to the time to ascites development
as well as the volume of ascites removed may also be useful endpoints. Furthermore,
since abdomen circumference is mostly affected by the generation of ascites, this is likely
not a useful endpoint for the future if it is routinely removed.
Despite the fact that animals in the second study (Figure 40) received 50% fewer
cells than in the first (Figure 39), the length of the studies was not tremendously different,
with the last animal euthanized 71 days after implantation in the first study and 70 days
after implantation in the second. Interestingly, the effect of AvFc treatment was much
more pronounced in the first study with 2x106 cells, increasing the median survival time
from 46 to 63 days, than it was in the second, where the increase was only from 60 to 66
days. The exact reason for this is unclear from the data. One hypothesis is that in the ID8
model (and perhaps in the peritoneal cavity in general) AvFc acts more as a cancer-static
drug, inducing cell death through ADCC and slowing growth without completely
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eliminating the tumor, so that when drug administration ends the tumors resume growing
at their normal rate. There are two observations that that corroborate this hypothesis.
Firstly, the time between the last dose of drug and the first euthanasia in the first study
was only 6 days, whereas in the second study with fewer cells that time was 11 days. The
second observation is that the delay between dosing and euthanasia also seems to have
affected the span of time between the first and last euthanasia within each group. For
instance, in the first study (2x106 cells), the first vehicle animal was euthanized 41 days
after tumor implantation and the last on day 54 (a span of 14 days). For the AvFc group,
the first animal was euthanized on day 53 and the last on day 71 (a span of 19 days). In
the second study (1x106 cells), the time from first to last euthanasia for the vehicle group
was 17 days (with one outlier that was euthanized on day 70) but only 4 days for the
AvFc group (64 to 68 days). Based on these observations it appears that with fewer cells
implanted the disease progressed more slowly after drug administration ended, and when
the animals began to develop severe enough disease to need to be euthanized the drugeffect was essentially nonexistent, as the time from the last dose was much greater, and
all of the animals decompensated rapidly. Two modifications could be made to the model
to determine if this is true and possibly improve the effectiveness of AvFc: inject more
than 2x106 cells and prolong the drug administration. These two changes would have the
added effect of decreasing the median survival time for the vehicle group while also
decreasing the amount of time between the end of drug administration and the beginning
of the development of disease in the AvFc group, which in theory could be prolonged by
extending the length of drug administration.
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Using co-immunoprecipitation with conjugated AvFc and AvFcΔlec and LC-MS
we identified a number of potential binding partners on the surface of SKOV3 and
SW626 cells that may be decorated with high-mannose glycans, ranging from ion and
amino acid transporters and growth factor receptors to intracellular adhesion molecules.
Several of these were found to be commonly isolated between the two cell lines including
the receptors EGFR, IGF2R, TFR1, and SORL1, adhesion proteins such as ITGA5 and
ITGA2, and transporters like NPC1. These results are consistent with work that was
previously conducted to determine binding partners on the surface of the lung and blood
cancer cell lines A549, H460, HL-60, and K562. The results of the lung cancer
experiments were reported by Oh et al. [105], and both the lung and blood cancer datasets
are reproduced below in Table 9. Two of the proteins identified in lung cancer, EGFR
and IGF1R, have had their interactions with AvFc validated using both coimmunoprecipitation with receptor specific-antibodies and in vitro receptor stimulation
assays and western blotting with A549 and H460 cells. AvFc was found to both bind to
and inhibit the function of these receptors leading to anti-cancer activity in vivo [105].
Interestingly, several other proteins have been identified as being recognized by AvFc in
all 6 of the cancer cell lines tested: IGF2R, ITGA5, M6PR, PLXNB2, and TFR1. Each of
these proteins individually are fairly heavily glycosylated, and all but PLXNB2 exist as
dimers on the cell surface, which significantly increases the number of clustered glycans
for AvFc to potentially recognize. While further work remains to validate these
interactions, there is some evidence to suggest these proteins contribute to malignancy in
a way that may be interfered with by binding to AvFc, contributing to its overall anticancer mechanism.
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Commonly identified in A549 and H460 lung cancer cells
Gene
Accession
Protein
name
number
Plexin-B2
PLXNB2
O15031
Epidermal growth factor receptor
EGFR
P00533
Transferrin receptor protein 1
TFR1
P02786
Insulin-like growth factor 1 receptor
IGF1R
P08069
Integrin alpha 5
ITGA5
P08648
Cation-independent mannose-6-phosphate
IGF2R
P11717
receptor
Integrin alpha 2
ITGA2
P17301
Integrin beta 5
ITGB5
P18084
Cation-dependent mannose-6-phosphate
M6PR
P20645
receptor
Contactin-associated protein 1
CNTP1
P78357
Neutral amino acid transporter B(0)
SLC1A5
Q15758
Sortilin-related receptor
SORL1
Q92673
Plexin-A1
PLXNA1
Q9UIW2
Endothelial protein C receptor
EPCR
Q9UNN8

Predicted
N-glycans
10
10
5
14
10
14
8
7
5
12
1
22
13
4

Commonly identified on K562 and HL-60 blood cancer cells
Gene
Accession Predicted
Protein
name
number N-glycans
Plexin-B2
PLXNB2
O15031
10
Transferrin receptor protein 1
TFR1
P02786
5
Intercellular adhesion molecule 1
ICAM1
P05362
7
Integrin beta 1
ITGB1
P05556
12
Integrin alpha 5
ITGA5
P08648
10
Lysosome-associated membrane glycoprotein
LAMP1
P11279
17
1
Cation-independent mannose-6-phosphate
IGF2R
P11717
14
receptor
Cation-dependent mannose-6-phosphate
M6PR
P20645
5
receptor
Plexin-A1
PLXNA1
Q9UIW2
13
Commonly identified in lung and ovarian cancer cell lines
Gene
Accession Predicted
Protein
name
number N-glycans
Epidermal growth factor receptor
EGFR
P00533
10
Integrin alpha 2
ITGA2
P17301
8
Sortilin-related receptor 1
SORL1
Q92673
22
Commonly identified in lung and blood cancer cell lines
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Gene
name
PLXNA1

Protein
Plexin-A1

Accession
number
Q9UIW2

Predicted
N-glycans
13

Commonly identified in all cell lines
Gene
Accession Predicted
Protein
name
number N-glycans
Cation-independent mannose-6-phosphate
IGF2R
P11717
14
receptor
Integrin alpha 5
ITGA5
P08648
10
Cation-dependent mannose-6-phosphate
M6PR
P20645
5
receptor
Plexin-B2
PLXNB2
O15031
10
Transferrin receptor protein 1
TFR1
P02786
5
Table 9. Identification of putative cell-surface binding partners of AvFc on lung and
blood cancer cell lines.
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In conclusion, the results described in this chapter demonstrate that AvFc has
selectivity for OVCA tissues and cell lines by binding to high-mannose glycans, and that
it is capable of potently inducing ADCC against them. Furthermore, AvFc administration
was shown to prolong the survival of animals in the orthotopic murine ID8 EOC
challenge model. Further optimization of the model is required to generate reliable and
reproducible study conditions, and three major parameters have been identified which
may be amenable to modification: routine removal of the ascites from diseased mice,
increasing the number of cells implanted, and lengthening the time for drug
administration. Lastly, activity against OVCA by AvFc may be due to a combination of
ADCC and receptor binding, and several potential binding partners for AvFc have been
identified on ID8, SKOV3, and SW626 cells. Overall, these data justify further
development of AvFc as a drug against OVCA alone or in combination with other
chemotherapeutics or immunotherapeutics.
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CHAPTER 7: SUMMARY AND FUTURE DIRECTIONS
7.1: Summary
The results presented herein summarize the work relating to the preclinical
development of Avaren-Fc (AvFc), a lectibody targeting cancer and virus-associated
high-mannose glycans, which consists of a fusion of the lectin Avaren and the Fc region
of human IgG1. High-mannose glycans represent a relatively underutilized
glycobiomarker that is aberrantly abundant on the surface of malignant cells and on the
surface of some highly-glycosylated viral glycoproteins such as those from HIV and
HCV.
Chapter 4 describes the in vitro activity of AvFc against HCV as well as the
safety and efficacy of its administration in a chimeric human liver mouse model of HCV
infection. We found that AvFc had high affinity for the E2 envelope glycoprotein, and
that binding to those glycoproteins on the surface of the virus resulted in potent inhibition
of viral entry in a genotype independent manner, determined using an in vitro
neutralization assay with both pseudoviruses and replication-competent cell-culturederived virus (Figure 9, Table 2). In order to facilitate the use of AvFc in mouse models
as well as improve its stability following purification, we identified a more optimal buffer
formulation composed of histidine, sucrose, and sodium chloride that allowed us to
achieve concentrations as high as 10 mg/mL without precipitation and protected against
degradation (Figure 10, Figure 11, Table 3). We then evaluated AvFc’s activity in vivo
using a chimeric human liver mouse model of HCV infection in PXB-mice® and found
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that treatment Q2D with intraperitoneally administered AvFc at 25 mg/kg could
completely prevent infection while a non-sugar-binding mutant AvFcΔlec failed to
meaningfully inhibit virus, suggesting that AvFc inhibited HCV in a glycan-dependent
manner (Figure 16). Up to 11 injections of drug were found not to result in any overt
toxicity in the animals and did not result in damage to liver as determined by
measurements of ALT, Alb, and by histopathology (Figure 14, Figure 15, Table 4).
The first report of the anticancer activity of AvFc was by Oh et al., which
demonstrated the growth inhibition of A549 and H460 xenografts likely due to a
combination of receptor inhibition (in particular EGFR and IGF1R) as well as ADCC,
though the relative contributions of these functions in vivo are unclear [105]. Chapter 5
describes the further anticancer activity of AvFc against murine B16F10 melanoma while
also demonstrating that Fc functions are likely the key mechanism of action against
cancer. This was evaluated in mouse models using Fc variants of AvFc that had either
high ADCC activity (AvFcΔXF) or lacked it entirely (AvFcΔgly) to evaluate the relative
contribution of Fc functions (Table 1). Modification of WT AvFc to create the ΔXF
variant by defucosylation resulted in significantly increased affinity for the various FcγRs
(Figure 19, Table 6). We showed that none of the variants exhibited changes in their
cancer-binding ability, saturating B16F10 cells at nanomolar concentrations (Figure 18).
Furthermore, while coincubation with AvFc was not found to directly induce cytotoxicity
or inhibit cell proliferation, the high ADCC variant induced high levels of ADCC in vitro
at nanomolar concentrations suggesting that it and not direct inhibition is the more
important anticancer mechanism (Figure 20). This result was corroborated in the B16F10
flank tumor model, where we showed that removal of Fc effector functions with the
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AvFcΔgly variant did not have any impact on the growth of tumors while the AvFcΔXF
variant significantly slowed tumor growth beginning 9 days after implantation (Figure
21). Interestingly, the presence of pre-existing immunity to AvFc in the form of ADAs
did not eliminate its activity in the flank tumor model (Figure 23). Indeed, the presence of
ADAs may have somewhat improved the activity of AvFc by extending the survival of
tumor-bearing animals. The mechanism by which this occurred however will be the
subject of future work. While some data seem to indicate that ADAs against AvFc
increase ADCC activity against tumor cells (Figure 36), the contribution of changes to
the tumor immune cell microenvironment have yet to be adequately measured, though
preliminary studies have suggested that AvFc administration results in an increase in
myeloid cell infiltration (Figure 27, Figure 30, Figure 34). Quantifying the impact of
AvFc on the cellular makeup of this niche will be important for determining what impact
AvFc has on tumor immunogenicity and whether or not it can act as an
immunostimulating agent in addition to inducing ADCC.
Lastly, in Chapter 6, we presented data on the activity of AvFc against OVCA,
the optimization of the murine ID8-luciferase model of OVCA, and the effects of AvFc
treatment therein. We found that AvFc was highly selective for malignant human OVCA
tissues over normal adjacent tissues, and that this was due to specific recognition of highmannose glycans as the non-sugar-binding mutant displayed no binding to either tissue
(Figure 37). Additionally, AvFc could potently bind and induce ADCC against a number
of OVCA cell lines (both murine and human) and was found to recognize a number of
important cell-surface receptors, the consequences of which are still being elucidated as
these interactions are validated (Figure 38, Table 8). In the murine ID8-luciferase OVCA
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challenge model, intraperitoneal administration of AvFc at 25 mg/kg Q2D resulted in a
significant increase in survival time that was dependent on the number of cells originally
administered (Figure 39, Figure 40). However, much work remains to optimize the model
in terms of cells administered, dose amount, and dose duration in order to generate a
reliable and reproducible model that can be used for future efficacy studies or to explore
the efficacy of other molecules, such as lectikines (see below). Additionally, more
relevant and translational data can be obtained ex vivo by conducting binding and
immunophenotyping/immunoactivation studies on ascitic fluid from OVCA patients,
since this fluid contains large numbers of both tumor cells and immune cells. In
particular, aspects of immune function such as induction of ADCC and pro-inflammatory
responses by drug administration can be measured using primary cell immunoassays like
the CD107 assay as well as by measuring cytokine releases and by profiling the
composition of immune cells using flow cytometry [330]. Overall, the data suggest that
AvFc has activity against OVCA in vivo, and that further development is needed to fully
demonstrate the utility of targeting high-mannose glycans in OVCA therapy.

7.2: Lectikines and other conjugates
Cytokines are small signaling molecules that act as key regulators of the immune
system, both inducing and controlling inflammation. The forced induction of antiinflammatory cytokines and localized deactivation of the immune system is considered a
hallmark of cancer, and the conversion of tumors from an anti-inflammatory “cold” state
into a pro-inflammatory “hot” state is seen as integral to modern immunotherapy and has
been the subject of much recent research [331]. The principal example of drugs acting to
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improve tumor immunogenicity are the checkpoint inhibitors, which act by preventing
the tumor-induced deactivation of cytotoxic T lymphocytes by binding to and inhibiting
the programmed death ligand and/or receptor (PD-1, PD-L1) and CTLA4 [332].
Checkpoint inhibitors have revolutionized therapy for a number of different types of
cancer, the importance of which was recognized by the Nobel Committee when it
awarded the 2018 Nobel Prize in Medicine to their inventors, Drs. James Allison and
Tasuku Honjo, and the success of these drugs has placed increased emphasis on the host
immune response to cancer as a therapeutic target [332].
A number of pro-inflammatory cytokines have been investigated for their
potential use as therapeutic agents, the most well-studied of which is the T cell growth
factor IL-2 [333]. IL-2, among other functions, stimulates the growth and proliferation of
both CD8 and CD4 cells, assisting in the reversal of cancer-associated deactivation of
these cells [334]. Clinical research into IL-2 therapy culminated in the FDA approval of
the first cytokine-based therapy, aldesleukin, for the treatment of metastatic melanoma
and renal cell carcinoma [335, 336]. Another widely studied cytokine, interferon alpha
(IFNα), has been approved for use as an immunotherapeutic agent against leukemia and
melanoma under the trade name Roferon-A [337]. However, there are several major
hurdles to the regular therapeutic use of cytokines as immunotherapies, the first of which
is that cytokines typically exhibit an extremely short half-life, necessitating frequent
high-dosing that can induce significant toxicities to the patient [338]. Furthermore, the
diversity of cytokine functions dictates that under certain situations cytokines can be
tumorigenic, which in turn requires very careful management during treatment. For
instance, IL-2 is known to also induce the proliferation of T regulatory cells, which are
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generally considered to be anti-inflammatory and pro-tumorigenic [339]. The major
strategy that has emerged to limit systemic toxicity and improve cytokine targeting to
tumor sites is through fusion of the cytokine to mAbs targeting tumor-associated antigens
(TAAs) [340]. These so-called immunocytokines more efficiently concentrate the
cytokines to the tumor microenvironment, allowing for improved interaction with
immune cells and enhancing the conversion of “cold” tumors to “hot” ones. A number of
TAA targets have been preclinically and clinically evaluated including GD2, TnC-A1,
CD20, EpCAM, fibronectin extra-domain A and B (EDA and EDB), fibroblast activation
protein (FAP), and histone H1 [341-347]. Furthermore, in addition to IL-2 fusions, which
are by far the most frequently used, a number of other important cytokines have been
fused to TAA-targeting mAbs including IL-12, IL-15, TNF, IFNα, and GM-CSF [348352]. Though many of these have shown efficacy in phase II trials, only the anti-EDBIL2 and anti-EDB-TNF fusions have progressed to phase III for malignant melanoma
(NCT02938299 and NCT03567889).
The selectivity of the Avaren lectin for cancer-associated high-mannose glycans
led us to hypothesize that AvFc-cytokine fusions may function similarly to mAb-based
immunocytokines, and that such a fusion may offer significant benefit in OVCA, which
is generally considered to be a poorly immunogenic cancer [300]. To this end we have
recently proposed and received pilot funding for a project investigating fusion of Avaren
and AvFc to TNFα and IL-2, respectively, for the treatment of OVCA (summarized in
Figure 41). In this study we will create translational fusions of Avaren to TNFα and AvFc
to IL-2 and express them in our plant-based transient over-expression platform in N.
benthamiana. After confirming their producibility, proper structure, and bioactivity using
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in vitro bioassays we plan to evaluate their activity using an orthotopic murine OVCA
challenge model using ID8-luciferase cells, which are injected intraperitoneally to induce
ascites and tumor formation (see Chapter 6). We predict that administration of these
“lectikines” will result in a decreased tumor burden over time and greater survival by
increasing the immunogenicity of the tumors. In particular, for the IL-2 fusion, we expect
to see increases in CD8 and CD4 T cell populations in addition to NK cells, all of which
respond to IL-2 stimulation and exhibit natural anticancer activity. Furthermore, TNF
fusions (which form trimeric structures) suppress tumor growth both by binding and
inducing apoptosis through TNF receptors as well as by recruiting macrophages and
neutrophils. These lectikines could also be compared in the OVCA challenge model to
the parent AvFc molecule, exploring cotreatment as a means to further increase any
antitumor activity by the induction of ADCC. If successful, these studies will
demonstrate the versatility of high-mannose glycan-targeting as a therapeutic strategy and
open the door to further preclinical development of AvFc as an anticancer drug.
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Figure 41. Summary of lectikine approaches using AvFc- or Avaren-cytokine
fusions.
The goal of lectikine therapy is to improve the immunogenicity of the tumor while
decreasing systemic toxicity resulting from off-target effects. Avaren-TNF fusions form a
multimeric structure through the trimerization of TNF. Binding of TNF to its receptor and
Avaren to the cancer cell surface is hypothesized to induce cell death by apoptosis and
recruitment of immune cells such as macrophages and neutrophils. AvFc-IL2 fusions, on
the other hand, bind to the target cell and form a complex with IL-2R-bearing cells (T
cells, NK cells) inducing their activation and proliferation. We hypothesize that this will
improve the immunogenicity of the tumor by converting inactivated or silenced T and
NK cells to an activated form capable of inducing cytotoxicity.
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7.3: Receptor targeting activities and their contribution to the mechanism of action
In the studies described in Chapter 6, we identified a number of potential binding
partners for AvFc on the surface of OVCA cells using a proteomics approach with wholecell lysates (Table 8). We have also performed similar analyses to identify binding
partners on the surface of blood cancer and lung cancer cells (Table 9). We previously
reported the validation of AvFc’s recognition and inhibition of EGFR and IGF1R on the
surface of A549 and H460 cells, which may contribute to its molecular mechanism of
action in those models [105]. Further studies should be conducted to evaluate the impact
of binding to other receptors on AvFc’s mechanism of action and to validate these
interactions in OVCA cell lines and primary cells using co-immunoprecipitation or the
proximity ligation assay.
One of the major proteins identified in the proteomics analyses was integrin α5.
Integrins are the principal receptors that are used by animal cells to bind to the
extracellular matrix and direct movement and adhesion, in addition to facilitating some
cell-to-cell communications and providing a link between the extracellular environment
and the actin cytoskeleton of the cells [353]. All integrins form highly glycosylated
heterodimers on the cell surface, which consist of an α and a β subunit, and their
expression is regulated from within the cell based on extracellular conditions. Cancers
often manipulate expression of integrins to promote invasion and metastasis to secondary
sites, and as such expression of certain integrins like integrin α5 can be prognostic of
lung, breast, colon, ovarian, and brain tumors [354-358]. Integrin α5 (ITGA5) primarily
forms a heterodimer with the β1 (ITGB1) subunit (α5β1) to recognize fibronectin, a
major component of the extracellular matrix, to which binding facilitates cell migration
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and invasion [353]. Antibodies targeting the α5β1 receptor, such as Pfizer’s PF04605412, have not seen tremendous clinical efficacy due in large part to the severity of
infusion-related reactions [359]. However, clinical trials with other antibodies such as
volociximab have not resulted in such toxicity [360]. Thus, the α5 subunit may still be
considered a druggable target, one that can potentially be recognized and inhibited by
AvFc, however significant hurdles remain as integrins are commonly expressed on the
surface of normal cells leading to adverse effects. The presence of high-mannose glycans
on this could possibly provide a mechanism by which cancer-associated integrins are
selectively targeted, limiting off-target effects.
Another protein potentially recognized by AvFc is plexin-B2. Plexin-B2 belongs
to a family of plexin proteins that act as receptors for the semaphorin-family of signaling
proteins, which primarily function in the guidance of axon development in the nervous
system but also play roles in angiogenesis and immune cell trafficking [361, 362]. More
recently, the plexin/semaphorin axis has been implicated in tumorigenesis and tumor
metastasis, though the exact mechanisms have not been clearly identified, as the large
number of semaphorins and plexin receptors also have complex interactions with not just
the tumors but with cells in the environment [363, 364]. Semaphorin/plexin signaling,
among other pro-survival functions, regulates the expression of integrins not through
direct kinase activity but through activation or inhibition of plexin-associated receptortype and nonreceptor-type tyrosine kinases [364, 365]. Disruption of this axis by
inhibition of plexin-B2 has been shown to decrease proliferation and invasion of OVCA
cells [366], chemosensitize prostate cancer cells [367], and decrease invasion of
glioblastoma cells [368]. Semaphorin/plexin signaling is also important in trafficking and
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migration of immune cells, though any potential relationship between this and other
functions in cancer have yet to be elucidated [369]. Taken together, the evidence suggests
that plexin-B2 expression may be important in tumor development and that binding and
inhibition of it by AvFc may contribute to the lectibody’s anti-cancer activity, though this
hypothesis has yet to be tested.
The transferrin receptor TFR1 is a well-established target for cancer
immunotherapy not only because iron plays a crucial role in physiological processes but
because targeting TFR1 can result in the effective endocytosis of antibody-drug or
transferrin-drug conjugates [370, 371]. TFR1 forms a disulfide-bond-linked homodimer
at the cell surface with each of the monomers displaying several N-glycans [372].
Binding of the receptor to the iron transporter transferrin results in the endocytosis of the
receptor-ligand complexes, bringing iron into the cell where it is used in the formation of
heme- and iron-containing proteins that participate in oxygen transport, energy
metabolism, DNA synthesis, and hormone synthesis, among others [370]. TFR1 is
abnormally expressed in many cancers including liver, breast, lung, and colon [373-376].
As such, many groups have explored targeting TFR1 as a method to both disrupt iron
metabolism and direct the internalization of cytotoxic drugs [371]. Both of these
functions are potentially relevant to the development of AvFc as a therapeutic and should
be explored further following formal validation of the interaction beyond proteomics.
First, AvFc could bind to and inhibit iron transfer by selectively blocking cancerassociated (high-mannose glycan-bearing) TFR1. Secondly, AvFc-drug conjugates could
theoretically be generated that utilize this pathway to internalize the drug leading to
increased anti-tumor activity.
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7.4: Further assessment of the immunogenicity and immunotoxicity of Avaren-Fc
As discussed in Chapter 5 (5.2.7 and 5.3), AvFc is a non-native protein to both
humans and mice and as such may be immunogenic and generate an ADA response upon
administration. Indeed, we reported in Figure 23 that mice generate high-titers of ADAs
to AvFc after repeated intraperitoneal administration of AvFc at 25 mg/kg, though these
serum antibodies did not neutralize the activity of the drug within the B16F10 flank
tumor model. Instead, a slight but non-significant enhancement effect was seen (Figure
23). Whether or not this is due to the animals being in a state of general inflammation due
to repeated administration of AvFc (and is therefore not specific to AvFc) or if this is due
to an enhancement of ADCC activity by ADAs is not clear, and repetitions of this study
should include a group of animals that receives an irrelevant antigen during the pretreatment phase and a group of animals with extended time between the last pretreatment
dose and the first treatment to determine the specific impact of ADAs or inflammation.
Interestingly, 6 of the 10 animals in the group that received AvFc pretreatment developed
symptoms consistent with a hypersensitive or anaphylactic reaction within an hour of the
first administration of AvFc in the treatment phase of the study (day 26), including
labored breathing, hunching of the back, closed eyes, and lack of responsiveness to touch
[297, 298]. While this condition abated within 5 hours and was not observed again after
subsequent doses, the possibility of AvFc inducing such a toxic response is important to
investigate further.
Adverse drug reactions (ADRs) to biologics can be classified into 5 types
according to a scheme devised by Pichler et al., which is summarized in Table 10 [377].
Type alpha ADRs consist primarily of infusion reactions that result in cytokine release
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syndrome or cytokine storm, or ADRs resulting from cytokine therapy. The severity of
these reactions can range from minor gastrointestinal symptoms, fever, or edema to major
respiratory distress syndrome, cardiovascular shock, and multi-organ failure [378]. Most
often, these side effects occur during the first infusion and are dose and infusion-rate
dependent [379]. Type beta ADRs are the immediate or delayed hypersensitivity
reactions and will be discussed further below. Type gamma ADRs comprise druginduced immunosuppression, opportunistic infections, cytokine imbalances,
autoimmunities, and atopy. In some cases, drug-induced immunosuppression is a result of
the intended mechanism of action of the drug (such as infliximab), however these
treatments can result in the development of opportunistic infections such as tuberculosis,
fungal infections, or herpes zoster [377]. Additionally, biologic drug administration can
lead to autoimmune-like reactions including Guillain-Barré syndrome, vasculitis,
psoriasis, and sclerosis [380]. Type delta ADRs occur when the drug or antibodies
generated against a drug cross-react with antigen on normal host cells. A common
example of this type of ADR is the development of acneiform eruptions in the skin of
patients treated with cetuximab, due to the expression of EGFR on normal tissues [381].
Type delta reactions will likely be critical to examine during the preclinical investigation
of AvFc, as high-mannose glycans can be found, albeit rarely, on normal tissues which
may lead to off-target binding and toxicity. Off-target binding by AvFc can be assessed
using tissue cross-reactivity assays, wherein ex vivo immunohistochemical staining of
panels of frozen human or mouse tissues is performed with AvFc. While these studies
cannot conclusively predict toxicity or efficacy in a tissue, their results are typically
included in the Investigational New Drug (IND) application submitted to the FDA and
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can direct further animal toxicity studies by shifting focus to particular organs or tissues
[382]. Lastly, type epsilon ADRs are ambiguous and cover drug-mediated impairment of
physiological functions that don’t fit into other categories. Examples of these types of
ADRs include heart failure induced by anti-TNF agents and neuropsychiatric/retinopathic
effects caused by IFNα [383-385]. In the case of AvFc, the rapid onset of symptoms
suggests either a type alpha ADR due to cytokine release in the peritoneal cavity (the site
of drug administration) or a hypersensitivity reaction related to the presence of ADAs.
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Type alpha

Type beta

Type gamma

Type epsilon

Immunostimulation,
high cytokine or
cytokine release
syndrome

Type
delta

Hypersensitivity

Immune or
cytokine imbalance
syndromes

Crossreactivity

Nonimmunological
side effects

Gell and
Coombs type IIV

Immunodeficiency
Autoimmunity
Allergy/atopic
disorders

Table 10. Pichler classification of adverse reactions to biologics.
In this system, ADRs are classified according to the underlying mechanism of action.
Type alpha ADRs comprise those induced by cytokine therapy or those induced by drugs
that cause the sudden release of cytokines. Type beta ADRs consist of the classical
hypersensitivities as defined by Gell and Coombs. Type gamma ADRs consist of druginduced immunosuppression, autoimmunity, or allergies (to non-drug antigens). Type
delta ADRs consist of toxicities that come about as a result of off-target binding of the
drug to unintended tissues. Type epsilon ADRs are those that do not have an
immunological mechanism.
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Hypersensitivity reactions (HSRs), more commonly referred to as “allergies”, are
undesirable reactions of the immune system to antigens, including innocuous antigens
such as plant pollens, or therapeutic drugs. Antigens that cause such a reaction are
referred to as allergens, regardless of their composition. These types of reactions can
have a wide variety of physiological consequences ranging from simple discomfort, such
as the congestion and itchiness associated with seasonal allergies, to far more serious
systemic disease or anaphylaxis, often popularly associated with things like bee stings or
food allergies. Reactions against drugs can also result in significant toxicity, which can
limit the therapeutic benefits and options for patients who develop them. While the
outward signs and symptoms of HSRs vary tremendously, they are generally divided into
4 groups based on the criteria established by Gell and Coombs, which considers the
underlying immune mediators and effectors. The 4 classes in this system are thus defined
as: IgE-mediated (type I), IgG-mediated (type II), immune complex-mediated (type III),
and cell-mediated hypersensitivities (type IV) [386]. Most biologic drug
hypersensitivities belong to classes I, III, and IV, and have been particularly well
documented in monoclonal antibody therapies to cancer, where their development can
result in significant toxicities resulting in the cessation of therapy [387, 388].
Type I HSRs are mediated by IgE-type antibodies, with FcϵRI-bearing cells such
as mast cells and basophils being the primary cellular effectors [386]. IgE is generated
following the initial exposure to the allergen, or sensitization, when allergen-specific Th2
T helper cells secrete cytokines such as IL-4, IL-5, and IL-10 that cause B cells to
undergo isotype switching from IgM to IgE [389]. Circulating IgE antibodies then bind to
FcϵRs on the surface of mast cells, which are rapidly activated following reintroduction
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of the allergen to the body through subsequent exposure and cross-linking of the surfacebound IgE antibodies [390]. Activated mast cells degranulate, releasing histamine, βhexoseaminidase, and other immune mediators (such as prostaglandins) that recruit other
immune cells (primarily basophils and eosinophils) and cause the symptoms commonly
associated with allergies including urticaria, pruritis, pain, edema, and congestion [390].
This activation of preformed IgE/FcϵR complexes can happen within minutes of the
secondary exposure to the allergen, and as such type I HSRs are considered immediate or
rapid-onset hypersensitivities [388]. Severe type I HSRs can also result in anaphylaxis,
which is a rapid systemic immune response caused by the massive production of proinflammatory mediators by mast cells and basophils following exposure to an allergen
and can be fatal [391]. Type I HSRs are relatively common and have been well
documented in patients receiving monoclonal antibody therapy with cetuximab or
rituximab [392, 393].
Type II and III HSRs often occur simultaneously and are both mediated primarily
by IgG-type antibodies but can also be mediated by IgM and to a lesser extent IgA [390].
In a type II HSR, antibodies targeting haptens composed of drug-modified cellular or
extracellular matrix antigens result in the destruction of cells and damage to tissues by
complement activation, phagocytosis, and ADCC [380]. These reactions are commonly
observed in patients with penicillin and cephalosporin allergies, which are antibiotic
compounds that fairly readily form haptens in the body [394]. Type II reactions are
generally less relevant for biologics, however, as their administration does not routinely
result in the formation of such autoantibodies [388]. Instead, biologics are more likely to
induce type III HSRs, which result from the formation of large antibody-antigen
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complexes that deposit in tissues and induce chronic inflammation via complement and
activation of pro-inflammatory macrophages, damaging the surrounding cells and
structures [380, 390]. The resulting symptoms are determined not by the antigen but by
the site of deposition, which often occurs in small arteries, the renal glomeruli, and the
synovial joints as they are too large to effectively clear from the circulation by
phagocytosis [395]. Type III HSRs are often indistinguishable from autoimmune
reactions. Examples of the prototypical conditions caused by type III HSRs include
anemia, leukopenia, thrombocytopenia, pneumonitis, vasculitis, lupus-like reactions, or
glomerulonephritis, and such reactions have been reported in patients receiving
infliximab, etanercept, and adalimumab [395-398].
Lastly, type IV HSRs are cell-mediated, not antibody mediated, and are driven
primarily by anti-allergen helper and cytotoxic T cell responses [379]. In this case,
damage to tissues is caused directly by sensitized cytotoxic CD8+ T cells or by T cellmediated activation of macrophages, eosinophils, and neutrophils [390]. This type of
HSR is likely involved in the pathogenesis of some autoimmune diseases including
multiple sclerosis and type 1 diabetes [390]. In the context of drug administration, type
IV HSRs manifest primarily as severe skin reactions but can also cause significant
systemic disease in the form of Drug Reaction with Eosinophilia and Systemic Symptoms
(DRESS) syndrome, Stevens-Johnsons syndrome (SJS), and toxic epidermal necrolysis
(TEN), which occurs when cytotoxic CD8 T cells induce apoptosis and necrosis of
keratinocytes [396]. Unlike type I, type II, III, and IV HSRs are delayed reactions, often
occurring days after the exposure [386].
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The acute reaction to AvFc by pretreated animals and subsequent resolution of the
symptoms over time resembles a drug-induced HSR or anaphylaxis, likely of type I due
to the time of onset, however this study was not designed to assess such an unexpected
adverse event. Further studies need to be conducted to A) determine whether or not the
reaction is repeatable and B) what the cause of the reaction was and whether or not it can
be mitigated. To answer these questions, the study outlined in section 5.2.7 should be
repeated in both healthy animals as well as in animals bearing B16F10 tumors, as it is
possible that the presence of tumors in the animals contributed to the condition. If a
similar adverse reaction is consistently observed after the first treatment dose on day 26
in pretreated animals, then further investigation into the nature of the reaction is
warranted, as this would suggest a possible HSR.
Studies concerning the immunogenicity and immunotoxicity of biologic drugs are
described in several FDA guidance documents, importantly in “Immunogenicity
Assessment for Therapeutic Protein Products”, “Nonclinical Safety Evaluation of the
Immunotoxic Potential of Drugs and Biologics”, and ICH S6 “Preclinical Safety
Evaluation of Biotechnology-Derived Pharmaceuticals”. It is generally acknowledged
that immunogenicity or immunotoxicity in animals is not predictive of either in humans,
and the FDA does not recommend running a routine battery of tests for biotechnologyderived pharmaceuticals in the absence of a particular pathology. However, in instances
where there is a particular immunotoxicological concern (such as was observed for AvFc)
then in vitro and in vivo studies may provide valuable information and contribute to the
overall risk assessment of the drug. In our case, it may be necessary to determine whether
or not the acute reaction observed was due to one of the above-mentioned HSRs (Type I-
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IV), anaphylaxis, or another immune-related reaction such as massive cytokine release,
the latter of which can easily be assessed with a serum ELISPOT assay or multiplex
Luminex assays to measure pro-inflammatory cytokines. In the event anaphylaxis is
suspected, a scoring system can be used to gauge the severity of the reaction such as that
developed by Li et al. [298], where 0 = no symptoms; 1 = scratching around the nose and
head; 2 = puffiness around eyes and mouth, closed eyes; 3 = wheezing, labored breathing,
cyanosis around mouth and tail; 4 = no activity after prodding, tremors or convulsions.
Anaphylaxis would likely be evaluated concurrently while performing experiments to
assess the type of HSR being induced.
For type I HSRs, one of the most important endpoints is the presence of anti-drug
IgE in the serum, which can be measured using a simple ELISA, though this is not
conclusive in and of itself. A number of further studies should be conducted to evaluate
the risk of an IgE-mediated HSR including the mast cell activation test (MAT), the
passive cutaneous anaphylaxis assay (PCA), the active cutaneous anaphylaxis assay
(ACA), and the active systemic anaphylaxis assay (ASA). The MAT makes use of
cultured primary mast cells (human or mouse) that would be sensitized with serum from
animals exposed to AvFc followed by the addition of AvFc [399]. As a positive control,
sensitized mast cells can be incubated with a goat anti-IgE antibody which will cross-link
the bound IgE leading to degranulation. Negative controls can include serum from
unexposed animals as well as coincubation with an unrelated antigen apart from AvFc.
Mast cell activation is measured by flow cytometry with CD117, CD107a, CD63, and
FcϵR1a antibodies, while secretion of inflammatory mediators such as βhexoseaminidase and prostaglandin D2 can be measured by ELISA. Dose-dependent
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activation of mast cells by AvFc/IgE complexes would be indicated by the increase in
CD107a and CD63 expression as well as by the increase in β-hexoseaminindase and
prostaglandin D2 levels. This assay can be performed in tandem with the PCA, ACA, or
ASA, any of which would provide strong evidence for a drug-induced type I HSR. In the
PCA, serum from animals exposed to AvFc is injected dermally into the ear followed by
intravenous administration of AvFc and Evans Blue dye [400]. Changes in vascular
permeability as a result of the HSR can be measured by the increase or decrease in Evans
Blue dye in the ear. The ACA, which is a variation of the PCA, uses a similar protocol
except the animals to be tested are exposed to the drug themselves (actively immunized)
as opposed to simply injecting serum from other exposed animals into the ear [401]. The
last test, the ASA test, simply extends the analysis of the animal to the development of
anaphylaxis and can be performed simultaneously with the ACA or PCA [402].
Combined, these assays can help determine whether or not IgE is present and whether or
not that IgE leads to an immunotoxicity, though these studies are not conclusive by
themselves.
No standard non-clinical methods exist to predict type II and III HSRs [403]. In
the case of drug-induced anemia (which can be detected through routine complete blood
counts), a positive direct Coombs test can be indicative of a type II or III immunopathy
targeting red blood cells [404]. In this test, erythrocytes taken from the exposed mice are
incubated with anti-mouse antibodies, which will cause agglutination of the cells if they
are coated with drug-induced anti-erythrocyte antibodies. In the event tissue damage is
suspected, IHC can be performed to determine the presence of antibody or complement
proteins in the tissues, which may suggest immune complex deposition [405].
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Lastly, Type IV HSRs are cell-mediated and primarily manifest in the skin,
making them a particular concern for topically applied compounds. While biologics are
not typically applied in such a manner, even systemically administered drugs can be
assessed for their potential ability to elicit a type IV HSR using established skin
sensitization/challenge models. The most commonly used assays to do this are the
Buehler Assay and the guinea pig maximization test (GPMT), both of which assess the
ability of a drug to induce a skin reaction weeks after the initial subdermal exposure in
guinea pigs [406]. The local lymph node assay (LLNA) in BALB/c mice can also be used
to assess potential contact allergens and involves removal of the draining lymph nodes
nearest to the site of drug administration and assessment of lymphocyte proliferation in
response to drug administration after dermal sensitization [407].
In summary, the preclinical development of AvFc will require further study of the
impact of immunogenicity to the drug, especially in light of the ADR observed in the
pretreatment study described in Chapter 5.2.7. The rapid onset of the reaction indicates
that it is likely due to a type alpha or beta reaction, and the assays described above can be
used to determine whether or not AvFc administration is likely to lead to an HSR or
cytokine release and can help determine the immunological mechanism behind the
reaction.

7.5: Conclusion
In conclusion, we have demonstrated that AvFc binds to cancer cells through the
recognition of cancer-associated high-mannose glycans, which are aberrantly
overexpressed on the surface of cells as they undergo the transformation to malignancy.
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AvFc appears to primarily exerts its anti-cancer activity by binding to the cancer cell
surface and inducing Fc-mediated effector functions, most importantly antibodydependent cell-mediated cytotoxicity. However, much work remains to demonstrate its in
vivo activity using more clinically relevant patient-derived xenograft models as well as to
perform IND-enabling preclinical toxicological assessments that will enable future
clinical evaluation of the drug candidate. In addition, it is possible that interaction with
and inhibition of cell-surface receptors may contribute to its overall mechanism of action
in certain models, and validation of the binding interactions elucidated in the proteomics
analyses will be critical for understanding its activity in the future. Lastly, it will be
critical to further understand the immunological mechanism of action of AvFc, in
particular by examining its impact on the makeup of the tumor immune
microenvironment and its ability to activate primary NK and myeloid cells. Overall, the
data presented herein justify AvFc’s continued development as a first-in-class cancer
therapeutic that targets a novel cancer-associated glycobiomarker.
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